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Low-grade inflammation is a characteristic of the obese state, and adipose tissue releases many inflammatory mediators. The source of
these mediators within adipose tissue is not clear, but infiltrating macrophages seem to be especially important, although adipocytes them-
selves play a role. Obese people have higher circulating concentrations of many inflammatory markers than lean people do, and these are
believed to play a role in causing insulin resistance and other metabolic disturbances. Blood concentrations of inflammatory markers are
lowered following weight loss. In the hours following the consumption of a meal, there is an elevation in the concentrations of inflam-
matory mediators in the bloodstream, which is exaggerated in obese subjects and in type 2 diabetics. Both high-glucose and high-fat
meals may induce postprandial inflammation, and this is exaggerated by a high meal content of advanced glycation end products
(AGE) and partly ablated by inclusion of certain antioxidants or antioxidant-containing foods within the meal. Healthy eating patterns
are associated with lower circulating concentrations of inflammatory markers. Among the components of a healthy diet, whole grains, veg-
etables and fruits, and fish are all associated with lower inflammation. AGE are associated with enhanced oxidative stress and inflammation.
SFA and trans-MUFA are pro-inflammatory, while PUFA, especially long-chain n-3 PUFA, are anti-inflammatory. Hyperglycaemia induces
both postprandial and chronic low-grade inflammation. Vitamin C, vitamin E and carotenoids decrease the circulating concentrations of
inflammatory markers. Potential mechanisms are described and research gaps, which limit our understanding of the interaction between
diet and postprandial and chronic low-grade inflammation, are identified.
Preamble
Inflammation is a normal defence mechanism that protects the
host from infection and other insults; it initiates pathogen
killing as well as tissue repair processes and helps to restore
homeostasis at infected or damaged sites. It is typified
by redness, swelling, heat, pain and loss of function, and
involves interactions among many cell types and the pro-
duction of, and responses to, a number of chemical mediators.
Self-regulation of the inflammatory response involves the
activation of negative feedback mechanisms such as the
secretion of anti-inflammatory cytokines, inhibition of pro-
inflammatory signalling cascades, shedding of receptors for
inflammatory mediators and activation of regulatory cells. As
such, and controlled properly, regulated inflammatory
responses are essential to remain healthy and maintain
homeostasis. Pathological inflammation involves a loss of
tolerance and/or of regulatory processes. Where this becomes
excessive, irreparable damage to host tissues and disease can
occur(1). Such diseases are characterised by markedly elevated
concentrations of inflammatory markers and of activated
inflammatory cells at the site of tissue damage and in the
systemic circulation. While the existence of inflammatory
diseases has been long recognised, it is only more recently
that the condition of chronic low-grade inflammation has
received attention, particularly in relation to obesity, the
metabolic syndrome and CVD. Chronic low-grade inflam-
mation is characterised by raised concentrations of inflamma-
tory markers in the systemic circulation. This article sets out to
explain the nature of chronic low-grade inflammation in the
context of overweight and obesity, and to describe the factors
that might influence it, in particular those related to diet.
The literature in the areas of adipose tissue, obesity and
inflammation, and dietary components and inflammation is
vast, and it is not possible to mention all studies here.
In particular, the review of diet and its components and
inflammation is not exhaustive, although the main studies of
relevance are included.
Concept and markers of low-grade inflammation
Obesity and low-grade inflammation
The concept of systemic, chronic, but low-grade inflammation
as a risk factor for the metabolic syndrome and for type 2
diabetes is based on the observation of elevated blood
levels of inflammation-associated markers in people with
incident type 2 diabetes or with the metabolic syndrome(2,3).
The up-regulation of systemic indicators of inflammation
such as leucocyte count, and serum and plasma concen-
trations of acute-phase proteins, pro-inflammatory cytokines,
chemokines, soluble adhesion molecules and prothrombotic
mediators is modest, usually less than 2-fold above what
is observed in controls. Diagnostic criteria for low-grade
inflammation have not been precisely defined, but the
phenotype per se is not disputed.
Systemic concentrations of pro-inflammatory mediators are
higher in obese (BMI .30 kg/m2) than in normal-weight per-
sons(4,5). Serum or plasma concentrations of TNF-a or IL-6 in
healthy adults are typically 0·01–2 pmol/l(6). Other inflamma-
tory mediators, such as monocyte chemoattractant protein
(MCP)-1, interferon (IFN)-g-induced protein-10 and IL-18,
may reach mean concentrations of 10 pmol/l; macrophage
migration inhibitory factor (MIF) and regulated on activation,
normal T expressed and secreted (RANTES) concentrations
may get close to the nanomolar range; and C-reactive protein
(CRP) concentration is often above 10 nmol/l. The variation in
concentrations of most mediators among non-obese or obese
individuals is at least 10-fold. Hence, there is a substantial
overlap between non-obese and obese persons. However,
there is a positive relationship between BMI and other
measures of obesity such as waist circumference and circulat-
ing concentrations of CRP and other inflammatory markers(7).
A mechanistic link between obesity and low-grade inflam-
mation was first proposed by Hotamisligil et al.(8) who showed
that white adipose tissue synthesises and releases the pro-inflam-
matory cytokine TNF-a. The expression of TNF-a is elevated
in adipocytes of obese and insulin-resistant mice, while insulin
sensitivity is improved following administration of anti-TNF-a
antibodies. Based on these data, it was suggested that adipose
tissue plays an important immune role and may be a major
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source of pro-inflammatory mediators which initiate the
development of chronic inflammation, insulin resistance and
atherosclerosis, all of which are characteristics of the metabolic
dysregulation associated with obesity. The discovery of leptin
modified the view of adipose tissue as being an ‘inert’ energy
store to being the largest endocrine gland in the body. Leptin is
produced and secreted by white adipose tissue. The discovery
of leptin introduced the concept of ‘adipocytokines’ or
‘adipokines’, substances produced by adipose tissue and which
circulate in the bloodstream, so exerting systemic effects as
hormones(9). Some adipokines are produced within adipose
tissue exclusively by adipocytes (e.g. leptin, adiponectin, serum
amyloid A (SAA)), while others are produced by both adipo-
cytes and other cell types of the non-adipocyte fraction of
adipose tissue. It is now recognised that macrophages accu-
mulate in the adipose tissue in obesity(10,11) (Fig. 1) and that
these may represent major contributors to the production of
adipokines(12,13).
Adipose tissue as a source of inflammatory mediators
Adipose tissue expresses and secretes into the systemic circu-
lation a growing list of hormones, inflammatory mediators and
immune system effectors. The products of adipose tissue can
be categorised into several groups (Table 1):
(1) Hormones: many of the hormones produced by adipose
tissue affect the immune system and insulin sensi-
tivity. Leptin appears to be pro-inflammatory(14), while
adiponectin appears to be anti-inflammatory and
insulin-sensitising(15). Similarly, visfatin(16) and resistin(17)
contribute to the development of insulin resistance,
while omentin(18,19) appears to be an insulin sensitiser.
It should be noted that most studies identifying the
roles of these hormones have been performed in rodents
and the immune and insulin-sensitising effects of these
hormones in humans remain unclear(20,21).
(2) Acute-phase proteins: these proteins are secreted in the
acute phase of inflammation and include plasminogen
activator inhibitor 1 (PAI-1)(22), pentraxine-3, lipocalin
24p3, haptoglobin, SAA(23) and a1-glycoprotein.
(3) Cytokines: these are the classic peptide mediators of
inflammation and include IL-1, IL-1 receptor antagonist
(IL-1ra)(24–26), IL-6, IL-7, IL-18(27–30), IL-10(31,32), MIF(33)
and TNF-a.
(4) Chemokines: these include IL-8(34,35), MCP-1, -3, -4, RANTES
(now known as chemokine (C–C motif) ligand (CCL) 5),
angiopoietin, metallothioneins, macrophage inflammatory
protein (MIP)-1a and -1b (now known as CCL3 and CCL4,
respectively)(36), and induced protein-10(37).
(5) Growth factors: transforming growth factor (TGF)-b(38).
(6) Components of the alternative complement system:
adipsin and factors C2, C3, C4, C7, B and D (these
are expressed more highly in omental compared with
subcutaneous adipose tissue(39,40)).
(7) Retinol-binding protein 4 which is linked with insulin resis-
tance(41,42), although its precise role has been debated(43).
Adipose tissue distribution and its impact on inflammation
Obesity is characterised by an expansion of the mass of
adipose tissue and dramatic changes in its distribution in the
body. Simplistically speaking, accumulation of adipose tissue
in the thorax and abdomen (variously termed abdominal,
central, visceral, splanchnic or android obesity) results in an
increased risk for diabetes and atherosclerosis, while excess
adipose tissue in the lower part of the body (termed
gynoid obesity) does not appear to be associated with major
metabolic consequences(44,45). The increase in abdominal fat
mass is associated with a chronic elevation of the circulating
concentrations of inflammatory mediators including several
acute-phase inflammatory proteins such as CRP(46,47), pro-
and anti-inflammatory cytokines, adhesion molecules and
pro-thrombotic molecules(22,47–49). It should be noted that
the liver and the lymphoid organs are usually the major pro-
duction sites of these inflammatory mediators but in obesity,
adipose tissue becomes a major producer resulting in a chronic
and constant local and systemic inflammatory milieu (Table 2).
Abdominal obesity is a risk factor for type 2 diabetes, hyperten-
sion, dyslipidaemia and CVD(50), and also probably obesity-
associated hepatic diseases (non-alcoholic fatty liver disease
and non-alcoholic steatohepatitis). Glucose intolerance is sig-
nificantly more common in subjects with abdominal obesity
compared with those with fat mass accumulation in their
lower part of the body. Plasma TAG concentrations are also sig-
nificantly more elevated in individuals with abdominal obesity.
It appears that the anatomical localisation of adipose tissue is
of paramount importance in relation to its physiological func-
tion, i.e. handling of lipids (lipogenesis, lipolytic activity),
expression of multiple genes, and response to insulin, catechol-
amines, sex hormones and cortisol(51). In addition, the profile
of adipokines produced is dissimilar between the subcutaneous
and abdominal adipose tissues. Thus, leptin is preferentially
expressed and secreted by subcutaneous adipose tissue(52),
while the expression of adiponectin, visfatin, omentin, resistin,
PAI-1, IL-8, IL-7, IL-1a, MCP-1, TGF-b, growth-related oncogen-
a, CCL5 and MIP-1b is higher in abdominal fat. In contrast to
such distributions, there are reports that IL-6 and TNF-a seem
to be equally synthesised by the different sites(28,36,53–59). It is
important to mention that in severe obesity, the part played
by the abdominal or the very abundant subcutaneous adipose
tissue in the systemic delivery of inflammatory mediators
is still not well understood. Nevertheless, the distinct profile
of adipokine secretion between the abdominal and subcu-
taneous adipose tissues probably contributes to the increased
risk of metabolic and cardiovascular complications and to the
development of other complications such as hepatic steatosis
and non-alcoholic steatohepatitis in obese individuals. Finally,
other adipose tissue depots in so-called ‘ectopic sites’, such
as within the liver, heart or skeletal muscle, may contribute
to the production of inflammatory mediators in the absence
of obesity. In this regard, the local production of the inflamma-
tory molecules by adipose tissue within the heart may
be important; the amount of this tissue and its proximity to
the coronary vessels could contribute to the development of
coronary pathologies(60,61).
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Cell populations of adipose tissue
Adipose tissue is a heterogeneous tissue composed of several
cell types: mature adipocytes, pre-adipocytes, fibroblasts,
endothelial cells, mast cells, granulocytes, lymphocytes and
macrophages. Cells within adipose tissue, apart from mature
adipocytes, are collectively termed the stroma-vascular
fraction. The various cell types have not been precisely
characterised, nor has the relative change of their quantitative
contributions to the tissue in obesity. Because of the hetero-
geneity of cells in the adipose tissue, the cellular source of
the inflammatory factors secreted by the tissue into the sys-
temic circulation remains unknown. In vitro studies have
demonstrated that mature adipocytes express inflammatory
factors such as TNF-a(56). SAA is overexpressed and secreted
in abundance by isolated adipocytes from obese subjects, as
is leptin, while secretion of adiponectin is suppressed. SAA
and leptin production by adipose tissue depends on adipocyte
size(18,19,23,62). Adipocyte size also influences the expression of
other inflammatory mediators as demonstrated by fraction-
ation studies of adipocytes coupled with studies of gene
expression profiles(62). Adipocyte size, for example, deter-
mines the production of IL-6, IL-8, MCP-1 and granulocyte
colony-stimulating factor(29). Although adipocyte hypertrophy
precedes the development of type 2 diabetes(63), a growing
number of studies indicate that the principal site of production
of inflammatory mediators appears to be the stroma-vascular
fraction(36,64–67). More recent studies in mice have suggested
that the infiltration of obese adipose tissue by macrophages
is accompanied or even preceded by an influx of T-lympho-
cytes(68–71) and that T-cells have a key early role(69). Early
work indicated the presence of CD3-positive T-lymphocytes
in human adipose tissue(72), and more recent studies have
shown high numbers of T-cells in the adipose tissue of
Lean adipose tissue
Weight gain
Obese adipose tissue
Adipocyte
Blood
vessel
Macrophage Apoptotic
adipocyte
Macrophage-
derived factors
    Resistin (human)
    IL-1β
Crosstalk
Pro-inflammatory cytokines and chemokines
    TNF
    IL-6
    CCL2
Adipocytokines
   Adiponectin
   Leptin
   Resistin
Fig. 1. Schematic representation of the interaction between adipocytes and macrophages showing some of the molecules released. Expansion of adipose tissue
during weight gain leads to the recruitment of macrophages through various signals (e.g. chemokines such as chemokine (C–C motif) ligand 2 (CCL2)) released
by adipocytes. Macrophages accumulate around apoptotic adipocytes. Mediators synthesised by adipocytes and resident macrophages contribute to local and
systemic inflammation. Reproduced with permission from Tilg & Moschen(10).
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diet-induced obese insulin-resistant mice(71). Furthermore,
Wu et al.(71) demonstrated the presence of CD3-positive
T-lymphocytes in human adipose tissue and described the
expression of RANTES, a T-cell-specific chemokine, and its
respective receptor CCR5 in the visceral adipose tissue of mor-
bidly obese patients. A recent study in mice reported mainly
CD8-positive lymphocyte infiltration in hypoxic areas within
the adipose tissue(70). Most recently, it has been shown that
pro-inflammatory T-lymphocytes are present in visceral
adipose tissue and may contribute to local inflammatory cell
activation before the appearance of macrophages, suggesting
that these cells could play an important role in the initiation
and perpetuation of adipose tissue inflammation as well as
the development of insulin resistance(69).
It has been proposed that macrophages and mature adi-
pocytes are derived from the same precursor cells and show
close gene expression profiles including the Toll-like recep-
tors (TLR). Pre-adipocytes exert ‘macrophage-like’ effects
when exposed to strong pro-inflammatory environments(73,74).
It should be noted, however, that the vast majority of the
macrophage infiltration in adipose tissue in obesity originates
most probably from the circulation. In obese subjects, these
macrophages typically aggregate in crowns around apoptotic
adipocytes(31) (Figs. 1 and 2). Although these macrophages
express activation markers, they could be pro- or anti-
inflammatory depending on the degree of obesity and its evol-
ution as suggested by studies in mice showing that weight
gain is accompanied by transformation from a macrophagic
M2 (anti-inflammatory) phenotype towards an M1 (pro-
inflammatory) profile(75) (Fig. 3)(76). Consequently, secretion
profiles of the adipose tissue can change depending on
the phenotype of the cell population infiltrating it during
the different stages of obesity (initiation, aggravation, mainten-
ance and weight loss; Fig. 4)(77).
Adipose tissue macrophages may contribute to the mainten-
ance of the low-grade inflammatory state linked to obesity(36).
Factors that induce the infiltration and activation of macro-
phages in the adipose tissue are probably multifactorial. Para-
crine, autocrine and endocrine signals, as well as mechanical
modifications (hypertrophy and adipocyte hyperplasia),
could play a role in this phenomenon. Many adipokines
synthesised by the adipose tissue are candidates to attract
inflammatory cells. In vitro studies have suggested that
leptin itself (at supra-physiological levels) induces adhesion
proteins, hence facilitating the migration of monocytes(78).
Conversely, adiponectin may inhibit this process(79). Very
little is known about the role of selectins, integrins and
elements of adhesion to the extracellular matrix, in the process
of macrophage attraction to the adipose tissue. Gene
expression studies with human adipose tissue have demon-
strated that the levels of expression of MCP-1, colony-stimulat-
ing factor-3 and the urokinase plasminogen activator CD87
increase significantly in the adipose tissue of subjects with
morbid obesity(31). MCP-1 is a strong chemoattractant and it
acts via its receptor CCR2. MCP-1 is synthesised predominantly
by macrophages and endothelial cells and, to a lesser extent,
by adipocytes. In one study, CCR2 gene knockout mice
showed a reduction of macrophage infiltration in the adipose
tissue and improvement of insulin sensitivity(80). This led to
the suggestion that MCP-1 and its receptor CCR2 are major
players in the macrophage accumulation within the adipose
tissue(80). However, contradictory data suggest that MCP-1
might not be such a crucial candidate(81). The role of MCP-1
in the macrophage accumulation in human obesity needs to
be established. Other candidate molecules and other mechan-
isms continue to be explored. Local hypoxia could also play
an important role in the attraction and retention of macro-
phages within the adipose tissue(82). Hypoxia-inducible
factor-1a, a transcription factor normally induced by hypoxia,
is overexpressed in the subcutaneous adipose tissue of obese
subjects and its expression is decreased during weight
reduction(31). Tissue hypoxia induces macrophage attraction
into solid tumours as well as into atherosclerotic plaques. Adi-
pose tissue of obese subjects could be hypoxic in some areas
and a local expression of chemokines could be induced.
It should be noted that leptin, which possesses indirect
chemoattractant properties, is induced by hypoxia(83).
It is generally considered that macrophage accumulation in
adipose tissue is detrimental. However, macrophage accumu-
lation could be related to an adaptation process associated
with the augmentation of fat mass, and macrophage accumu-
lation could be necessary for the upkeep of the tissue and
perhaps to limit its expansion. It appears that macrophage
aggregates within the adipose tissue are localised around
apoptotic adipocytes, suggesting that one of their functions
is to clean up the debris of dying and dead cells(84). In
addition to their role in cleaning up the old cells, the accumu-
lation of macrophages may also be useful for the formation of
new vessels, particularly at the site of inflammation and in
ischaemic zones when adipose tissue grows(85). Macrophages
also control fat mass growth and modify the biology of adipo-
cytes and pre-adipocytes in a paracrine manner. The specific
effects of TNF-a and IL-6 on different adipocyte functions
(increased lipolysis, modification of adipocyte secretion
patterns and induction of adipocyte insulin resistance) have
been shown(86). In the presence of a medium derived from
human macrophages, human pre-adipocytes showed a drastic
change in their phenotype, acquiring a pro-inflammatory
phenotype and secreting significant amounts of IL-6 and
IL-8, and they grew well(87), but differentiated poorly(87,88).
Table 1. Cytokines expressed or secreted by human adipose tissue
Family Example(s)
Chemokines MCP-1 (known as CCL2), MCP-3,
MCP-4, RANTES (known as CCL5),
MIP-1a (known as CCL3)
IL IL-6, IL-8 (acts as a chemokine), IL-1ra, IL-10, IL-18
Interferons IP-10
TNF TNF-a
Growth factors Vascular endothelial growth factor, TGF-b,
hepatocyte growth factor
Others Leptin
MCP, monocyte chemoattractant protein; CCL, chemokine (C–C motif) ligand;
RANTES, regulated on activation, normal T expressed and secreted; MIP,
macrophage inflammatory protein; IL-1ra, IL-1 receptor antagonist; IP, interferon-
g-induced protein; TGF, transforming growth factor.
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These cellular alterations are induced in co-cultures without
direct cellular contact, suggesting the key role of soluble
factors, although it cannot be excluded that a direct cell–cell
interaction also plays a role in modifying pre-adipocyte or
adipocyte biology. The mature adipocyte also endures pro-
found modifications of its biology in culture systems with a
medium from activated macrophages. Other than the pro-
inflammatory state, increased lipolysis and resistance to insulin
have been observed(89,90). TNF-a has been proposed to
mediate these effects. From the molecular point of view, the
NF-kB pathway, implicated in the primary regulation of
inflammatory responses(91–93) (Fig. 5)(94), is induced in the
pre-adipocyte(87) and in the adipocyte in the presence of a
medium from macrophages(95). The NF-kB pathway is also
brought into play in macrophages in contact with a medium
from adipocytes. TLR appear to be important players which
lead to the induction or suppression of genes orchestrating
the inflammatory response. TLR-4 is the bacterial lipopolysac-
charide (LPS) receptor, but data have shown that the NEFA
produced by adipocytes after adrenergic stimulation are also
strong inducers of the TLR-4/NF-kB system(95) (Fig. 5). TLR-4
is expressed by adipocytes and is overexpressed during
obesity(96). TLR-4 knockout mice are protected from insulin
resistance induced by lipid infusions(97).
Based on these different studies, a dual effect of macro-
phages of the adipose tissue could be expected: first, a local
‘beneficial’ effect in clearing out old adipocytes, and in the
control and of the development of fat mass and second,
a deleterious local and systemic effect via the increase in the
production and secretion of adipokines, promoting the pro-
gression of complications of obesity and the induction of insu-
lin resistance.
Adipokines and chronic low-grade inflammation
Adipokines and the complications of obesity. Inflammatory
molecules are likely candidates exerting a molecular link
between the adipose tissue and the metabolic, cardiovascular,
hepatic and thrombotic complications, and certain cancer
types occurring in conjunction with or as a consequence
of human obesity. A myriad of candidate adipokines are
proposed to play this role(98–100). In the cardiovascular
field, they can be considered as risk factors, and even
directly play a pathophysiological role favouring the initiation
and progression of atherosclerosis. Relationships between
abnormalities of cardiac function in obese subjects, the
accumulation of abdominal fat and low-grade inflammation
have been suggested(101,102). Among the candidates secreted
by the adipose tissue, the increase in IL-6, IL-8 and MCP-1
and the decrease in adiponectin are considered to be particu-
larly important(101,102). The studies of the pathophysiological
links between adipokines and cardiovascular health can be
illustrated by the analysis of the effects of adiponectin in
rodents. Overexpression of adiponectin results in diminished
size of the lesions observed following acute ischaemic
myocardial infarction, increased angiogenic properties and
reduced size of atheromatous plaques in the genetically pre-
disposed apoE2/2 mouse(103).
Table 2. Modification of circulating inflammatory marker concentrations in relation to obesity and weight loss
Effect of obesity Effect of weight loss
Acute-phase proteins
C-reactive protein Increase Decrease
Fibrinogen Increase Decrease
Orosomucoid Increase Decrease
Haptoglobin Increase Decrease
Serum amyloid A Increase Decrease
Cytokines
IL-6 Increase Decrease
IL-8 Increase Decrease
IL-18 Increase Decrease
IL-10 Increase Decrease
IL-1 receptor antagonist Increase Decrease
TNF-a Increase None or decrease
Monocyte chemoattractant protein-1 Increase Decrease
Monocyte chemoattractant protein-4 Increase Not known
Macrophage migration inhibitory factor Increase Decrease
Other adipokines
Leptin Increase Decrease
Visfatin Increase Decrease
Resistin Decrease None or increase
Adiponectin Decrease Increase
Omentin Decrease Not known
Adhesion proteins/extracellular matrix remodelling proteins/prothrombotics
Matrix metalloproteinase 9 Increase Decrease
Soluble intercellular adhesion molecule-1 Increase Decrease
Soluble vascular cell adhesion molecule-1 Increase Decrease
Soluble E-selectin Increase Decrease
Hepatocyte growth factor Increase Not known
Plasminogen activator inhibitor 1 Increase Decrease
Cathepsin S Increase Decrease
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Several inflammatory mediators produced by adipose tissue,
such as CCL5, IL-1b and IL-8, as well as markers of oxidative
stress, are increased in diabetic or glucose-intolerant patients,
and the amelioration of hyperglycaemia by insulin therapy
reduces circulating concentrations of these molecules(104,105).
The increase in the concentrations of TNF-a, IL-6, IL-1b,
IL-8, resistin and many other factors produced by macrophage
activation could contribute to the deterioration of insulin
sensitivity (Fig. 6)(106). The precise relationship between the
importance of macrophage and T-cell accumulation in adi-
pose tissue depots, adipokine secretion and the modifications
of insulin sensitivity needs to be further addressed in humans.
Macrophage accumulation is more abundant in the abdomi-
nal adipose tissue(65) than in the subcutaneous tissue, and this
could explain some of the risks associated with the accumu-
lation of intra-abdominal fat. For example, a relationship
between the increase in macrophages in the abdominal adi-
pose tissue and hepatic inflammation and fibrosis has been
reported(65). In another study, the expression of the MCP-1
and colony-stimulating factor-1 genes and proteins was associ-
ated with macrophage accumulation in obese subjects(107).
Since the abdominal adipose tissue is partly drained by the
portal system, it cannot be excluded that some adipokines,
together with high NEFA fluxes and hormones delivered by
the adipose tissue, could contribute to the alteration of hepatic
function observed in obese subjects, the mechanism of which
needs to be better dissected.
Adipokines and weight loss. Even modest weight
reduction improves the metabolic and cardiovascular risks
associated with human obesity. Measures of endothelial acti-
vation also improve after weight reduction(108–110). Many
studies have shown that weight loss induced by a decrease
in energy intake, and sometimes an increase in exercise,
reduces systemic inflammation. A reduction in concentrations
of numerous inflammatory molecules and endothelial risk
factors, and an increase in adiponectin concentration have
been observed during weight-loss programmes, and these are
sometimes associated with improvement of insulin sensi-
tivity(111). Such changes have been described for CRP(112),
IL-6(113), IL-18(114), IL-1ra(26), PAI-1(115), SAA(23,116), cathepsin
S(117), matrix metalloproteinase-9(118), soluble adhesion mol-
ecules (soluble intercellular adhesion molecule-1 (sICAM-1),
soluble vascular cell adhesion molecule-1 (sVCAM-1))(110),
tissue factor(119), MIF(120), MCP-1(121), soluble receptors of
TNF (sTNFR) and for eotaxin, an inflammatory factor
implicated in asthma, another complication of obesity(122).
Weight loss induced by gastric bypass reduced the circulating
concentrations of visfatin(123) and TNF-a(124,125). One study
followed sixty obese patients during the course of weight
loss induced by bariatric surgery and reported a reduction of
30 % of initial weight, a decrease in CRP, SAA, orosomucoid
protein, IL-6, TNF-a and fibrinogen concentrations, and an
increase in adiponectin concentration(126). After the surgery,
the concentration of IL-6 dropped slowly while the concen-
trations of SAA and CRP dropped more quickly(126).
There was a significant modification in the expression of
inflammatory genes in the subcutaneous adipose tissue
of obese women following a hypoenergetic diet(127). The
expression of 100 genes linked to inflammatory processes
was modified after 4 weeks (41 % increased and 59 %
decreased). These genes belonged to at least twelve functional
families including cytokines, the complement factor cascade,
acute-phase proteins of inflammation, and molecules involved
in cellular adhesion and in the remodelling of the extracellular
matrix. The improvement of the inflammatory profile (at the
level of gene expression) involved both the decreased
expression of pro-inflammatory factors and the increased
expression of anti-inflammatory factors such as IL-10 and
IL-1ra. The modification of the inflammatory gene expression
profile was very similar in subjects following bariatric
Non-obese subject
Macrophages
Obese subject
Obese subject
Fig. 2. Adipose tissue from non-obese and obese human subjects showing macrophage infiltration. Macrophages are stained with HAM56 antibody. Reproduced
with permission from Cancello et al.(65).
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surgery and was associated with a reduction of macrophage
infiltration. In this study, the protein expression of IL-10
increased, suggesting a possible M1 to M2 (pro-inflammatory
to anti-inflammatory) switch of macrophage phenotypes(31).
Overall, the mitigation of the systemic inflammatory profile
observed during weight loss is associated with modifications
of adipose tissue inflammatory gene expression, and this
may be linked with altered profiles of inflammatory protein
secretion. The eventual consequence of this phenomenon on
the local biology of the adipose tissue remains to be identified.
Chronic low-grade inflammation and insulin resistance
Experimental model systems in vitro
In obesity and the metabolic syndrome, key organs displaying
increased insulin resistance are the liver, skeletal muscle,
adipose tissue and the endothelium (Fig. 6). Experimental
model systems in vitro have shown that hepatocytes as well
as muscle cells, adipocytes and endothelial cells respond to
exposure to the pro-inflammatory cytokines TNF-a, IL-6
and/or IL-1b with impaired insulin signalling(128). Since
these cytokines mediate their effects by binding to their
cognate receptors, downstream components of the signalling
cascade must interfere with insulin receptor function. Several
such pathways have been identified (Fig. 7)(128). Pro-
inflammatory cytokine signalling usually activates the kinases
IkB kinase b and C-jun N-terminal kinase 1, both of which
in turn phosphorylate the Ser 307 residue of insulin receptor
substrate (IRS)-1. This prevents the phosphorylation of
tyrosine residues of IRS-1 by the insulin receptor and the
downstream signalling cascade. TNF-a mediates insulin resist-
ance also via the activation of p38 mitogen-activated protein
kinase (MAPK) which interferes with the IRS–phosphatidyl-
inositol 3-kinase–Akt pathway(129). Another mechanism
involves cytokine-induced suppressor of cytokine signalling 1
and 3, which also prevent tyrosine phosphorylation of IRS
proteins, by direct interference, or ubiquitylation and sub-
sequent degradation(130,131). Induction of suppressor of cyto-
kine signalling 3 by IL-6 occurs via the signal transducer
and activator of transcription 3 (STAT3) mammalian target of
rapamycin (mTOR) pathway(132).
In vivo models
The impairment of insulin signalling by TNF-a has also been
observed in vivo after infusion of the cytokine into
rodents(133,134). A critical mediator downstream of TNF-a
appears to be MIF, since mice with a disrupted MIF gene pre-
serve normal insulin signalling(135). In this context, it is of
interest that adipocytes are able to secrete MIF(33). The latter
finding demonstrates that there are still substantial gaps in
our understanding of the pro-inflammatory cytokine signalling
Classically activated
macrophage
LPS, IFN-γ
TNF-γ , IL-Iβ,
IL-6, resistin,
NO, etc.
Alternatively activated
macrophage
Lean
insulin sensitive
Obese
insulin resistant
Anti-inflammatory
NEFA
IL-13
IL-4
Proinflammatory
NEFA
Chemokines
TNF-α
Adipocyte
IL-10
IL-4, IL-3
IL-10
Fig. 3. Schematic representation of factors regulating macrophage polarity and insulin resistance in adipose tissue. Under lean conditions, adipocytes secrete factors,
such as IL-13, that promote alternative activation of macrophages. Alternatively activated (M2) macrophages secrete anti-inflammatory mediators, such as IL-10, and
may secrete insulin-sensitising factors. Obesity induces changes in adipocyte metabolism and gene expression, resulting in increased lipolysis and the release of
pro-inflammatory NEFA and factors that recruit and activate macrophages, such as chemokines and TNF-a. Activated M1 macrophages produce large amounts of
pro-inflammatory mediators, such as TNF-a, IL-1b and resistin, that act on adipocytes to induce an insulin-resistant state. This establishes a positive feedback loop
that further amplifies inflammation and insulin resistance. IFN, interferon; LPS, lipopolysaccharide. Reproduced with permission from Olefsky & Glass(76).
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cascade leading to insulin resistance. Most importantly, it
remains unclear where other known regulators of insulin
sensitivity fit into the chain of events. There is convincing
evidence that reactive oxygen species (ROS) are critical to
the effects of TNF-a on insulin signalling(136), and also that
mitochondrial dysfunction is involved(137). The impact of
insulin on cellular metabolic activity, proliferation and differ-
entiation can also be impaired by inflammatory mediators
via an indirect pathway, i.e. by enhancing or suppressing
the production of hormones that modulate cellular responses
to insulin. These effects include the up- or down-regulation of
the synthesis of resistin(138), leptin, adiponectin(139), lipocalin
2(140), osteopontin(141), and of insulin itself. When considering
the subnanomolar systemic concentration of many pro-
inflammatory mediators (see section ‘Obesity and low-grade
inflammation’), it is possible that only a few of them contri-
bute to the metabolic derangements seen in obesity and the
metabolic syndrome.
A different situation emerges when paracrine effects of
inflammatory mediators are considered. As described above,
there is substantial local production of inflammatory mediators
in organs affected by insulin resistance. Hepatocytes, adipo-
cytes, muscle cells and the endothelium are sites of inflamma-
tory mediator synthesis, but local activated macrophages
appear to be the dominant site of synthesis and secretion,
which leads to spillover into the general circulation(66,67,142).
Paracrine concentrations of inflammatory mediators are suffi-
cient to induce insulin resistance(128). Indeed, co-culture of
adipocytes with macrophages caused impairment of insulin
signalling(75). In addition to paracrine effects, it is conceivable
that the functions of liver cells are affected by inflammatory
mediators released from the abdominal adipose tissue because
of their blood link.
Evidence supporting the link between inflammatory
mediators and insulin resistance
In human subjects, the most direct approach to assess the
contribution of low-grade inflammation to the development
of insulin resistance and the metabolic syndrome is to analyse
the consequences of anti-inflammatory pharmacotherapy.
The longest experience is with the use of salicylates which
are weak inhibitors of IkB kinase b and of serine phosphoryl-
ation of IRS proteins(143,144). Early clinical trials with high
doses of salicylates, notably aspirin, yielded both positive
and negative effects on glycaemia and insulin resistance.
Later studies have revealed that only very high doses are
effective in improving glucose metabolism(145). A randomised
placebo-controlled pilot trial of salsalate treatment for 1 month
in twenty non-diabetic obese individuals found decreased
Over-nutrition
Adipose tissue
expansion/inflammation
Obesity-associated
pathologiesLean/healthy state
Insulin sensitivity
Normal endothelial function
Insulin sensitivity
Endothelial dysfuction
Anti-inflammatory adipokinesAdiponectin, omentin
TNF-α, IL-6, IL-8, MIF,
MCP-1, RANTES
Leptin, adipsin, chemerin,
visfatin, apelin, vaspin
SAA, haptoglobin, PAI-1
HGF, NGF, TGFβ, VEGF
Activation of COX, NOS,
RAS and MMP
Insulin sensitivity
Pro-inflammatory adipokinesAnti-inflammatory adipokines
Pro-inflammatory adipokines
Hypoxia/inflammation
Fig. 4. Schematic representation of the alterations in adipose tissue that accompany body-weight gain. In the lean state, the tissue secretes elevated levels of adi-
ponectin and other anti-inflammatory adipokines and is insulin responsive. Energy intake in excess of expenditure is followed by adipocyte hypertrophy and death
and chemotactic adipokine release (see Fig. 1). This facilitates macrophage infiltration into the tissue and exacerbates the inflammatory response. These
secretory changes are accompanied by local insulin resistance and hypoxia. Many of the adipokines released by inflamed adipose tissue cause insulin resistance
and endothelial dysfunction. COX, cyclo-oxygenase; HGF, hepatocyte growth factor; MIF, macrophage migration inhibitory factor; MMP, matrix metalloproteinase;
NGF, nerve growth factor; NOS, NO synthase; PAI-1, plasminogen activator inhibitor-1; RANTES, regulated on activation, normal T expressed and secreted;
SAA, serum amyloid A; TGF, transforming growth factor; VEGF, vascular endothelial growth factor; MCP, monocyte chemoattractant protein; RAS, renin-angiotensin
system. Reproduced with permission from Karastergiou & Mohamed-Ali(77).
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blood glucose and insulin responses to an oral glucose
challenge consistent with improved insulin sensitivity(146).
A secondary analysis of a prospective multicentre observa-
tional study of 4905 adults with rheumatoid arthritis, of
whom 1808 had taken hydroxychloroquine, indicated a
reduced risk of diabetes in patients using this drug(147).
More specific anti-inflammatory intervention is possible
through the use of recombinant proteins antagonising pro-
inflammatory mediators. A first controlled double-blind trial
was performed with daily injections of recombinant human
IL-1ra for 13 weeks. This resulted in decreased glycated Hb
levels and enhanced endogenous insulin production(148).
However, although there was a significant decrease in sys-
temic CRP and IL-6 concentrations in response to anti-inflam-
matory treatment, there was no change in insulin resistance
(homeostasis model assessment index and euglycaemic–
hyperinsulinaemic clamp studies). It is difficult to judge the
extent of inflammation persisting during therapy because
absolute serum concentrations of CRP and IL-6 were not
reported. There was no significant decrease in circulating
TNF-a, MCP-1 or IL-8 concentrations, which indicates that
there was no general down-regulation of pro-inflammatory
cytokines. Another target-specific approach is the neutralis-
ation of TNF-a by injections of recombinant antibodies or
sTNFR. In animal models of insulin resistance, infusion of
TNF-a antibodies has been reported to ameliorate insulin sig-
nalling(8,149). In obese non-diabetic or diabetic individuals,
several studies have observed improvement of insulin sensi-
tivity after prolonged treatment with neutralising TNF-a anti-
bodies(150,151), whereas other trials did not report such
effects of TNF-a antibody injections, despite dampening of
systemic inflammation(152). Possible explanations are that the
recombinant antibodies do not reach sufficiently high concen-
trations in target tissues, or that TNF-a neutralisation is effective
only in skeletal muscle tissue but not in adipose tissue as has
been observed in rats(153). The overall conclusion is that results
of studies of anti-inflammatory therapy generally support
the concept of inflammatory mediators as contributors to the
pathogenesis of insulin resistance, but have as yet not provided
clear evidence of a critical pathogenic role of TNF-a or IL-1.
Postprandial inflammatory response
The foregoing discussion has dealt with chronic changes in
concentrations of inflammatory mediators but a rise in
inflammation also appears to take place acutely following
meals. The postprandial inflammatory response lasts for
only few (4–8) h but it recurs several times a day following
eating. Although the postprandial inflammatory response has
been known for several years(154), it is only recently that its
probable importance in the generation of insulin resistance
and atherosclerosis has been appreciated(155–157). Several
cells in the body associated with the innate immune
system, including abdominal adipocytes and monocytes/
macrophages, respond to acute postprandial elevation of
several components of a meal by mounting a transient
inflammatory response. The most efficient triggers of the
postprandial inflammatory response appear to be TAG,
SFA, oxysterols and glucose(158–161). The pathophysiological
significance of a postprandial inflammatory response in
causing insulin resistance, the metabolic syndrome and
atherosclerosis is currently under investigation, and this
response appears to play a much more crucial role than pre-
viously thought(162).
Non-dietary factors influencing the magnitude of the
postprandial inflammatory response
Body weight. Obesity is considered an important determi-
nant of the magnitude of the postprandial inflammatory
response(163), perhaps being more important than any specific
component of a meal inducing the response. The exaggerated
postprandial inflammatory response of the obese is reversible
upon reduction of body weight(155,164).
Hyperglycaemia and type 2 diabetes. Patients with type 2
diabetes exhibit a higher postprandial inflammatory response
than non-diabetics, irrespective of their body weight(165,166).
Infiltrated
macrophages
NF-kB
NF-kB
TLR4
TNF-α
Chemoattraction
Lipolysis
Adipokine
secretion
(MCP-1.....)
Hypertrophied
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TLR4
NEFA
CXCR
CCR
Fig. 5. Schematic representation of the cross-talk between adipocytes and
macrophages of adipose tissue in obesity. TNF-a produced by macrophages
activates adipocytes via TNF-a-receptor-1 (TNFR1) and the NF-kB pathway.
TNF-a also induces lipolysis leading to the release of NEFA. Saturated
NEFA in turn activate the Toll-like receptor 4 (TLR4)/NF-kB pathway in both
macrophages and adipocytes, thereby further amplifying the inflammatory
process. Some of the adipokines produced (e.g. monocyte chemoattractant
protein-1 (MCP-1)) exert chemoattractant activity through binding to specific
receptors (CXC chemokine receptor (CXCR) and CC chemokine receptor
(CCR)) of macrophages, leading to their infiltration in obese adipose tissue.
Reproduced with permission from Maury & Brichard(94).
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The magnitude of the postprandial inflammatory response
appears to correlate with the degree of insulin resistance(165).
Drugs. Certain medications including statins and angioten-
sin II receptor antagonists ameliorate the postprandial inflam-
matory response in obese patients(167).
Pathophysiology of the postprandial inflammatory
response
The daily influx of TAG, SFA, glucose and other food com-
ponents initiates an acute innate immune (i.e. inflammatory)
response that lasts for a few hours. Meals or food components
may contain LPS which directly triggers systemic inflam-
mation. Related to this effect, the absorptive process may
allow translocation of LPS from gut bacteria into the systemic
circulation(168). Meals may contain oxidised components
which initiate oxidative stress and/or inflammatory responses
upon absorption. Postprandial hyperglycaemia can suppress
antioxidant capacity(169) and thus its ability to curb an
inflammatory reaction. Hyperglycaemia induces the pro-
duction of free radicals which themselves initiate an inflam-
matory reaction. A six-transmembrane protein of prostate 2
(STAMP2) has been proposed as a major determinant of
the postprandial inflammatory response(170), acting to block
activated inflammatory signalling pathways in adipocytes
and possibly in macrophages. In vivo, feeding induces
STAMP2 expression in visceral white adipose tissue(170). Fur-
thermore, the visceral tissue of STAMP gene knockout mice
is resistant to insulin action(170,171).
Ageing and low-grade inflammation
Ageing is associated with complex changes in, and a dysregul-
ation of, the immune system, including its inflammatory com-
ponent. The ageing of the immune system, immunosenescence,
has been suggested to be a consequence of continuous
attrition caused by chronic antigenic overload(172). Ageing is
accompanied by a low-grade, chronic inflammatory state
clearly shown by 2- to 4-fold increases in serum levels of
several inflammatory mediators in older persons(173). Studies
have reported increased plasma/serum levels of the pro-
inflammatory cytokine IL-6 in healthy subjects with advanced
age (55–75 v. 26–54 years)(174), an increase of 0·016 pg/ml per
year of life(175) and a significant increase with overall age
(from 20 to 102 years)(176), and in elderly diabetic subjects
(65–80 years)(177). Ageing is also associated with increased
concentrations of TNF-a(178,179), CRP(180) and IL-1ra(176,181). It
is hypothesised that failure of anti-inflammatory mechanisms
to neutralise inflammatory processes that are continuously
triggered lifelong plays a role in chronic low-grade inflam-
mation in the elderly(182). In line with this, it has recently
been shown that ageing (two groups with a mean age of
77·9 and 102·5 years, respectively v. a group with a mean
age of 43·5 years) is characterised by a profound reduction
in anti-inflammatory lipoxin A4 levels
(183).
The effect of ageing on the immune system, however,
cannot be completely separated from the contribution of
co-morbidity, medication use or malnutrition(184,185). Since
several inflammatory markers act as disease markers, it is
possible that some of the chronic low-grade inflammation
patterns found in the elderly may be related to the presence
of co-morbidities(180,186). Interestingly, however, successful
ageing (ageing without co-morbidities) has also been
associated with chronic low-grade inflammation(173). Other
factors that may affect and modulate circulating levels of
inflammatory mediators, including obesity, infections,
physical activity, age-related decline in sex hormones and
altered host–microbiota interaction at the gut level, may
also be involved in the age-associated increase in low-
grade inflammation(172,187–189). Furthermore, high plasma
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Fig. 6. Schematic representation of the role of adipose tissue inflammation in the initiation and maintenance of systemic insulin resistance. Reproduced with
permission from de Luca & Olefsky(106).
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levels of IL-6 (and TNF-a) in the elderly were associated
with truncal fat mass(177), suggesting that some of this
effect might be mediated with age-associated increase in
fat mass.
There is strong evidence that low-grade elevations of
circulating inflammatory mediators are associated with the
development of age-related conditions such as atherosclero-
sis, cognitive decline and frailty. This may in part reflect
the inflammatory nature of these conditions which involve
local or generalised inflammation (e.g. neuroinflammation
in cognitive decline), with the increase in circulating con-
centrations of inflammatory mediators reflecting overspill
from the inflammatory lesion(s). Additionally, the increased
inflammatory burden could make a contribution to the
ongoing pathology and to a worsening clinical situation.
Increases in the levels of circulating TNF-a, IL-6, IL-2R and
CRP are also strong predictors of all-cause mortality risk
in longitudinal studies of several elderly cohorts(190–193).
However, whether increased inflammatory activity causes
age-associated pathology or reflects the sum of ongoing
pathological processes(173,194) remains uncertain. Survival
analyses in studies from the USA and Europe with several
populations (healthy, non-disabled, $65-year-old sub-
jects(191), high-functioning subjects aged 70–79 years(192),
disabled women aged $65 years(193) and relatively healthy
80-year-old people(190)), however, show that effects of
inflammatory mediators were independent of pre-existing
morbidity and other traditional risk factors for death. This
indicates that these inflammatory mediators influence
pathological processes or act as very sensitive markers of
subclinical disorders in the elderly(173).
Exercise and low-grade inflammation
Influence of acute and regular physical activity and fitness
on low-grade inflammation
The health benefits of a physically active lifestyle are well
recognised. Physical inactivity and obesity are also increas-
ingly recognised as modifiable behavioural risk factors for
a wide range of chronic diseases, and in particular for CVD(195).
Physical fitness, physical exercise and physical activity are
often used as interchangeable concepts, but it is important
to point out the differences among these. Physical activity is
any body movement that increases energy expenditure(196).
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Fig. 7. Schematic representation of the direct interaction between inflammatory and insulin signalling pathways. The insulin signalling cascade branches into
two main pathways. The PI3K-Akt pathway mediates insulin action on nutrient metabolism including glucose uptake. The Ras-mitogen-activated protein kinase
(MAPK) pathway mediates the insulin’s effect on gene expression, but also interacts with the PI3K-Akt pathway to control cell growth and differentiation. Acti-
vation of the insulin receptor leads to tyrosine phosphorylation of insulin receptor substrate (IRS)1, thereby initiating signal transduction. Stimulation of the
NF-kB and activator protein-1 (AP-1) Fos/Jun inflammatory pathways results in the activation of serine kinases, Ikkb and C-jun N-terminal kinase 1, which
reduce the signalling ability of IRS1. Related negative regulators of IRS proteins include the suppressor of cytokine signalling proteins and NO, which are
induced in inflammation, and promote IRS degradation. NO also reduces PI3K-Akt activity by nitrosylation of Akt. Reproduced with permission from de Luca
& Olefsky(128). TLR, Toll-like receptors.
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Self-reported data of physical activity are easy and feasible to
ask in a questionnaire or interview in large populations but
are a measurement subject to recall and reporting biases. Exer-
cise is planned, structured and repetitive physical activity,
while physical fitness is the capacity to perform physical
activity, and makes reference to a full range of physiological
and psychological qualities. To eliminate reporting bias that
could be present in self-reported physical activity measure-
ment, several studies have examined the relationship between
cardiorespiratory fitness and inflammatory markers. Maximal
oxygen consumption (VO2max) attained during a graded maxi-
mal exercise to voluntary exhaustion is considered as the
single best indicator of cardiorespiratory fitness(197). There
are excellent reviews of the evidence addressing the influence
of physical activity and fitness on low-grade inflammation
from epidemiological studies as well as clinical trials on
the general adult population(198–202), athletes(203,204), and in
children and adolescents(205).
Acute v. regular exercise. IL-6 and other cytokines that
are produced and released by skeletal muscles have been
suggested to be involved in mediating the health-beneficial
effects of exercise and to play important roles in the protection
against diseases associated with low-grade inflammation.
The following chain of events is based on observations by
Pedersen and colleagues and has been excellently reviewed
elsewhere(206–208):
(1) Contracting skeletal muscle is a major source of circulat-
ing IL-6 in response to acute exercise. Plasma IL-6
increases in an exponential fashion with exercise and is
related to exercise intensity, duration, the mass of
muscle recruited and endurance capacity. During heavy
exercise, such as a marathon, there is up to a 60-fold
increase in plasma IL-6 concentration(209), with the dur-
ation of the event explaining more than 50 % of the vari-
ation in concentration(210). Interestingly, IL-6 shows a
markedly lower response to acute exercise in trained
subjects.
(2) Physiological concentrations of IL-6 stimulate the appear-
ance in the circulation of the anti-inflammatory cytokines
IL-1ra and IL-10 and inhibit the production of the pro-
inflammatory cytokine TNF-a. The health benefits of
long-term regular exercise are ascribed to the anti-inflam-
matory response elicited by an acute bout of exercise,
which is partly mediated by muscle-derived IL-6.
(3) The anti-inflammatory effects of exercise may therefore
offer protection against TNF-induced insulin resistance.
Moreover, IL-6 stimulates lipolysis as well as fat oxidation.
The increase in IL-6 at the end of exercise is responsible
for the increased CRP levels during late recovery.
In response to regular physical activity, basal as well as
post-exercise plasma concentrations of IL-6 will decrease by
mechanisms that might include increased glycogen content,
improved antioxidant capacity and improved insulin sensi-
tivity. The lower concentrations of IL-6 in the circulation will
subsequently result in lower CRP levels.
Few studies have prospectively examined the effect of exer-
cise training on low-grade inflammatory status, and the data
obtained from intervention studies are less consistent when
compared with cross-sectional population studies. A lower
number of subjects or a good physical condition in the start
of some intervention studies may explain a part of this incon-
sistency. Nevertheless, two longitudinal studies in athletes
show that regular training induces a reduction in CRP concen-
tration(211,212). Conflicting findings exist in clinical trials that
have involved exercise only. Several training interventions
have not produced changes in basal IL-6 or CRP concen-
trations(213–218), while significant reductions in inflammatory
markers have been observed following training without
changes in BMI or body fat in elderly participants(219,220).
The largest trial was performed in 652 sedentary healthy,
young and middle-aged, white and black women and men
in the HEalth, RIsk factors, exercise Training And Genetics
(HERITAGE) Family Study(221). They were subjected to a
20-week standardised exercise training programme; there
was no control group, and each subject served as its own con-
trol. A non-significant reduction in CRP concentration was
consistent across all groups and varied between 1·2 and
2·2 mg/l. Considering that the over-time variation in CRP in
healthy individuals with stable lifestyle is small(222), the
reduction, although not significant, could nevertheless reflect
the true effect of exercise training. Further stratification
according to basal CRP levels showed a reduction by about
1·3 mg/l in subjects with initial CRP levels above 3·0 mg/l.
Effects of exercise in elderly people. Elderly people have
higher basal levels of inflammation independently of disease
status, and a considerable number of studies have been
carried out in this population to assess associations bet-
ween physical activity and inflammatory markers(190,223–230).
Rather consistent inverse, BMI-independent, associations
are found and the associations are suggested to be dose-
dependent; the more physically active the person, the lower
the inflammatory markers(208,224). Also subjects over 80 years
of age show consistent inverse associations between inflam-
mation and physical activity(190). Functional fitness was
inversely associated with IL-6 and IL-1ra concentrations (but
not with CRP, TNF-a, IL-10 or IL-1b) in a prospective popu-
lation-based study of 1020 participants aged 65 years and
older(223,231). Muscle strength was also evaluated in this study
and low hand-grip strength was associated with high levels of
CRP and IL-6(231). Other studies have also shown a negative
association of CRP, IL-6 and TNF-awith muscle strength(228,232).
Exercise intervention in elderly people or in patients
with CVD shows consistent anti-inflammatory effects. After
a 6-month individualised, supervised exercise programme
for forty-three subjects at high risk of IHD, a 35 %,
albeit non-significant, reduction in CRP concentration was
observed. The subjects exercised for a mean of 2·5 (range
0·3–7·4) h/week(233). One reason for the lack of a significant
effect despite the fairly large reduction in CRP concentration
is the small size of the study. Another study reported a
decrease in basal plasma IL-6 concentration after aerobic train-
ing in patients with coronary artery disease(234). A randomised
trial of thirty-nine patients with intermittent claudication
demonstrated that both serum CRP and SAA concentrations
were significantly reduced after 3 and 6 months of supervised
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exercise compared with controls(235). In a relatively large
intervention study of exercise training on cardiac rehabilitation
patients, the median CRP concentration was reduced by 41 %,
while CRP concentrations did not change in subjects who
did not exercise(236). Again, the exercise training seemed
to be more effective in those with the highest initial CRP
concentrations, independently of changes in body weight or
percentage of body fat, indicating that baseline levels of
low-grade inflammation may be an important factor.
Studies in patients with diabetes(237) or the metabolic syn-
drome(238,239) have consistently demonstrated inverse associ-
ations between fitness and inflammation, independently of
fatness. In one study, the independent associations of fitness
were in fact more prominent among metabolic syndrome
patients compared with healthy participants(238,239).
Effects of exercise in middle-aged and younger adults and
in children. Several studies of large population cohorts,
such as the British Regional Heart Study(225), the Greek
ATTICA study(240), the Third National Health and Nutrition
Examination Survey (NHANES)(241,242), the Men’s Health Pro-
fessionals’ Follow-Up Study(243), the Nurses’ Health Study(243)
and the Women’s Health Study(244), provide evidence for an
inverse, independent dose–response relationship between
plasma CRP concentration and level of physical activity in
both men and women, but the consistency is less than in
elderly subjects, or in disease states. In contrast, the associ-
ations found between self-reported physical activity and
TNFR1, TNFR2, IL-6 and CRP concentrations in a study includ-
ing healthy men from the Men’s Health Professionals’ Follow-
Up Study and healthy women from the Nurses’ Health
Study(243) were no longer significant when adjusting for BMI
and leptin. Thus, the effect of physical activity on circulating
markers of low-grade inflammation appears to be mediated
by weight loss. In another study in healthy men and
women, BMI, but not previous year or current physical
activity, predicted CRP concentration(245). Similarly, a cross-
sectional study(246) in men found no relationship between
leisure-time physical activity and CRP, fibrinogen and SAA
concentrations, after correction for BMI and current smoking
status. CRP levels in 2120 Finns were associated with obesity
indices and physical activity among both sexes(247); in multi-
variate analyses, the determinants of CRP concentration
included obesity and smoking in men, and obesity, oral con-
traceptive use and physical activity in women. The study
showed that about one in three of healthy women who
used oral contraceptives had a CRP concentration exceeding
3 mg/l, which should be taken into account when studying
younger females. Cross-sectional studies in men from the
Aerobics Center Longitudinal Study have demonstrated that
cardiorespiratory fitness levels are inversely associated with
CRP concentration and also the prevalence of elevated CRP
concentrations(248). Analyses with fibrinogen and white
blood cell count showed similar results(249). The competing
effect of weight and fitness (assessed by submaximal graded
exercise treadmill testing) on cardiorespiratory fitness levels
was studied in the NHANES, which included 2112 US adults
without previously diagnosed CVD(250). Both fitness and BMI
were independently associated with increased fasting insulin
and CRP concentrations. However, when patients with low,
moderate and high fitness were further stratified as normal,
overweight or obese, weight remained significantly associated
with CRP, but fitness did not. This study concludes that ‘fat but
fit’ subjects require weight-loss interventions to improve their
CRP levels. Future interventions should emphasise weight
control, even for those with high cardiorespiratory fitness.
In disease-free young populations, studies have assessed
the interaction between inflammatory markers (CRP, IL-6 and
TNF-a), physical activity or cardiorespiratory fitness and fat-
ness(47,251–258). Organised leisure-time exercise (assessed by
a questionnaire) in children has shown negative correlations
with serum IL-6 concentrations, independently of adiposity
and fat localisation(256), and in 10-year-old children, a border-
line significant negative association was observed between
CRP and self-reported physical activity, independently of
ponderal index(47). US children and young adults (aged
6–24 years) from the Columbia University BioMarkers Study
showed an inverse correlation between cardiovascular fitness
and CRP concentration but only in boys, which remained after
adjustment of confounders including BMI(251). Only one study
has used accelerometry (an objective measure of total physical
activity compared with leisure-time physical activity or
exercise) instead of questionnaires as well as cardiovascular
fitness(257). In this study of 9-year-old Swedish children, total
physical activity was unrelated to CRP, fibrinogen, C3 or C4
concentrations, but exercise was. Nevertheless, once body
fat was entered into the regression models, no associations
with cardiovascular fitness or physical activity and the inflam-
matory markers measured were observed(257). Similarly,
no associations were found between cardiorespiratory fitness
or self-reported physical activity and CRP concentration in
12-year-old healthy Welsh children(259).
CRP, C3 and ceruloplasmin (but not C4) concentra-
tions were negatively associated with muscle strength after
controlling for sex, age, pubertal status, weight, height,
socio-economic status and cardiorespiratory fitness, but did
not remain when adjusting for body fat. Nevertheless, when
stratifying according to overweight status, CRP (but not C3,
C4 or ceruloplasmin) concentration was associated with
muscle strength in overweight, but not in normal-weight,
adolescents after controlling for potential confounders,
including body fat and fat-free mass(260).
Conclusions for effects of physical activity and fitness on
low-grade inflammation
Most research on this topic hypothesised that the association
between fitness and inflammatory factors is independent of
fatness. Given that physical activity and obesity are often
inversely related, it is not clear as to whether the anti-
inflammatory health benefits of a physically active lifestyle
are due to exercise per se or result from favourable changes
in body composition. Related anti-inflammatory effects could
be mediated by increased insulin sensitivity and/or improved
concentrations of HDL-cholesterol, ROS or endothelial func-
tion, which all demonstrate anti-inflammatory actions(261),
and are related to both body fat and exercise. A systematic
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review addressed whether fitness or fatness has the greatest
impact on inflammatory factors(198). The review concluded
that both fitness and fatness are associated with systemic
inflammatory status, although the relative contributions of
both may be dependent on age, disease status and sex.
These determinants do most probably involve a strong back-
ground of low-grade inflammatory status, which consistently
is shown to determine any possible inverse association.
Although increasing physical activity may be an effective
therapy for weight loss and may also emerge as a promising
treatment for reducing overall inflammation, the magnitude
of the effect to produce clinically meaningful results in the
general population requires further research(200). Neverthe-
less, exercise is uniquely positioned to reduce inflammation,
and even small non-significant reductions in CRP levels may
contribute to clinical benefits by reducing cardiovascular and
metabolic risk(222).
A consideration of different approaches to identify
relationships between diet and its components and
markers of chronic low-grade inflammation
The following sections review the effects of dietary factors,
including dietary patterns, whole foods, individual nutrients
and other bioactive components on the markers of low-
grade inflammation described above. Due to the physiological
complexities detailed above, assessment of effects requires
careful attention to treatment interventions and study designs,
in the context of the endpoints described. Here, important
aspects of study design are briefly mentioned.
Epidemiological studies
Epidemiological studies, where available, are discussed for
each of the dietary factors. As mentioned above, body-
weight changes and exercise may have profound effects on
biomarkers of low-grade inflammation; therefore, adjustments
for BMI and activity level are critical. An accurate assess-
ment of the analysed dietary parameter is also necessary.
Although difficult to rectify, it is important to consider cultural
differences in food consumption habits, for example differ-
ences in coffee preparation procedure and brew strength
between the USA and Europe. Attention should also be
paid to the assessment of dietary patterns. For example, the
Mediterranean diet has been variously defined and scored as
inclusive or exclusive of fish, poultry, dairy, eggs, moderate
alcohol consumption and ratio of monounsaturated:saturated
fat. However, it is not clear whether these differences in
scoring would result in alternative conclusions being drawn,
and as such, this body of literature is best viewed in totality.
Intervention studies
Intervention studies, where available, are also discussed for
each of the dietary factors. The studies presented here
typically fall into three design categories: (1) chronic dietary
interventions in individuals with some degree of existing
low-grade inflammation, based on changes in markers
measured in fasting blood, sometimes in the context of
weight loss; (2) acute dietary interventions in which the
acute effect of a putative anti-inflammatory dietary treatment
is assessed against some background level of low-grade
inflammation; (3) challenge studies in which inflammation is
induced by either a dietary or exercise challenge, in the
presence or absence of a putative anti-inflammatory dietary
treatment. As with epidemiological studies, body weight and
activity levels require careful control and monitoring because
of their possible impact on low-grade inflammation. Chronic
interventions are most commonly either parallel-arm designs
or cross-over designs, and may be most relevant since
they directly evaluate the effect of the dietary component on
low-grade inflammation. However, acute intervention and
postprandial challenge studies may also provide valuable
insight, and postprandial inflammation has recently been
hypothesised to play an aetiological role in the progression
of CVD. Additionally, between-subject variations in bio-
markers of the inflammatory response can be controlled for
statistically in cross-over designs. In contrast to epidemiologi-
cal studies, which often have a large sample size and may
evaluate outcomes over a long duration, intervention studies
are most often relatively small and of short duration (hours
for acute studies; weeks to months for chronic studies).
Small studies can limit power to identify significant effects.
Another difficulty with intervention studies can be compliance
among subjects; although an ideal study design would include
actions to ensure compliance and would monitor this, such
approaches are not always considered. Lack of compliance
may limit the effectiveness of an intervention.
Dietary patterns and low-grade inflammation
For the purposes of this article, low-grade inflammation
was defined as elevated circulating concentrations of pro-
inflammatory cytokines, acute-phase proteins and adhesion
molecules, and low circulating concentrations of adiponectin.
Eating patterns
Studies on diet and disease have traditionally examined the
associations of individual nutrients, foods or food groups
with risk factors and health outcomes. However, this approach
has certain limitations: many nutrients are highly correlated,
and have synergistic or interactive effects; examination of
nutrients or foods singly may not provide enough statistical
power due to the small effect size; and the possibility of find-
ing significant associations by chance alone, due to multiple
testing, is large. In response to the challenges of the traditional
approach to understanding diet–disease relationships, more
recently, nutrition epidemiologists have studied dietary or
eating patterns that examine combinations of foods and nutri-
ents, in relation to health and disease(262,263). Dietary pattern
research is generally based on two kinds of methods: a priori
using diet scores; or a posteriori using data-driven techniques
such as factor analysis and cluster analysis(264–266).
Hypoenergetic diet. One diet-dependent but apparently
quite non-specific way of decreasing low-grade inflammation
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is energy restriction(267). Weight loss is accompanied by
decreased concentrations of circulating mediators of inflam-
mation, such as CRP, TNF-a, IL-6 and sICAM-1(155,268–270),
although it is difficult to dissect whether this effect is due to
the weight loss per se or to the nature of the diet used to
induce weight loss. On the other hand, it seems likely that
reduced secretion of pro-inflammatory mediators from adipo-
cytes or activated macrophages of adipose tissue contributes
to the effect of weight loss(31,36,65,67,142). However, energy
restriction itself may also play an anti-inflammatory role,
with key mediators of the effect being proteins of the sirtuin
and Forkhead box, sub-group O (FoxO) families which are
induced/activated during states of limited energy supply.
The sirtuins are NAD þ -dependent deacetylases of substrates
ranging from histones to transcriptional regulators. As a conse-
quence, metabolic efficiency is improved, cell defences
against stress are strengthened and inflammatory activities
are dampened, notably by decreasing the activation of
NF-kB(271–274). FoxO proteins are transcription factors which
regulate the expression of genes involved in energy homeo-
stasis, cell survival and inflammatory responses including
NF-kB(274–278). Early studies have shown that reduced
energy intake is paramount compared with the nature of
low-energy food, i.e. decreased concentrations of inflamma-
tory markers are observed with a low-energy, fat-rich as well
as with a low-energy, carbohydrate-rich diet(279). However, it
is conceivable that some dietary components are better regu-
lators of sirtuin or FoxO activity than others. Resveratrol, pre-
sent in red wine, was found to directly or indirectly interact
with sirtuins and promote their deacetylase activity. This led
to increased lifespan in model organisms and in animal
models(280,281). It is likely that dietary components will be
identified that mimic or counteract the anti-inflammatory
effects of energy restriction.
Mediterranean diet. The term Mediterranean diet refers to
a traditional dietary pattern characteristic of many parts of
Greece, Southern Italy, Southern Spain and elsewhere in the
Mediterranean region. The traditional Mediterranean diet is
rich in fruit, vegetables, whole-grains, legumes (beans), nuts,
fish and low-fat dairy products, with moderate consumption
of wine, and whose principal source of fat is olive
oil(282–286). Most studies have assessed the adherence to the
Mediterranean diet by assigning a score in relation to the con-
sumption of these foods. Others(284,285) have used modified
versions of this score by not considering certain food
groups, i.e. dairy products.
Observational studies have examined the association of the
Mediterranean diet with inflammatory markers in healthy per-
sons(282,283,285), and they generally report inverse correlations.
In a recent study(282) investigating psychological, behavioural
and biological risk factors for subclinical CVD in 345 middle-
aged male twins, an inverse association between adherence
to the Mediterranean diet and inflammation, as measured by
plasma IL-6 concentration, was noted. This association was
independent of several known cardiovascular risk factors,
and persisted when twins within pairs were compared,
suggesting that the results were not confounded by shared
environmental and genetic factors. Although a marginal
relationship between CRP concentration and the Mediterra-
nean diet was observed, this association was no longer signifi-
cant when other cardiovascular risk factors were considered in
the models. It is likely that IL-6 is a more sensitive marker of
chronic low-grade inflammation and that CRP reflects a
more downstream effect associated with IL-6. In a subsample
of the Nurses’ Health Study(285), a Mediterranean diet index
score was inversely associated with markers of inflammation
(circulating IL-6 and CRP) as well as markers of endothelial
dysfunction (the adhesion molecules sICAM-1, sVCAM-1 and
soluble E-selectin (sE-selectin)); these associations persisted
upon adjustment for traditional CVD risk factors. Similar find-
ings were reported in the ATTICA study, involving 1514 men
and 1528 women; specifically, subjects with greater adherence
to the Mediterranean diet (those in the highest tertile) had
17 % lower IL-6 and 20 % lower CRP concentrations, compared
with those in the lowest tertile in analyses that adjusted for
other cardiovascular risk factors(283). Although a marginal
association was noted between TNF-a and the Mediterranean
diet, it was not significant in adjusted models(283). In another
observational study with obese subjects (625 men and 712
women with abdominal adiposity), those with high CRP
levels (.3 mg/l) were less likely to adopt the Mediterranean
diet(287). The authors reported that adoption of the Mediterra-
nean diet in conjunction with moderate physical activity was
associated with a reduced likelihood of having high CRP
levels by 72 %, highlighting the potential importance of the
Mediterranean diet in diminishing inflammation. In subjects
at high risk for CVD, those with diabetes or with multiple
CHD risk factors, however, no association between the Medi-
terranean diet and CRP or adhesion molecule (sICAM-1 and
sVCAM-1) concentrations was seen(288). However, a significant
relationship between higher consumption of some typical
Mediterranean diet components (cereals, fruit, nuts and
virgin olive oil) and circulating inflammatory markers (IL-6)
and markers of endothelial function was noted in these
at-risk subjects.
Few intervention studies have been conducted to examine
the effect of consuming the Mediterranean diet on markers
of low-grade inflammation. In two cross-over studies invol-
ving short-term interventions (1–3 months) with healthy
subjects, differential effects of the Mediterranean diet on mar-
kers of inflammation (and endothelial dysfunction) were
observed. In the study by Ambring et al.(289), healthy subjects
received their typical Swedish diet for about 4 weeks, and a
Mediterranean-inspired diet for about 4 weeks in a random-
ised cross-over design, with 4 weeks of washout in-between.
A marked reduction in the number of leucocytes, including
monocytes, neutrophils and lymphocytes, and in the number
of platelets after 4 weeks of the Mediterranean diet was
noted, suggesting a lower inflammatory activity than during
the Swedish diet period. On the other hand, IL-6 and CRP con-
centrations did not change with the Mediterranean diet; the
authors speculated that the study may not have been powered
to detect those effects. In another study(290), twenty healthy
young males were provided three dietary interventions, each
lasting 4 weeks. First, all subjects consumed a diet high in
saturated fat, next they were randomly assigned to either
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of the two intervention diets: a Mediterranean-style diet
(MUFA-enriched diet, 22 % energy from MUFA) or a low-fat,
high-carbohydrate diet (,30 % energy from fat and 55 %
from carbohydrates). LDL was isolated and oxidised. Oxidised
LDL from subjects on either the Mediterranean diet or the
high-carbohydrate diet decreased TNF-a-induced VCAM-1
and E-selectin expression in human umbilical endothelial
cells in vitro. A consistent decline in inflammatory markers
has been observed in intervention studies involving obese
subjects or those with the metabolic syndrome. In a random-
ised controlled study with 120 pre-menopausal obese women,
the effects of a multidisciplinary approach (aiming at 10 %
weight reduction with a combination of a low-energy,
Mediterranean-style diet and increased physical activity)
were evaluated compared with a control group (given general
information about healthy choices and exercise)(111). The
intervention group received regular sessions (18 over a
2-year period) with a nutritionist to ensure compliance.
Significant reduction in several markers of inflammation
(CRP, IL-6 and IL-18) and an increase in adiponectin concen-
tration were noted in the Mediterranean diet group compared
with the control group. In a randomised controlled trial lasting
2 years, 180 subjects with the metabolic syndrome were
assigned either to a Mediterranean-style diet (instructions
were provided on increasing daily consumption of whole
grains, fruit, vegetables, nuts and olive oil) or to a control
group (prudent diet, with same macronutrient composition
as the Mediterranean diet)(284). After 2 years, body weight
decreased more in the intervention group and inflammatory
markers (CRP, IL-6, IL-7 and IL-18) decreased and endothelial
function improved, compared with the control group. Interest-
ingly, even after controlling for weight loss, the inflammatory
markers declined more in subjects following the Mediterra-
nean-style diet. In other related studies involving individuals
with the metabolic syndrome, a consistent reduction in CRP
concentration in the intervention group receiving the Mediter-
ranean diet has been shown(291,292). In the Prevencio´n con
Dieta Mediterra´nea study, 772 asymptomatic subjects at high
cardiovascular risk (diabetes or more than three CHD risk fac-
tors) were randomly assigned to a low-fat diet or one of two
Mediterranean diets(293). Those allocated to the Mediterranean
diets received nutritional education and either free virgin olive
oil, or free nuts for 3 months. Both Mediterranean diets were
beneficial in terms of significant reductions in serum IL-6,
sICAM-1 and sVCAM-1 concentrations, while CRP concen-
tration was reduced only in the Mediterranean diet sup-
plemented with olive oil. Taken together, the results from
these often large intervention studies strongly suggest that
Mediterranean diets can lead to reductions in chronic low-
grade inflammation and improvement in endothelial function,
thereby offering cardioprotective effects.
Vegetarian diets. Observational studies have compared
vegetarian with non-vegetarian diets in healthy subjects in
relation to inflammatory markers. Dietary patterns consistent
with vegetarianism were associated with lower concentrations
of markers of chronic low-grade inflammation and endothelial
function when compared with non-vegetarian diets(294–296). In
one study comparing a group of thirty Taoist adults who had
been vegetarian for 5–55 years (average 22 years) with a
group of thirty age- and sex-matched non-Taoist adults con-
suming a non-vegetarian diet, lower CRP concentrations
were noted in the former group(295). Specifically, plasma
CRP concentration averaged 0·77 and 1·30 mg/l in vegetarians
and non-vegetarians, respectively. Another study with a simi-
lar design comparing vegetarians with non-vegetarians also
found that the average CRP concentration was significantly
lower in the vegetarian group (0·72 v. 1·62 mg/l)(294). Similarly,
lower levels of the adhesion molecules sICAM-1 and sE-selec-
tin have been reported in those following a vegetarian v. a
non-vegetarian diet(296). Thus, these cross-sectional studies
suggest that a vegetarian-style diet can lead to lower chronic
low-grade inflammation than an omnivorous diet. However,
it is important to recognise that vegetarians may differ from
non-vegetarians in aspects of lifestyle other than diet such as
physical activity, smoking behaviour and socio-economic
class. Studies considering vegetables and fruits are described
in section ‘Vegetables and fruits’.
Eating patterns. The healthy eating index (HEI) was
developed by the US Department of Agriculture, based on
the Dietary Guidelines for Americans and the Food Guide
Pyramid(297). It has ten subcomponents: grains, fruits, vege-
tables, dairy, meats, fats, saturated fat, cholesterol, Na and
dietary variety. Individuals are assigned scores for each of
the ten components (from 0 to 10) based on their typical
intakes; the maximum value for the HEI being 100. Recently,
the HEI was revised as the Alternate HEI (AHEI) to focus on
healthier items in the Food Guide Pyramid food groups(298)
such as protein source, ratio of polyunsaturated:saturated
fats and cereal fibre, as well as cis- v. trans-fat. Additionally,
moderate alcohol consumption and long-term multivitamin
use are also considered in the AHEI. The Diet Quality Index
(DQI) is a composite score of an overall healthy diet that
reflects an individual’s adherence to the eight diet and
health recommendations of the National Academy of Science.
The revised DQI (DQI-R) is based on similar guidelines but
also includes Fe and Ca intakes(299).
Using the data from NHANES III on a representative
sample of the US population, Ford et al.(300) found a negative
correlation between the HEI and CRP concentration after
adjustment for several CVD risk factors including BMI and
waist:hip ratio; when stratified by sex this finding was signifi-
cant in women only. The authors noted that this association
was primarily driven by grain consumption. The authors
speculated that because HEI score was determined based on
dietary intake data collected by a 24 h recall, the possibility
of misclassification of individuals with respect to HEI status
could have attenuated the associations. In a study by Fung
et al.(285), the association of several diet-quality scores, such
as the HEI, AHEI, DQI-R and an alternate Mediterranean diet
index with various markers of inflammation, was evaluated
in a subsample of the Nurses’ Health Study (n 690 healthy
women). The key findings were that the AHEI and alternate
Mediterranean diet index scores were negatively associated
with CRP, IL-6, sE-selectin and sICAM-1 concentrations, and
that these associations persisted upon adjustment for potential
confounding variables including BMI. In contrast, the HEI and
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DQI-R did not correlate with any of the inflammatory markers
when potential confounders were taken into consideration in
the regression models(285). A more recent study evaluated the
impact of the AHEI among 1922 women from the Nurses’
Health Study (62 % of whom were overweight) who had no
history of diabetes or CVD on plasma inflammatory marker
concentrations(301). After adjustment for age and energy
intake, women with the highest adherence to the AHEI had
24 % higher median total adiponectin and 32 % higher
median high-molecular-weight adiponectin concentrations,
as well as 16 % lower resistin, 41 % lower CRP and 19 %
lower sE-selectin concentrations than did women with the
lowest adherence to the AHEI. These associations remained
significant after adjustment for potential confounders. Inverse
associations between the AHEI and CRP, sTNFR2, IL-6, sICAM-
1 and sVCAM-1 concentrations were evident, but they did not
remain significant after adjustment for BMI. In a small cross-
sectional study involving 114 ‘apparently healthy’ overweight
or obese postmenopausal women, Boynton et al.(302) found
little evidence of an association between dietary quality, as
measured by the HEI and DQI, and markers of inflammation
(CRP and SAA). Marginal associations were noted between
the DQI and these inflammatory markers. These associations
were, however, attenuated and no longer significant, after
adjusting for adiposity (percentage of body fat or BMI),
suggesting that the decrease in CRP or SAA concentration
seen with a higher-quality diet is most probably mediated by
obesity. The authors speculated that consuming a healthier
diet may lead to decreased adiposity, which in turn could
result in less low-grade inflammation.
Several studies have examined the relationship between
consuming a ‘prudent diet’ and markers of low-grade inflam-
mation. In one study, in 732 healthy women from the
Nurses’ Health Study aged 43–69 years, a prudent pattern
was characterised by higher intakes of fruit, vegetables,
legumes, fish, poultry and whole grains, and a Western pattern
was characterised by higher intakes of red and processed
meats, sweets, desserts, French fries and refined grains(303).
The prudent pattern was inversely associated with plasma
concentrations of CRP and sE-selectin after adjustment for
age, BMI, physical activity, smoking status and alcohol con-
sumption. The Western pattern showed a positive relationship
with CRP, IL-6, sE-selectin, sICAM-1 and sVCAM-1 after adjust-
ment for all confounders except BMI; with further adjustment
for BMI, the coefficients remained significant for CRP,
sE-selectin, sICAM-1 and sVCAM-1.Using data from the
Nurses’ Health Study, Schulze et al.(304) identified a dietary
pattern that was significantly associated with increased con-
centrations of CRP, IL-6, sTNFR2, sE-selectin, sICAM-1 and
sVCAM-1. This pattern, which was high in sugar-sweetened
soft drinks, refined grains, diet soft drinks and processed
meat but low in wine, coffee, cruciferous vegetables and
yellow vegetables, was also associated with an increased
risk of diabetes. Most recently, Hoebeeck et al.(305) evaluated
the relationship between adherence to food-based dietary
guidelines and inflammatory markers among 2524 healthy
Belgian men and women aged 35–55 years. The dietary
index consisted of three subscores (dietary quality, diversity
and equilibrium) according to adherence to the Flemish
food-based dietary guidelines, using data from a semi-
quantitative FFQ. Higher dietary scores were inversely associ-
ated with IL-6 concentration and leucocyte numbers in the
bloodstream. Nettleton et al.(306) examined relationships
between dietary patterns and markers of inflammation and
endothelial activation among 5089 non-diabetic participants
in the Multi-Ethnic Study of Atherosclerosis. In this study,
four dietary patterns were derived by using factor analysis.
The fats and processed meats pattern (fats, oils, processed
meats, fried potatoes, salty snacks and desserts) was positively
associated with CRP and IL-6 concentrations. The beans,
tomatoes and refined grains pattern (beans, tomatoes, refined
grains and high-fat dairy products) was positively related
to sICAM-1 concentration. In contrast, the whole grains
and fruit pattern (whole grains, fruit, nuts and green leafy
vegetables) was inversely associated with CRP, IL-6 and
sICAM-1 concentrations, while the vegetables and fish pattern
(fish and dark-yellow, cruciferous and other vegetables) was
inversely related to IL-6 concentration. There are few such
studies using data from outside of the USA or Europe.
A cross-sectional study of 486 healthy Iranian women aged
40–60 years identified dietary patterns by factor analysis and
related these to circulating markers of inflammation(307). The
healthy dietary pattern (high in fruits, vegetables, tomatoes,
poultry, legumes, tea, fruit juices and whole grains) was
inversely related to plasma CRP, sE-selectin and sVCAM-1 con-
centrations after controlling for potential confounders; with
further adjustment for BMI and waist circumference, the
associations remained significant for CRP and sVCAM-1. In
contrast, the Western dietary pattern score (high in refined
grains, red meat, butter, processed meat, high-fat dairy,
sweets and desserts, pizza, potatoes, eggs, hydrogenated
fats and soft drinks) was positively related to CRP, SAA,
IL-6, sICAM-1 and sVCAM-1 concentrations; however, after
additional control for BMI and waist circumference, the
associations remained significant only for SAA and IL-6.The
traditional dietary pattern (high in refined grains, potatoes,
tea, whole grains, hydrogenated fats, legumes and casserole)
was positively associated with the plasma IL-6 concentration
after controlling for BMI and waist circumference. Nanri
et al.(308) investigated the relationship between dietary pat-
terns and circulating CRP concentration in 7802 Japanese
men and women with CRP ,3 mg/l. The dietary patterns
were derived from principal component analysis of the fre-
quency of consumption of forty-nine food items ascertained
by the FFQ. The following four dietary patterns were ident-
ified: healthy, high-fat, seafood and Westernised breakfast
patterns. The healthy dietary pattern, characterised by high
intakes of vegetables, fruits, soya products and fish, was inver-
sely related to CRP concentrations, even after adjustment for
age, BMI, smoking, alcohol consumption and physical activity
in both men and women. Neither the high-fat dietary pattern
nor the Westernised breakfast pattern was related to CRP
concentrations. Most recently, the relationship between two
dietary patterns (Healthy and Western), which were derived
by principal component analysis using data collected by a
FFQ from subjects in the Atherosclerosis Risk in Communities
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Study, and markers of inflammation has been described(309).
The measures of inflammation were quantified by flow
cytometry in fresh whole blood from 1101 white adults.
After multivariable adjustment, monocyte LPS receptor
(CD14), monocyte TLR-2 and platelet glycoprotein IIb
(CD41) showed inverse associations with the healthy dietary
pattern. In contrast, the Western dietary pattern was positively
associated with CD41 and platelet–granulocyte aggregates.
Taken together, these studies suggest that healthy eating
patterns are associated with lower concentrations of markers
of chronic low-grade inflammation.
Whole foods
Whole grains/refined grains. Published studies have so far
investigated a narrow and low range of whole grain intakes,
which limits the interpretation of associations between whole
grain intake and markers of low-grade chronic inflammation.
Observational studies (Table 3)(300,310–314) including data from
NHANES III have suggested that a high intake of whole grain
is inversely associated with plasma CRP concentration (quintile
(Q) 1 , 3·5 servings/d, Q5 . 9·7 servings/d)(300). In contrast,
Jensen et al.(310) reported no association between a moderate
whole grain intake (Q1 8·2 g/d, Q5 43·8 g/d) and markers of
inflammation (CRP, IL-6 and fibrinogen) in the Health Pro-
fessionals’ Follow-Up Study. However, bran intake correlated
inversely with CRP concentration and germ intake with IL-6 con-
centration(310). Data from the Nurses’ Health Study showed
lower CRP and sTNFR2 concentrations in diabetic women
with a moderate intake of whole grain compared with those
with a low intake(314). In another study with diabetic males
(n 780; from the Health Professionals’ Follow-Up Study),
Qi et al.(315) showed that cereal fibre was positively associated
with adiponectin concentration after controlling for a number
of confounding factors. A higher intake of whole grain (low
0·8 servings/d, high 2·1 servings/d) within a Mediterranean
diet in diabetic women was associated with increased adipo-
nectin concentration(312). Data from the Multi-Ethnic Study of
Atherosclerosis (MESA) showed a higher whole grain intake
(Q1 0·02 servings/d, Q5 1·39 servings/d) to be associated with
lower CRP concentration in elderly subjects(311).
Evidence from intervention studies (Table 4)(111,316–320)
includes a study whereby overweight and obese subjects con-
sumed a hypoenergetic diet with or without whole-grain
foods. CRP concentration decreased by 38 % (CRP at baseline
5·9–6·0 mg/l) in the whole-grain group independent of the
observed weight loss(319). However, plasma concentrations
of IL-6 and TNF-a and PAI-1 activity did not change within
the 12-week-study period. Based on the outcome of this
study, the authors concluded that the changes seen in CRP
concentration with a whole-grain diet were not part of a sys-
temic anti-inflammatory effect(319). In a study from Sweden
with a similar design but only a 6-week intervention (whole-
grain v. refined-grain products), the whole grain intake was
not associated with changes in the concentrations of CRP
and IL-6 or in PAI-1 activity of moderately overweight sub-
jects(316). Baseline CRP concentration (2·03–2·86 mg/l) and
BMI were much lower than in the previous study, which
may explain the different outcomes between these studies.
Recent intervention trials with whole grain (60–120 g/d) or
wholemeal intake (30–40 g/d) and comparable CRP baseline
concentrations also did not observe any changes in plasma
markers of inflammation(317,320). In the study by Brownlee
et al.(317), whole-grain products did not substitute refined-
grain products but were consumed in addition to the refined
products. Bioprocessing of whole wheat affected the anti-
inflammatory potential in a human intervention study when
compared with unprocessed whole wheat(321). Bioprocessing
modulated the ratio of pro-inflammatory:anti-inflammatory
cytokines during 24 h after the intake of 300 g whole wheat
bread. This study suggests that subtle changes in the proces-
sing of whole grains may be relevant for their anti-inflamma-
tory activity, which could in part explain the contradictory
findings of the human intervention studies.
Replacing a refined-wheat flour pizza by a similar pizza
prepared from whole-wheat flour resulted in a decreased
postprandial concentration of the pro-inflammatory cytokine
IL-18 in both non-diabetic and diabetic subjects(318).
In summary, whole grain intake appears to inversely associ-
ate with markers of low-grade inflammation. Processing status
of whole-grain products should be more precisely defined in
future studies. Potential mechanisms still have to be eluci-
dated, as well as the active constituents which may include
dietary fibre, minerals, vitamins and phytochemicals such as
lignans and phenolic acids.
Vegetables and fruits. A number of cross-sectional studies
have investigated the association between vegetable and fruit
intake and biomarkers of inflammation (Table 5)(288,322–330).
Study participants included healthy, normal-weight adults as
well as overweight/obese adults with associated diseases.
Each study applied different criteria to stratify the intake of
vegetables and fruits which makes it difficult to compare the
outcomes. Of the ten cross-sectional studies, seven reported
an inverse association between a high intake of vegetables
and fruits, either in combination or alone, and blood CRP con-
centrations(322–325,327–329). In one study, no association with
CRP was observed(288), while in a second study, an inverse
association was seen in men but not in women(327). For the
other biomarkers reported, the outcome is less consistent.
A recent study reported that a high intake of vegetables and
fruits was associated with a lower peripheral blood mono-
nuclear cell gene expression for several pro-inflammatory
cytokines and adhesion molecules(326). An important obser-
vation is that besides the quantity of total intake of vegetables
and fruits, the variety consumed in a given time has a signifi-
cant impact on these biomarkers. A high number of varieties
of vegetables and fruits were inversely correlated with blood
CRP levels(322). This suggests that plant-specific constituents
of vegetables and fruits such as the phytochemicals may con-
tribute to the anti-inflammatory activities.
A number of intervention studies have investigated the
impact of vegetables and fruits in total or of specific varieties
on biomarkers of inflammation (Table 6)(331–346). Of the four
studies focusing on vegetables and fruits as a food group,
three reported a reduction in blood concentrations of different
biomarkers of inflammation(318,342,345), while one study did
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not find any significant effect(336). In twelve studies with a
specific focus on a single variety of vegetable or fruit, incon-
sistent results were reported. Most studies have used fruits
or fruit extracts high in polyphenols. Results from such studies
suggest an anti-inflammatory effect; however, mostly, only a
single biomarker was affected, and never the complete set
of inflammation biomarkers investigated(331–334,337–340,346).
In conclusion, current evidence for specific effects of single
vegetable and fruit varieties is not convincing, while a high
overall intake of vegetables and fruits seems to be associated
with a lower state of inflammation.
Soya. Several randomised controlled intervention trials
have shown that supplementation with different quantities
of soya protein did not affect markers of inflammation
(CRP, IL-6, IL-18, sICAM-1, sVCAM-1 and sE-selectin)
(Table 7)(345,347–364). Variations in soya protein isoflavone con-
tents did not modulate the outcome in these studies. In one
study, reduced plasma CRP, TNF-a and IL-18 concentrations
were reported in postmenopausal Iranian women with the
metabolic syndrome consuming soya nuts but not soya pro-
tein(347). The major difference between soya protein and soya
nuts (comparable contents of isoflavones) was a much higher
content of PUFA in the soya nuts, suggesting that rather than
soya-specific constituents, the increased intake of PUFA may
be responsible for the reduction in biomarkers of inflam-
mation(347). The same group investigated in diabetic patients
with nephropathy the anti-inflammatory effect of textured
soya protein compared with animal protein after 4 years of
intake. Consumption of soya protein significantly lowered
plasma concentrations of CRP(348). In another study investi-
gating soya nuts in normotensive and hypertensive postmeno-
pausal women, no effect on CRP, IL-6, sICAM-1 or matrix
metalloproteinase-9 concentrations was observed compared
with the control diet(361). However, in hypertensive women,
levels of sVCAM-1 were significantly lower after soya nut
consumption(361). Again, the increased PUFA intake may have
caused this effect. Long-term soya exposure did not affect
CRP, IL-6, leptin and adiponectin concentrations in postmeno-
pausal women(357), or CRP, IL-6, leptin, adiponectin, MCP-1 or
MIP-1b concentrations in men(365). Short-term soya inter-
vention in postmenopausal women with or without exercise-
induced inflammation had no effect on IL-1b, IL-6 or TNF-a
concentrations(349,350). Among men with prostate cancer
undergoing androgen deprivation therapy, soya intervention
had no effect on the concentrations of several inflammatory
markers(366). Overall, these data suggest that soya protein
does not affect markers of inflammation, that soyabean
processing may affect the anti-inflammatory potential of
soyabean constituents and that the health status of the study
subjects might determine the anti-inflammatory efficacy of
specific foods.
Nuts. To date, only few studies have investigated the
effect of nuts on inflammatory markers. The MESA reported
that a high intake of nuts and seeds ($5 times/week) com-
pared with a low intake (rarely or no consumption) was
associated with lower plasma concentrations of CRP, IL-6 and
fibrinogen(367). In contrast, data from the Nurses’ Health Study
suggest that nut intake is not associated with inflammatory T
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markers including sTNFR2, CRP, fibrinogen, sICAM-1 and
sE-selectin(368). An 8-week intervention with walnuts or cash-
ews (63–108 g/d) in subjects with the metabolic syndrome
observed no effect on serum CRP concentrations(360). A pista-
chio intervention (60–100 g/d providing about 20 % of total
energy) for 4 weeks in healthy young subjects had no effect
on plasma CRP or TNF-a concentrations, while the concen-
tration of IL-6 was significantly reduced(369). A recent interven-
tion study with two doses of almonds (10 and 20 % of total
energy) in healthy adults reported reduced serum concen-
trations of sE-selectin and CRP, but IL-6 and fibrinogen were
not affected(370). No clear dose–response relationships were
observed. In contrast, an earlier study in hyperlipidaemic
subjects providing two doses of almonds did not observe
an effect on CRP concentrations(356). A systematic review on
walnut consumption and inflammatory markers also reported
inconsistent results for plasma CRP, while walnuts added to a
Mediterranean diet resulted in significantly lower sVCAM-1
concentrations(371). This suggests that rather than a general
anti-inflammatory effect, walnuts may exert anti-inflammatory
effects primarily in the endothelium. Major contributors to any
anti-inflammatory activity of nuts are likely to include PUFA,
Mg and phytochemicals including ellagic acid(372).
Fish. Increased frequency of fish consumption was associ-
ated with lower CRP and IL-6 concentrations in a cohort of
727 adults in the USA(373). sICAM-1 and sE-selectin concen-
trations also decreased but the effect of fish consumption was
weaker than what was observed for CRP and IL-6. sTNFR2 con-
centration was not associated with fish consumption. A study in
379 adults in Denmark reported a lack of association between
fish consumption and CRP concentration, even though the
subjects displayed a wide range of intakes including very high
intakes (e.g. over 30 % of subjects ate fish more than once
per d)(374). Data from 5037 adults in the NHANES showed no
association of fish consumption with CRP concentration after
adjusting for a range of confounders(375). In this study, 25 % of
subjects consumed fish more than 3 times per month. Most
recently, fish consumption among a cohort of 4077 Australian
adults was reported not to be associated with CRP concentration
before or after adjustment for confounders(376). In contrast to
these findings, a study in 3102 Greek adults reported that fish
consumption was ‘dose-dependently’ associated with lower
CRP, IL-6, TNF-a and SAA concentrations and white blood cell
counts; individuals consuming .300 g fish/week (n 259; 9 %)
had significantly lower concentrations of CRP (233 %), IL-6
(233 %), TNF-a (221 %), SAA (228 %) and leucocytes
(24 %) than seen in individuals not consuming fish (n 319;
11 %)(377). It is possible that the observations of Zampelas et al.
may be due to greater fish consumption than in the other
populations studied and/or to the type of fish consumed. No
studies have discriminated between consumption of lean v.
fatty fish. A 4-week intervention study with herring (150 g/d,
5 d/week) in overweight and obese adults in Sweden (n 13)
reported a trend towards lower CRP concentration compared
with the concentration seen when the subjects consumed
a reference diet, but the 30 % reduction in CRP was not sig-
nificant(378). The lack of statistical significance of the effect
seen may be due to the small sample size.T
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Tea. A cross-sectional study from Japan reported no
relationship between green tea consumption and the concen-
trations of several inflammatory markers(379), while a cross-
sectional study from Belgium detected significantly lower
CRP and SAA concentrations in regular tea drinkers after multi-
variate analysis(380). The effect of tea consumption (green or
black tea) has been investigated in several small intervention
studies usually with a fairly short duration (Table 8)(381–389).
Most studies indicate that tea consumption has no significant
effect on the markers of inflammation reported(382–386,388,389).
However, a longer supplementation period of 6 weeks with
black tea in healthy non-smoking men reduced plasma CRP
concentrations significantly(380,387). Overall, there are no con-
sistent data that tea consumption (black or green) has a ben-
eficial effect on inflammatory status, but studies of longer
duration than those currently reported need to be performed.
The modest or even absent effects of tea on inflammatory
and oxidative stress markers in vivo are surprising in view
of the potent inhibitory effects of tea components such as
catechins on the expression of pro-inflammatory mediators
in vitro (390–392). This may be due to the fact that the majority
of tea catechins undergo methylation, glucuronidation and
sulfation during uptake which may limit bioavailability(393).
Furthermore, studies in vitro have often used catechin con-
centrations .10mM, whereas plasma concentrations of cate-
chins after ingestion of tea rarely exceed 1mM(394).
Coffee. Habitual coffee consumption was analysed for
association with markers of low-grade inflammation in cross-
sectional epidemiological studies which yield conflicting
results (Table 9)(304,395–398). Consumption of decaffeinated
coffee was not associated with changes in systemic levels of
soluble adhesion molecules, but CRP concentrations were
lower in decaffeinated coffee drinkers in one of the two
studies(396). The contradictory findings from observational
studies may reflect the fact that coffee contains a mixture
of bioactives with divergent effects on physiology(399–403).
A recent intervention study providing two doses of coffee
(4 and 8 cups of filtered coffee/d) in the same individuals
confirmed in part the observations from the cross-sectional
studies. While IL-18 (decreased) and adiponectin (increased)
were significantly modulated by coffee consumption, concen-
trations of CRP, leptin, SAA, IL-6, MIF and IL-1ra were not
affected(404). No dose–response relationship was seen in
this study. Plasma caffeine concentrations were positively
associated with plasma adiponectin concentrations(404).
Taken together, the available data do not allow a firm con-
clusion as to whether coffee consumption modulates low-
grade inflammation.
Cocoa. Cocoa has a high content of monomeric (epi-
catechin and catechin) and oligomeric (procyanidin)
flavanols(405–407). These latter polymeric fractions are present
in higher concentrations/amounts in cocoa compared with
other flavanol-rich foods such as red wine or green
tea(408,409). Thus, certain cocoa-based products are rich in
flavanols(410,411), some of which have been found in model
systems to possess potential anti-inflammatory activities. How-
ever, the effect of cocoa flavanols and their related procyani-
dins appears to be related to the degree of polymerisation,T
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Table 6. Intervention studies investigating the effect of vegetable and fruit intake on markers of low-grade inflammation
Subjects n (sex) Age (years) Intake Study design and duration Effect on low-grade inflammation Reference
Healthy 13 (M)
12 (F)
23–40 High-fat meal
v. high-fat meal þ 400 g of vegetables
Single meal, short term # PAI-1 335
Healthy 6 (M)
6 (F)
Mean 22 500 ml/d of high-pressure orange juice Randomised, open label,
uncontrolled; 14 d
¼ CRP 343
Healthy 6 (M)
6 (F)
Mean 22 500 ml/d of vegetable soup Randomised, open label,
uncontrolled; 14 d
# MCP-1, PGE2
¼ TNF-a, IL-6, IL-1
342
Healthy 5 (M)
13 (F)
19–52 196 g/10 MJ v. 810 g/10 MJ of
vegetables þ fruit
Randomised, controlled,
parallel; 6 weeks
¼ CRP, sICAM-1, sP-selectin 336
Obese pre- and
postmenopausal women
24 (pre-)
20 (post-)
Mean 38 (pre-)
Mean 58·5 (post-)
36 g/d of lyophilised grape powder Randomised, controlled,
parallel; 4 weeks
# TNF-a, ¼ IL-6, CRP 346
Healthy 63 (M) 31–32 2, 5 or 8 servings/d of vegetables þ fruit Randomised, open label,
parallel; 4 weeks
# CRP with high intake
¼ IL-12, TNF-a
345
Overweight 25 (M)
29 (F)
Mean 49 Garlic powder (2·1 g/d) ( ¼ 5·2 g fresh garlic)
v. placebo
Randomised, double blind,
controlled; 3 months
¼ CRP, TNF-a, sICAM-1,
sVCAM-1, sE-selectin,
fibrinogen
344
Haemodialysis patients 4 (M)
6 (F)
100 ml/d of red grape juice Randomised, open label,
uncontrolled; 3 weeks
# MCP-1
¼ CRP, sICAM-1, sVCAM-1
332
Healthy 18 (M/F) 45–61 280 g/d of cherries Randomised, open label,
uncontrolled; 28 d
# CRP, RANTES
¼ IL-6
339
Healthy 61 (F)
59 (M)
40–74 300 mg/d of anthocyanins ( ¼ 100 fresh
bilberries) v. placebo
Randomised, controlled,
parallel; 3 weeks
# RANTES, IL-8, IFN-a
¼ CRP, IL-1, IL-6, TNF-a, MCP-1
337
Healthy 180 (M/F) 19–50 28 g/d of a frozen seabuckthorn
puree v. placebo
Randomised, controlled,
parallel; 3 months
# CRP 340
Patients with
peripheral arterial disease
47 (M/F) 57–61 250 ml orange juice þ 250 ml blackcurrant
juice v. placebo
Randomised, open label,
uncontrolled; 28 d
# CRP
¼ IL-6, PAI-1
334
Healthy postmenopausal
women
52 Mean 58 500 mg/d of elderberry extract ( ¼ 25 g/d
elderberries) v. placebo
Randomised, controlled,
parallel; 12 weeks
¼ CRP, IL-6, TNF-a, sTNFR1
and 2, RANTES
333
Metabolic syndrome 48 (M/F) Mean 52 (M)/48 (F) 960 ml/d water with 50 g/d of
freeze-dried blueberries ( ¼ 350 g/d fresh
blueberries) v. 960 ml/d water
Randomised, controlled,
parallel; 8 weeks
¼ CRP, sICAM-1, sVCAM-1,
IL-6, adiponectin
331
Elevated risk for CVD 62 (M/F) Mean 53 330 ml/d of bilberry juice diluted to 1 litre of
water v. water alone
Randomised, controlled,
parallel; 4 weeks
# CRP, IL-6, IL-15, MIG
¼ WBC count, IL-1, IL-1ra,
MCP-1, RANTES
" TNF-a
338
Healthy overweight 24 (M) Mean 56 500 ml/d of orange juice v. control drink Randomised, controlled,
parallel; 4 weeks
¼ CRP, IL-6, sICAM-1, sVCAM-1 341
M, male; F, female; # , decreased; PAI-1, plasminogen activator inhibitor-1; ¼ , no effect on; CRP, C-reactive protein; MCP-1, monocyte chemoattractant protein-1; sICAM-1, soluble intercellular adhesion molecule-1; sP-selectin,
soluble P-selectin; sVCAM-1, soluble vascular cell adhesion molecule-1; sE-selectin, soluble E-selectin; RANTES, regulated on activation, normal T expressed and secreted; IFN, interferon; sTNFR, soluble TNF receptor;
MIG, monokine-induced by IFN-g; WBC, white blood cell; IL-1ra, IL-1 receptor antagonist; " , increased.
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Table 7. Intervention studies investigating the effect of soya intake on markers of low-grade inflammation
Subjects n (sex) Age (years) Intake Study design and duration Effect on low-grade inflammation Reference
Hypercholesterolaemic
and postmenopausal
24 (F) 55 (SD 5) 25 g/d of soya protein v. milk protein Randomised, double blind,
controlled; 6 weeks
¼ sIL-2R, sE-selectin, sP-selectin,
sICAM-1, sVCAM-1
351
Healthy postmenopausal 50 (F) 50–75 40 g/d of soya protein v. casein Randomised, double blind,
controlled; 3 months
¼ CRP 363
Hypercholesterolaemics 32 (M/F) 57–59 25 g/d of soya protein v. milk protein Randomised, double blind,
cross-over; 6 weeks
¼ CRP, IL-6 355
Healthy postmenopausal 55 (F) 47–72 40 g/d of soya protein low
or high in isoflavones
Randomised, double blind,
controlled; 6 weeks
¼ CRP 354
Healthy and overweight 35 (M) 20–40 32 g/d of soya protein v. milk protein Randomised, double blind,
controlled; 57 d
¼ CRP 359
Healthy postmenopausal 52 (F) 50–65 706 ml/d of soya milk v. cows’ milk Randomised, double blind,
controlled; 14 d
¼ CRP, TNF-a 362
Postmenopausal with the
metabolic syndrome
42 (F) DASH diet with 1 serving/d of meat,
or soya protein or roasted soya nuts
Randomised, double blind,
controlled; 14 d
Soya protein: # CRP,
¼ sE-selectin
Soya nuts: # sE-selectin,
IL-18, TNF-a, CRP
347
Healthy postmenopausal 34 (F) 47–69 26 g/d of soya protein v. milk protein Randomised, double blind,
cross-over; 6 weeks
¼ CRP, sE-selectin,
sVCAM-1, sICAM-1
353
Hypercholesterolaemics 28 (M/F) .50 37·5 g/d of protein from whole soyabeans,
soyaflour, soyamilk or animal proteins
Randomised, double blind,
cross-over; 6 weeks
¼ CRP 358
Normotensive and
hypertensive
postmenopausal
60 (F) Mean ,55 25 g/d of soya protein (nuts)
v. non-soya protein
Randomised, double blind,
cross-over; 8 weeks
Normotensives: ¼ CRP,
IL-6, sICAM-1, sVCAM-1
Hypertensives: ¼ CRP,
IL-6, sICAM-1, # sVCAM-1
361
Healthy postmenopausal 75 (F) 46–74 20 g/d of soya protein v. milk protein Randomised, double blind,
controlled; 12 weeks
¼ TNF-a, IL-6, " adiponectin 352
Normal weight and obese
pre-menopausal
183 (F) Mean 43 2 servings/d of soya foods v. regular diet Randomised, controlled; 2 years ¼ CRP, IL-6, adiponectin 357
Healthy postmenopausal 31 (F) Mean 54 3 cups/d of soya milk v. low-fat cows’ milk Randomised, single blind,
controlled; 4 weeks
¼ TNF-a, IL-1b, IL-6 349, 350
Overweight and obese 20 (M/F) Mean 31 3 servings/d of soya milk v. cows’ milk Randomised, double blind,
cross-over; 28 d
¼ CRP, TNF-a, IL-6, IL-15,
MCP-1, adiponectin
364
Type 2 diabetics with
nephropathy
41 (M/F) Soya protein diet v. animal protein diet Longitudinal randomised; 4 years # CRP with soya protein diet 348
Obese with the metabolic
syndrome
64 (M/F) Mean 45 Walnut- or cashew nut-enriched
diet v. control diet
Randomised, controlled; 8 weeks Cashew nuts: " plasma glucose,
¼ lipid profiles, serum
fructosamine, blood pressure,
uric acids, S-hs CRP
360
Healthy hyperlipidaemic 41 (M/F) Mean 62 High- and low-isoflavone soya
diet v. control diet
Randomised, cross-over; 3 months Isoflavone: # blood lipids,
apolipoprotein B, homocysteine,
systolic blood pressure in men,
" urinary levels of daidzein,
glycitein, genistein, equol,
O-desmethylangolensin
356
F, female; ¼ , no effect on; sIL-2R, soluble IL-2 receptor; sE-selectin, soluble E-selectin; sP-selectin, soluble P-selectin; sICAM-1, soluble intercellular adhesion molecule-1; sVCAM-1, soluble vascular cell adhesion molecule-1;
CRP, C-reactive protein; M, male; # , decreased; " , increased; MCP, monocyte chemoattractant protein; S-hs CRP, serum high-sensitivity C-reactive protein; DASH, dietary approaches to stop hypertension.
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and opposing effects on inflammatory cytokine production in
vitro of low- and higher-degree of polymerisation flavanols
have been reported(412,413). Because of the focus on in vitro
exploration of the effects of cocoa flavanols, there is a need
for well-designed human studies, using cocoa properly
characterised in terms of flavanol content. In an Italian study
of over 10 000 people, of whom half were free of any chronic
disease, 1317 people reported having eaten any chocolate
during the past year; 824 ate chocolate regularly in the form
of dark chocolate only(414). Regular consumption of small
doses of dark chocolate seemed to decrease inflammation:
after adjustment for multiple confounders, dark chocolate con-
sumption was inversely associated with CRP concentration.
Serum CRP concentrations were 1·32 (1·26–1·39 mg/l) in cho-
colate non-consumers and 1·10 (1·03–1·17 mg/l) in consu-
mers. A J-shaped relationship between dark chocolate
consumption and serum CRP was observed; consumers
of up to 1 serving (20 g) of dark chocolate every 3 d had
significantly lower serum CRP concentrations than non-
consumers or those consuming more than 20 g chocolate
per d. In a small uncontrolled intervention study, healthy
subjects (n 25) consumed dark chocolate (36·9 g/d) and a
cocoa powder drink (30·95 g powder/d) for 6 weeks; there
was no change in concentrations of CRP, TNF-a, IL-1b, IL-6
or soluble P-selectin (sP-selectin)(415). Another small (n 28),
uncontrolled intervention study with dark chocolate for 1
week found a reduction in CRP concentration in women but
not in men(416). Most recently, Monagas et al.(417) reported
the effect of a 4-week randomised cross-over trial of 40 g
cocoa powder in skimmed milk daily v. skimmed milk in
forty-two older subjects: serum concentrations of sICAM-1
and sP-selectin were lower after the cocoa powder interven-
tion. Thus, there is some evidence that cocoa and cocoa-rich
foods reduce low-grade inflammation.
Alcohol. The regular consumption of alcohol-containing
beverages such as wine or beer has been reported to be
inversely associated with several markers of low-grade inflam-
mation, in a dose-dependent manner: i.e. moderate daily
intake (1–2 drinks/d) was often found to be associated with
decreased concentrations of inflammatory markers, although
this was not the case in all studies (Table 10) (418–432).
The short-term effect of alcohol intake on markers of low-
grade inflammation has been studied in intervention trials
which either determined acute effects during the next hours
following ingestion or changes compared with baseline after
2–4 weeks of daily alcohol consumption (Table 11)(433–448).
Although most studies were of small size, findings were
quite consistent in that there was little change in low-grade
inflammation in the hours following alcohol intake. In one
study, a decrease in NF-kB activation was reported after con-
suming a fat-rich meal when red wine was also consumed
compared with consuming the fat-rich meal(438). In general,
findings are fairly similar for trials with wine, beer, vodka or
ethanol (see Table 11). After 2–4 weeks of daily intake of
alcoholic beverages, changes in low-grade inflammation
were noted in five out of eight trials, with decreases in con-
centrations of CRP, cytokines and soluble adhesion molecules,
and an increased concentration of adiponectin (see Table 11).
These effects were seen in trials with white or red wine, or
beer. The three ‘negative’ trials(433–436) used red wine or
beer. Some variation of outcome between trials is to be
expected, notably because the lifestyle and characteristics of
participants will not be identical between trials, in particular
with regard to the local diet and the amount of daily physical
activity. Nevertheless, when taken together, these studies
suggest some beneficial long-term effects of moderate daily
consumption of wine or beer on low-grade inflammation. It
is not clear whether such effects are to due to the alcohol con-
tent of the beverages tested, or to other components, such as
phenolic compounds in these fermented beverages.
Process-related compounds: advanced glycation end
products and advanced lipoperoxidation end products
Introduction
Humans have been using fire to cook food for thousands
of years. They used boiling, baking, broiling, roasting, grilling
or frying to make food more hygienic, digestible, nutritive
and durable, and particularly to improve its flavour, aroma
and texture. Despite man’s long history of exposure to
heated food, the demonstration that the Maillard reaction
also occurs and is associated with ageing and age-related
conditions, such as diabetic complications, atherosclerosis,
Alzheimer’s disease and hypertension, has raised the question
whether dietary Maillard reaction products (MRP) might rep-
resent a risk to human health. A plausible mechanism for
adverse health effects of dietary MRP could be their potential
promotion of a state of low-grade inflammation. In fact, con-
sumption of a Western diet rich in these products was found
to correlate with impaired glucose metabolism, insulin resist-
ance and increased risk of cardiovascular and renal disease
associated with the metabolic syndrome and related con-
ditions(449,450). However, although excellent work has been
published in the past few years, it is still unresolved whether
MRP are causally involved in the aetiology of these con-
ditions(451–453). In particular, whether the potential harm of
a Western diet is mainly due to the increased intake of Maillard
compounds produced by heating of carbohydrate- and/or
lipid-rich food or rather to the excess intake of energy, refined
sugars and saturated fats, together with the lower intake of
fresh fruits and vegetables, can be debated. Alternatively,
other factors generated by thermal treatment of food or
the thermal destruction of vitamins, polyphenols and anti-
oxidants during food processing could also contribute to
adverse health effects.
Advanced glycation end products and advanced
lipoxidation end products
Advanced glycation end products (AGE) are a family of
heterogeneous, partly uncharacterised compounds that
encompass both pre-melanoidins and melanoidins. Pre-
melanoidins are not coloured and in general exhibit no
fluorescence, whereas melanoidins are yellow to brown and
are often fluorescent. The pre-melanoidins include uncoloured
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non-cross-linking AGE such as pyrraline, carboxymethyllysine
and carboxyethyllysine(454,455). The melanoidins include all
the fluorescent cross-linked AGE formed in the ‘non-enzy-
matic browning reaction’, such as pentosidine, and crossline,
but also non-fluorescent cross-linked AGE such as glyoxal
lysine dimer, methylglyoxal lysine dimer and the alkyl
formyl glycosyl pyrroles, formed by the reaction between
two sugar molecules with a single lysine residue, and argi-
nine-lysine imidazole, believed to be an intermolecular
cross-link. In addition, some compounds that are not AGE in
the strict sense are sometimes also considered as AGE.
These include the products of the Amadori rearrangement
such as fructoselysine (formed with glucose) and the unstable,
reactive dicarbonyl intermediates formed by the breakdown of
sugars or Amadori intermediates, which may be included in
the pre-melanoidins. AGE accumulate in the circulation
under several physiological and pathological conditions,
including diabetes and related disorders. In addition, circulat-
ing AGE accumulate when renal function is impaired(456–459).
AGE are formed within the body (endogenous AGE) due to at
least three mechanisms(460):
(1) Enhanced carbohydrate (and/or lipid) substrate avail-
ability, such as in hyperglycaemia (and/or hyper-
lipidaemia), which favours the nucleophilic addition of
a carbonyl group from a reducing sugar to a free amino
group of a protein (protein glycation) to form a reversible
Schiff’s base, which then rearranges to the more stable
ketoamine or Amadori product and subsequently,
through dicarbonyl intermediates such as 3-deoxygluco-
sones, to the irreversible AGE.
(2) Increased oxidative metabolism, such as in the presence
of transition metals and oxidative stress, which cause
auto-oxidation of glucose (auto-oxidative glycation)
or Amadori products (glycoxidation) via formation of
dicarbonyl compounds, such as glyoxal.
(3) Increased non-oxidative metabolism, with accumulation
of reducing sugars other than glucose, such as in the
case of increased glucose flux through the glycolysis
and polyol pathway (intracellular glycation) and/or
thiamin deficiency, which result in the formation of the
AGE precursor methylglyoxal.
AGE may also be derived from food(454,461) or tobacco(462).
AGE are formed during cooking and food processing pro-
cedures, and could accumulate in the body after intestinal
absorption. It has been suggested from experimental
animal models and studies in both healthy and type 2 diabetic
subjects that dietary AGE represent a significant source of cir-
culating and tissue AGE, although the absorption of individual
AGE from food is largely unknown(463). Little is known about
possible tissue deposition of food-derived AGE but in healthy
animals, it has been shown that AGE are rapidly and comple-
tely excreted(464,465). Finally, accumulation of both endogen-
ous and exogenous AGE may be favoured by reduced
kidney clearance as in the case of renal failure(466) and by
impaired detoxification caused by the utilisation of cofactors
of detoxifying enzymes.T
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The so-called advanced lipoxidation end products (ALE) are
similar to AGE but, rather than originating from sugars and sugar
breakdown products, ALE are derived from lipid oxidation(467).
Metal-catalysed oxidation of unsaturated lipids such as
PUFA and cholesterol results in the formation of lipid hydroper-
oxides and oxycholesterols, respectively. Lipid hydroperox-
ides, in the presence of metal ions or at high temperature,
form epoxyhydroperoxides, ketohydroperoxides and cyclic
peroxides, which decompose to low-molecular-weight break-
down products such as aldehydes, ketones or alcohols, or con-
dense to polymers. Malondialdehyde and 4-hydroxy-2-nonenal
are the main aldehydes generated during lipid peroxidation of
n-6 PUFA(468), whereas 4-hydroxy-2-hexanal is the predomi-
nant compound derived from the oxidation of n-3 PUFA(469).
Reactive lipid peroxidation products can form ALE by reacting
with amino groups of proteins to generate labile or stable
adducts or cross-links in protein, some of which may be
coloured or fluorescent. Some reaction products, such as
carboxymethyllysine, can originate from both sugars and lipid
oxidation products(470), and have been called ‘either advanced
glycation and lipoxidation end products’(466).
Advanced glycation end products/advanced lipoxidation
end products receptors
The putative deleterious effects of AGE may be attributed to
direct physico-chemical effects such as modification of extra-
cellular matrix proteins, resulting in cross-links, leading to
increased vascular stiffness or modification of proteins result-
ing in altered function, as well as via binding to a variety of
cell-surface receptors(471). AGE receptors have a dual function
and are involved in both AGE removal and AGE-induced cell
activation(140). Cell activation can occur via receptor-mediated
generation of ROS through both mitochondrial and cytosolic
pathways involving the electron transport chain and
NAD(P)H oxidase, respectively(472,473). ROS can trigger pro-
inflammatory signalling pathways causing MAPK-dependent
activation of transcription factors such as NF-kB(474–476) and
consequent modulation of the gene expression of several
pro-inflammatory cytokines(474,475,477).
Several AGE-binding proteins have been identified, including
the 42–45 kD receptor for AGE (RAGE), a member of the Ig
superfamily(478), the 60 kD protein a 48-kDa member of the
oligosaccharyltransferase complex (OST-48) or AGE-receptor
(AGE-R)1, the 90 kD protein 80K-H or AGE-R2(479), and the
32 kD protein galectin-3 or AGE-R3(480). This redundancy
could imply binding and/or functional specificity among AGE
receptors; alternatively, not all these receptors might be relevant
for AGE binding in vivo (140,481). At present, RAGE seems to be
the only receptor involved in cell activation(140). On the other
hand, AGE-R1, AGE-R2 and AGE-R3 seem to behave as an
AGE-receptor complex rather than individual receptor mol-
ecules and exert a predominant scavenging function(482,483).
In addition to the classical AGE receptors, AGE are cleared
also by scavenger receptors, which share with AGE receptors
the ability to bind modified lipoproteins such as oxidised
LDL(484). The scavenger receptor family can be broadly
classified into eight classes (A–H), which are expressed onT
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macrophages but also on other cells, including endothelial,
mesangial and vascular smooth muscle cells(485,486). Though
the ability of AGE receptors and scavenger receptors to clear
pro-inflammatory compounds such as AGE and oxidised
LDL from the tissue or circulation would seem initially
beneficial, the final net effect is dependent upon the balance
between this scavenging function and several other functions
of these receptors, including the clearance of other modified
self and non-self ligands, downstream pathways with
formation of cholesterol-laden cells, the initiation of pro-
inflammatory signalling cascades, and the regulation of
cellular lipid influx/efflux and synthesis/degradation(487).
However, it should be emphasised that the ligand affinity
of AGE proteins to scavenger receptors is dependent on
their modification, with mildly modified AGE not showing
significant affinity(488).
Among the AGE receptors, RAGE was shown to be impli-
cated in atherogenesis, based on the observations that soluble
RAGE, which is able to bind circulating AGE and other RAGE
ligands, and therefore to prevent their pro-inflammatory
effects, inhibited the development of atherosclerosis in
diabetic apoE2/2 mice(489), arrested its progression when
treatment was started after establishment of lesions(490) and
prevented experimental diabetic nephropathy(491), which
was conversely accelerated by RAGE overexpression(492). In
addition, RAGE ablation prevented diabetic nephropathy(493)
and neuropathy(494,495). Thus, the cell-surface RAGE appears
to be involved in inducing pro-inflammatory signalling while
the soluble form of RAGE appears to prevent this, by seques-
tering ligands away from the cell-surface RAGE. Conversely,
galectin-3 was proposed to exert a prevailing protective role
as indicated by reports that galectin-3 ablation resulted in
(1) the acceleration of glomerulopathy induced by dia-
betes(496), (2) increased AGE levels(497) and (3) accelerated
ageing(498). In the vessel wall, galectin-3 was induced in pro-
liferating vascular smooth muscle cells and particularly in
foam cells from arteries of experimental animal models of
atherosclerosis and human patients with advanced athero-
sclerotic lesions(499,500), and recent studies have shown that
galectin-3 ablation accelerates lipid-induced atherogen-
esis(501). Also AGE-R1 seems to play a protective role, as indi-
cated by resistance to oxidant and inflammatory injury in
mesangial cells overexpressing this receptor(482,502). This was
supported by the association of low AGE-R1 expression with
susceptibility to diabetic nephropathy in non-obese diabetic
mice(503) and the presence of diabetic complications in type
1 diabetic patients(504). Finally, the participation of class A
and B scavenger receptors in the process of atherogenesis
has been clearly established by a large body of experimental
studies, with scavenger receptor AI (SR-AI) and II and CD36
showing a predominant pro-atherogenic role and scavenger
receptor BI (SR-BI) exerting a protective function towards
lesion development(487). Thus, the net effect of the interaction
of AGE with AGE-binding receptors that can result in either
clearance or cell activation would be determined by the relative
expression of these different receptors on the respective cells.
Table 10. Observational studies on the association between alcohol intake and markers of low-grade inflammation
Subjects n (sex) Age (years) Association with low-grade inflammation Reference
Community based 2833 (M/F) Adult U CRP (lowest for 5–7 drinks/week) 418
Alcohol abusers and moderate drinkers 530 (M) Adult " CRP with higher intake 419
Population based 3697 (M/F) 18–90 U CRP 420
Healthy 340 (F) ¼ CRP
# IL-6 with higher intake
421
Population based (type 2 diabetics) 600 (F) Mean 64 # CRP, leucocyte count with higher intake
" Adiponectin (.9·2 g/d)
422
Population based 460 Adult ¼ IL-6 423
Blood donors 478 (M/F) 40–68 ¼ IL-6, sICAM-1, albumin
U CRP, SAA (1–40 g/d)
424
Population based 1776 (M/F) 18–88 U CRP, leucocyte count
iU Albumin, transferring
425
Population based 6739 (M/F) 25–74 U CRP, fibrinogen, leucocyte count (lowest for 1–40 g/d)
iU Albumin (highest for 20–40 g/d)
426
Population based 5865 (M/F) .65 ¼ CRP
# Leucocyte count, fibrinogen with higher intake
" Albumin with higher intake
427
Healthy health professionals 1432 (M/F) " sTNFR1, sTNFR2 (1–2 drinks/d v. 0 drinks/d)
# CRP, IL-6 (1–2 drinks/d v. 0 drinks/d)
428
Type 2 diabetic health professionals 726 (M) 47–82 ¼ CRP, sICAM-1
# sTNFR2, fibrinogen, sVCAM-1
" Adiponectin (12·5 g/d)
429
Population based 11 572 (M/F) .17 # CRP with higher intake 430
Healthy 2574 (M/F) 70–79 ¼ TNF-a, PAI-1
U CRP, IL-6 (lowest for 1–7 drinks/week)
431
Patients from general practices 3158 (M) 60–79 ¼ CRP ( # for higher intake of wine)
# Fibrinogen with higher intake
432
M, male; F, female; U, U-shaped relationship; CRP, C-reactive protein; " , increased; ¼ , no effect on; # , decreased; sICAM-1, soluble intercellular adhesion molecule-1;
SAA, serum amyloid A; iU, inverse U-shaped relationship; sTNFR, soluble TNF receptor; sVCAM-1, soluble vascular cell adhesion molecule-1; PAI-1, plasminogen activator
inhibitor 1.
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Table 11. Intervention studies investigating the effect of alcohol intake on markers of low-grade inflammation
Subjects n (sex) Age (years) Alcohol source and alcohol intake Study design and duration Effect on low-grade inflammation Reference
Healthy 16 (M/F) 22–33 Red wine (two doses: 12 or 20 g/m2
in men and 7·2 or 12 g/m2 in women)
or vodka (equivalent to high-dose red wine)
Acute; up to 9 h # NFkB activation after a
fat-enriched meal (only
red wine – both doses)
438
Healthy 29 Adult Red wine, white wine Acute; 4 h ¼ sP-selectin, von Willebrand
factor, thrombomodulin
" b-Thromboglobulin
439
Healthy 16 Adult Vodka (1255·2 joules ,42 g) Acute; 3 h ¼ NFkB activation 440
Postmenopausal women 20 (F) Alcohol (15 g) Acute; up to 6 h # CRP (after a high-carbohydrate,
high-fat meal)
442
Patients with coronary
artery disease
13 (M) White and red wine (2–3 glasses) Randomised, controlled,
cross-over, acute; 6 h
¼ sICAM-1, sVCAM-1
" IL-6
448
Healthy 6 (M) Red wine (60 g) Acute; 24 h ¼ TNF-a, IL-2, IL-4 435
Chronic pancreatitis
patients and healthy
controls
23 (M) Adult Alcohol (40 g) Acute; 24 h ¼ TGF-b
" IL-6 in patients
# MCP-1 in patients
443
Healthy 5 (M) 30–37 Red wine (60 g) Acute; 36 h ¼ IL-6, IL-10, IL-12
" IL-8
441
Lean and overweight 20 (M) 18–25 Beer (40 g/d) 3 weeks ¼ Resistin, leptin
" Adiponectin, grehlin
433
Lean and overweight 20 (M) Beer (40 g/d) Randomised, controlled,
cross-over; 3 weeks
¼ CRP 434
Subjects with increased
waist circumference
34 (M) 35–70 Red wine (40 g/d) Randomised, controlled,
cross-over; 4 weeks
¼ Resistin
" Adiponectin
437
Healthy 87 (M/F) Adult Red wine (15 g/d) Randomised, controlled,
cross-over; 3 weeks
¼ CRP
# Fibrinogen
444
Healthy 35 (F) Adult White or red wine (20 g/d) Randomised, cross-over; 4 weeks # CRP, sICAM-1, sCD40L, IL-6,
monocyte adhesion capacity
(both), sVCAM-1 (only red wine)
445
Healthy 20 (M/F) 45–64 Beer (40 g/d for male, 30 g/d for female) Randomised, diet-controlled,
cross-over; 3 weeks
# CRP, fibrinogen 446
Healthy 20 (M) Adult Sparkling wine or gin (30 g/d) Randomised, cross-over; 4 weeks # CRP, sICAM-1, IL-6, MCP-1
(only sparkling wine), sVCAM-1,
sE-selectin, P-selectin (both)
447
Healthy 24 (M) Adult Red wine (60 g/d) 2 weeks ¼ TNF-a, IL-2, IL-4, TGF-b 436
M, male; F, female; # , decreased; ¼ , no effect on; sP-selectin, soluble P-selectin; " , increased; CRP, C-reactive protein; sICAM-1, soluble intercellular adhesion molecule-1; sVCAM-1, soluble vascular cell adhesion molecule-1;
TGF, transforming growth factor; MCP-1, monocyte chemoattractant protein-1; sCD40L, sCD40 ligand.
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Significance of dietary advanced glycation end products/
advanced lipoxidation end products
The nutritional properties of heated food were initially ques-
tioned because of the reduced availability of lysine due to
the formation of Amadori-modified lysine(505). However,
cooking was also shown to increase the bioavailability of
some nutrients, especially proteins derived from some plant
sources(451). Subsequently, the concern was raised that AGE
(and ALE) formed during the Maillard reaction might exert
adverse health effects in cells, tissues and organs. As a poten-
tial mechanism, a role of AGE/ALE binding to RAGE followed
by triggering of RAGE-dependent downstream signalling
events leading to transcription of pro-inflammatory genes
has been postulated(460,506). This view is supported by a
number of studies conducted in both experimental animal
models and human subjects, showing that ingestion of diets
containing high AGE levels results in increased levels of
circulating AGE (see below). In addition, these high-AGE
diets, generated by more severe thermal treatment than the
control diets, also resulted in a series of metabolic and
micro/macrovascular abnormalities related to diabetes and
its long-term complications (see below). However, despite
this body of experimental data, a cause–effect relationship
between dietary AGE and development and progression of
disease conditions related to Western-type lifestyle and dietary
habits has not yet been conclusively demonstrated, and a
number of issues remain to be solved.
Evidence supporting a potential harmful effect of dietary
advanced glycation end products/advanced lipoxidation
end products
Animal studies. In spontaneously diabetic db/db mice(507)
and in normal mice fed high-fat diets(508), feeding of a
low-AGE diet reduced serum AGE levels and improved insulin
sensitivity, compared with a high-AGE diet. In addition, in
non-obese diabetic mice, a fetal or neonatal low-AGE environ-
ment prevented autoimmune diabetes, possibly by reducing
antigenic stimulus for T-cell-mediated injury or by attenuating
b-cell damage(509). In both type 1 and 2 diabetes models (i.e.
non-obese diabetic and db/db mice, respectively) low dietary
AGE content provided sustained protection towards the devel-
opment of diabetic nephropathy(510). Likewise, in genetically
hypercholesterolaemic apoE2/2 mice, low AGE content in
the diet attenuated the development of atherosclerosis after
induction of diabetes with streptozotocin(511) and neointimal
formation after arterial injury(512). Finally, in db/db mice,
wound healing was accelerated by a low-AGE diet, with
predominant wound contraction, compared with animals on
a high-AGE diet, which favoured the epithelialisation mode
of wound closure(513).
Human studies. In healthy younger (aged ,45 years) and
older (aged .60 years) human subjects, dietary AGE, but not
energy intake, correlated with serum AGE levels and markers
of oxidative stress (8-isoprostanes), which in turn correlated
with serum CRP concentration and insulin resistance(514–521)
(Table 12). It is noteworthy that in this study, some healthy
individuals showed AGE levels of similar magnitude as
found in diabetic patients.
AGE-rich diets used for intervention studies in human sub-
jects are usually generated by more severe thermal treatment
of food, particularly by frying, broiling and baking, whereas
AGE-poor food is prepared by steaming or simply without
heating at all. Therefore, unless specified, these are the
methods that were used for the preparation of test and control
diets in the studies reviewed below. Taken together, these
studies show that dietary AGE content correlates with circulat-
ing levels of AGE and with markers of inflammation, oxidative
stress, endothelial dysfunction and renal function. One caveat
that needs attention for future human studies is the significant
contribution of smoking to the endogenous AGE load(462,522).
Diabetic subjects with and without nephropathy were given
a single meal of egg-white, cooked with or without fructose,
with the AGE-rich food containing about three times more
AGE than a single meal of a regular diet(456). There was a sig-
nificant correlation between dietary AGE content and serum
AGE levels. Moreover, the serum AGE levels were directly
related to the degree of renal dysfunction, as estimated by
the increase in albuminuria and the decrease in creatinine
clearance, and renal AGE excretion was inversely correlated
with the degree of renal dysfunction. The relationship
between dietary AGE intake, serum AGE levels and renal
AGE clearance was confirmed in a cross-sectional study per-
formed in long-term haemodialysis and peritoneal dialysis
patients with or without diabetes. This study showed that cir-
culating AGE correlated significantly with the AGE content of
a regular diet, as estimated by means of 3 d dietary records
and food questionnaires, as well as with blood urea N
level(459). Likewise, in non-diabetic patients on maintenance
peritoneal dialysis randomly assigned to two groups consum-
ing either a high- or low-AGE diet for 4 weeks, serum AGE
levels correlated with AGE consumption as well as with
blood urea N, serum creatinine, total protein, albumin and
P, with AGE restriction profoundly reducing circulating
AGE(523). Finally, cross-sectional studies of healthy subjects
and of patients undergoing haemodialysis showed a positive
relationship between dietary AGE intake and plasma inflam-
matory markers(515,520).
A number of acute studies examining the effect of a single
high-AGE meal on inflammatory markers have been con-
ducted (see Table 12). Although these have been conducted
in a variety of subject/patient groups, they show rather similar
effects: typically, there is an elevation of various inflammatory
markers (CRP, cytokines and soluble adhesion molecules) in
the hours after consumption of a high-AGE meal, and this
increase does not occur with a low-AGE meal (see Table 12).
Furthermore, healthy and diabetic volunteers receiving a
single dose of a high-AGE (caffeine-free) cola drink showed
an increase in serum PAI-1(519).
In patients on haemodialysis or peritoneal dialysis randomly
assigned to a 4-week high- or low-AGE diet, circulating levels
of AGE as well as markers of inflammation and endothelial
dysfunction (which were markedly elevated at baseline,
although not correlated with AGE) decreased significantly
in response to AGE restriction, i.e. the low-AGE diet(515).
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The findings of this latter study are in accordance with earlier
data in diabetic subjects with normal renal function who
showed a decrease in several inflammatory markers following
2 or 6 weeks of a low-AGE diet(521).
Arguments against potentially harmful effects of dietary
advanced glycation end products/advanced lipoxidation
end products
In contrast to the aforementioned reports, circulating AGE
levels could not be identified as an independent risk factor
for cardiovascular or renal outcomes in diabetic subjects
with diabetic nephropathy(524), and circulating AGE levels
were even inversely correlated with mortality in haemodialysis
patients, the latter most probably due to a better nutritional
status(525). In addition, a recent study in obese children
found lower circulating AGE levels compared with lean con-
trols while inflammatory markers were significantly elevated
in obese children(517). Several issues concerning the method-
ology and interpretation of published data have been raised
that may question the alleged adverse health effects of dietary
AGE/ALE(451,526,527).
A first issue is the large heterogeneity of AGE/ALE and their
precursors, which would require examination of the effect
of each of these compounds separately. In particular, the
bioavailability and metabolic fate of individual AGE/ALE struc-
tures should be evaluated to assess whether and to what
extent they are digested, absorbed and cleared by the body,
and accumulate in tissues to produce any significant adverse
health effect(451,527). AGE, which are absorbed as free or
short peptide-bound AGE, may be cleared more rapidly and
efficiently by the kidney, except when renal function is signifi-
cantly impaired, than those formed endogenously, which are
usually protein-bound. Studies in experimental animals fed
or injected with radiolabelled protein-bound AGE and
human volunteers receiving diets enriched with MRP or
specific AGE have shown that absorption of ingested MRP is
variable and dependent on the MRP(464,465,527–529). Highly
cross-linked AGE and melanoidins were predominantly
excreted in the faeces while absorbed MRP were in general
rapidly excreted by the kidney, with limited accumulation in
tissues and organs(465,528–531). Both pyrraline and pentosidine,
the latter only in free form, were readily absorbed and
excreted in the urine(532,533). There are also reports that
some MRP may be degraded by the colonic microflora(534).
Concerning the structural requirements for AGE to interact
with their receptor, there is evidence that RAGE does not
bind small molecules and simple protein modifications(478).
Penfold et al.(535) recently showed that only serum fractions
isolated from diabetic patients with nephropathy containing
high-molecular-weight proteins (.50 kD) were able to stimu-
late RAGE but not medium- or low-molecular-weight serum
fractions, in line with mechanistic studies that showed
no binding of carboxymethyllysine-modified proteins to
RAGE(536–538), and that supramolecular complexes are a pre-
requisite for RAGE binding(539–542). Together this suggests
that dietary AGE, even if they are absorbed from the gut,
would have little effect on inflammatory processes via RAGE
activation in target tissues, since it appears highly unlikely
that free AGE-modified amino acids would be incorporated
into nascent proteins. In addition, a few reports show that
binding of AGE to RAGE is not sufficient to stimulate
inflammatory signalling(538,542,543), suggesting that endotoxin
contaminations of AGE preparations used in the in vitro
cellular test systems may be responsible for the observed
pro-inflammatory effects.
A further issue, which could complicate the interpretation of
results, is the suitability of experimental design/models used
in animal studies(451). In fact, the amount of AGE/ALE adminis-
tered, and particularly the extent of their modification, might
not correspond to that of AGE/ALE ingested with usual
diets, due to the higher extent of modification introduced by
the heating procedure used for preparing test diets in pub-
lished studies(527). In addition, the true AGE content of many
test diets has either not been determined or has been ques-
tioned by others, as in the case of the ten times concentrated
caffeine-free diet cola beverage described above. In fact,
others have found low to undetectable AGE levels in unconcen-
trated normal or diet cola(466,544). Similarly, the food AGE con-
tent published by Goldberg et al.(461) and recently updated(545)
using a non-validated ELISA method to determine AGE content
is difficult to bring in line with the Maillard reaction in general
and with other data on food AGE content(451,527,546).
To attribute adverse health effects to any food ingredient, it
is essential that this food ingredient be tested independently,
e.g. in pure form and possibly out of the food context.
Unfortunately, for most published intervention studies of
AGE and/or ALE, this has not been the case. The adverse
health effects observed with differentially processed/heated
food that result in different AGE/ALE contents have been
ascribed to these protein modifications, regardless of the
altered food context generated by the differential proces-
sing/heating. It may also be possible that AGE/ALE formed
under these conditions might be markers of other process/
heating-related alterations of food and not themselves the
cause for adverse health effects. This is highlighted by the
beneficial effects of melanoidins formed during heat proces-
sing of food(547). One of the very few studies that investigated
the direct effect of pure AGE by adding an AGE-modified
protein v. a non-modified protein to a basal animal diet and
fed to rats for 11 weeks was in fact unable to demonstrate
any adverse health effects of the AGE-supplemented diet(548).
A major issue is the difficulty to attribute the adverse
health effects observed with thermally modified diets to their
AGE/ALE content, since the possibility cannot be ruled out
that other products formed such as heterocyclic amines or
acrylamide(453) or ingredients destroyed/consumed such as
natural antioxidants contained in fruits and vegetables(526)
during cooking and food processing may be responsible for
these effects. The notion that AGE may not be the agent
causing postprandial inflammation is supported by a report
showing that volunteers taking a single dose of either a
glucose-modified, AGE-rich or a sorbitol-treated, AGE-poor
casein preparation showed an identical postprandial increase
in NF-kB activation in peripheral blood mononuclear
cells(516). There is a significant body of evidence linking
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Table 12. Studies on the association between advanced glycation end products (AGE) intake and markers of low-grade inflammation
Subjects n (sex) Age (years) Intake
Study design and
duration Effects on low-grade inflammation Reference
Diabetic and non-diabetic
haemodialysis patients
189 (M/F) Mean 61(SD 14)
Mean 50(SD 14)
Dietary AGE Cross-sectional " CRP, sVCAM-1, TNF-a
¼ PAI-1
515
Healthy stratified by age groups 172 (M/F) 18–45
60–80
Dietary AGE Cross-sectional Correlation of AGE intake with CRP 520
Obese type 2 diabetics,
smokers and non-smokers
13 Mean 57(SD 10) High-AGE meal Acute; up to 4 h " CRP, sICAM-1, sVCAM-1, sE-selectin
¼ TNF-a, IL-6, IL-8, fibrinogen
518
Healthy and type 2 diabetics 10 Healthy þ44
type 2 diabetics (M/F)
Mean 43(SD 13) (Healthy)
Mean 51(SD 13) (Diabetics)
High-AGE cola drink Acute; 90 min " PAI-1
¼ sICAM-1
519
Healthy, non-smokers 9 Mean 32(SD 8) High- and low-AGE meal Acute; 2 h " NF-kB activation in both groups
(effect of meal not of AGE?)
516
Overweight type 2 diabetics,
smokers and non-smokers
20 (M/F) Mean 55(SD 10) High- and low-AGE meal Cross-over,
acute; up to 6 h
High-AGE meal:
" IL-6, sICAM-1, sVCAM-1, sE-selectin
¼ CRP, TNF-a, fibrinogen
Low-AGE meal:
# IL-6, sICAM-1, sVCAM-1
¼ CRP, TNF-a, sE-selectin, fibrinogen
514
Non-smoking overweight
diabetics
11 (M/F) Mean 52(SD 17) High- and low-AGE diet Cross-over; 2 weeks # TNF-a mRNA, sVCAM-1
with low-AGE diet
¼ CRP
521
Non-smoking overweight
diabetics
13 (M/F) ,62 High- and low-AGE diet Randomised,
parallel; 6 weeks
" CRP with high-AGE diet
and # low-AGE diet
" TNF-a with high-AGE diet
# sVCAM-1 with low-AGE diet
521
Renal failure patients on
dialysis
18 (M/F) High- and low-AGE diet Randomised,
parallel; 4 weeks
# CRP, TNF-a, sVCAM-1 and PAI-1
with low-AGE diet
515
Healthy obese children
v. lean controls
18 (11 M/7 F)
18 (8 M/10 F)
5–18
4–17
– Cross-sectional Obese had lower plasma AGE and
higher CRP and IL-6
517
M, male; F, female; " , increased; CRP, C-reactive protein; sVCAM-1, soluble vascular cell adhesion molecule-1; ¼ , no effect on; PAI-1, plasminogen activator inhibitor-1; sICAM-1, soluble intercellular adhesion molecule-1; # ,
decreased.
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food intake with postprandial inflammatory signalling.
In fact, postprandial hyperglycaemia has been shown to be
associated with increased NF-kB activation in patients with
type 2 diabetes(549). Moreover, an oral glucose load, or
better the mean glucose excursions following an oral glucose
load, were associated with urinary excretion of 8-iso PGF2a
as a marker of oxidative stress within 2–3 h after the
challenge(550), and oral glucose and/or high fat additively
increased inflammatory markers (CRP and IL-6) and oxidative
stress (nitrotyrosine), while reducing flow-mediated dilata-
tion(167,551) in diabetic subjects(552). This activation during
postprandial hyperglycaemia or hyperlipidaemia may be
due to acute changes in markers of glycoxidative and
lipoxidative stress and may partly underlie the association of
postprandial derangements and cardiovascular risk(553).
These observations have prompted the hypothesis that it is
the sugar and lipid content of meals which is related to
postprandial inflammation, oxidative stress and vascular
dysfunction(157,167,551,554). In addition, AGE precursors and
AGE/ALE might simply be markers of oxidative processes
and inflammation, which would be the true injurious mechan-
ism(455,555,556). The reported beneficial effect of agents such
as aminoguanidine(557) in preventing MRP accumulation
following ingestion of high-AGE diets could be attributed
to the metal-chelating and antioxidant properties of this
drug(455). The increased circulating and tissue AGE levels
induced by AGE-enriched meals might result from oxidant
stress-dependent endogenous AGE formation. The reported
attenuation of inflammatory changes induced by fatty meals
by treatment with antioxidants is in keeping with this
view(456,514). Likewise, the preventive effect of benfotiamine,
a transketolase activator that directs glucose substrates to
the pentose phosphate pathway, might depend on the
consequent blockade of endogenous dicarbonyls and AGE
formation as well as of other hyperglycaemia-induced
pathways(536). In addition, benfotiamine administration restores
normal thiamin levels, which have been reported to be reduced
in diabetic patients(538), and compensate for decreased thiamin
ingestion with food subjected to severe thermal treatment,
which is known to degrade this heat-labile vitamin(537,558,559).
Acute v. chronic exposure to AGE-enriched food could
produce different effects, and, under both experimental con-
ditions, post-meal values should be considered separately
from basal fasting values. Also, the use of animals such as
rodents, which are not accustomed to the intake of heated
food, might result in outcomes that cannot be directly applied
to humans. In addition, the effects of AGE/ALE-rich diets may
be different in healthy subjects and patients with diabetes,
other age-related disorders or renal insufficiency. The large
variation in serum AGE levels detected in younger and older
healthy subjects(520), with some individuals showing values
similar to those found in diabetic patients, would suggest
that AGE might not be harmful unless a concomitant disease
condition is present.
The argument that highly cooked or processed food may
be responsible for adverse health effects because of their
elevated AGE content may be countered by the findings that
vegetarians consistently present with higher circulating AGE
levels than individuals eating a Western diet(560). Also, the
recent report that obesity in children, while correlating with
increased oxidative stress and inflammatory markers,
showed an inverse correlation with circulating AGE levels is
in disagreement with this argument(517).
Another important issue is the reliability of methods
for AGE/ALE quantification that are used by different
groups(452,527,561). In fact, the use of antisera for quantitative
immunoassays of protein-bound AGE is questionable because
the specificity of the antibodies is often difficult to ascertain
and monospecific antibodies are not commercially available.
Furthermore, proteins used to block non-specific binding in
immunoassays may also contain AGE epitopes, and thus
interact with the detection system. Finally, because of steric
constraints, not all AGE epitopes on the protein may be
available for interaction with the antibody, and factors com-
peting for the reaction between the anti-AGE antibody and
its antigen, including anti-AGE auto-antibodies and, possibly,
complement, have been demonstrated in plasma(562,563).
Thus, AGE measurements with immunoassays yield only
semi-quantitative results and results obtained with immuno-
assays in both serum samples and food should be interpreted
with care. The indirect immunoassay used by Vlassara and
co-workers only allows results to be expressed in units,
thus making comparison with other analytical data impossible.
A much better approach for the quantitative determination
of specific AGE epitopes in proteins is the use of specific
analytical techniques, such as liquid chromatography-MS–MS,
for the analysis of specific AGE in protein hydrolysates(544).
Application of this kind of analytical technique could lead to a
more comprehensive understanding of the putative effects of
AGE formed by the Maillard reaction in food as well as in the
body of healthy and diabetic human subjects. In fact, conflicting
carboxymethyllysine levels in different foodstuffs have been
reported using either an indirect ELISA method(461) or an ultra
performance liquid chromatography-MS–MS method(546).
A relevant objection to the hypothesis that dietary AGE/ALE
have adverse health effects is the fact that the human organism
is equipped with very effective and redundant defence mech-
anisms limiting the digestion and intestinal absorption of these
compounds, which are also trapped in the gastrointestinal
tract and detoxified in intestinal epithelia or, for those that
are absorbed into the blood or lymph, in liver and other
tissues. Based on the pivotal role of the gastrointestinal tract
in the protection against ingested MRP, it would be important
to assess whether AGE/ALE that are not absorbed have
any adverse effects on the intestinal mucosa and/or colonic
microflora. Preliminary studies have shown that a high-AGE
diet did not affect the number or class of bifidobacteria and
sulphate-reducing bacteria, which have beneficial and detri-
mental effects, respectively(451,564). In addition, Morales
et al.(547) recently summarised the beneficial health effects of
melanoidins generated during heat processing of food.
Despite all these arguments, it might be prudent to advise
renal failure patients to decrease their intake of highly
heated food. This may not necessarily be due to the presence
of AGE/ALE in thermally treated food but rather to other
factors present/absent in thermally treated food.
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Finally, there may even be a ‘chemoprotective’ role of
individual dietary AGE/ALE due to antioxidant(565,566) and
anti-cancer(567) properties, the former in part attributable to
pronyllysine modification of lysine residues of proteins
detected in certain foods including bread crust and malt(568).
Research gaps
Although there appears to be suggestive evidence for a
potential role of dietary AGE in inducing low-grade chronic
inflammation, insulin resistance and vascular dysfunction,
the supporting proof so far has been weak, inconclusive and
even contradictory. What the available studies have been
able to consistently show is the relationship between dietary
AGE/ALE exposure and postprandial circulating AGE
levels(520). Whether the uptake of AGE/ALE from the diet is
responsible for adverse biological consequences such as
chronic low-grade inflammation, vascular dysfunction or
insulin resistance will require further investigations.
The following research gaps have been identified:
(1) There is a need for reliable analytical methods for food
AGE with inter-laboratory cross-validations.
(2) There is a need for a food AGE database based on
reliable analytical methods.
(3) There is a need for preclinical and clinical studies with
pure and well-characterised AGE independent of food
in both healthy individuals and diabetic patients.
(4) There is a need to discriminate the biological effects
induced by protein-bound v. free well-characterised AGE.
(5) There is a need for toxicological evaluation of well-
characterised AGE in animal studies.
(6) There is a need to expand investigation of the
(patho)physiological role of food-derived ALE and lipid
peroxidation products.
(7) There is a need to evaluate the (patho)physiological con-
sequences of highly heated food beyond their AGE/ALE
content.
(8) There is a need to balance potentially adverse health
effects of AGE with the potentially beneficial health
effects of melanoidins, both of which are generated by
thermal treatment of food.
Macronutrients and low-grade inflammation
Fatty acids
Dietary fatty acids may affect inflammatory processes
through modulation of eicosanoid metabolism, and by
eicosanoid-independent mechanisms such as regulation of
membrane and cytosolic signalling processes that influence
the activity of transcription factors involved in inflam-
mation(569,570). These latter transcription factors include
NF-kB and PPAR-g, both of which are sensitive to fatty
acids. There is an intriguing interaction between these latter
two transcription factors because PPAR-g inhibits NF-kB
activation(571). A number of different fatty acids including
saturated, monounsaturated, trans, conjugated linoleic and
polyunsaturated of both n-6 and n-3 families have been
investigated in the context of inflammation. They have been
examined in many model systems, typically with isolated
cells in culture and in animal models of inflammatory
conditions, as well as in studies in human volunteers and in
various patient groups. In addition, associations between
intake or status of various fatty acids and inflammatory
markers have been examined in human studies.
SFA. In vitro studies have suggested that SFA may promote
inflammatory processes. Exposure of myotubes or adipocytes
to the SFA palmitic acid (16 : 0) increased IL-6 mRNA
expression and subsequent protein production, possibly via
activation of NF-kB(572,573). Monocytes are activated directly
by SFA, especially lauric acid (12 : 0), via TLR-4 and through
this mechanism induce NF-kB activity(574,575). A limited
number of observational studies have investigated the
relationship between SFA exposure and circulating markers
of inflammation (Table 13)(373,374,576–585). Fernandez-Real
et al.(577) did not see any relationship between serum SFA
and CRP or IL-6 in lean individuals, while in overweight
individuals, serum SFA were positively associated with IL-6
concentration, and the ratio of SFA:n-6 or n-3 PUFA was
positively associated with IL-6 and CRP concentrations,
respectively. A study in overweight adolescents showed posi-
tive relationships between total SFA in plasma phospholipids
or cholesteryl esters and IL-6, but not CRP, concentration(579).
Thus, there is general agreement between two studies in
overweight subjects that SFA exposure is associated with
higher IL-6 concentration. A study in lean individuals does
not show this. An intervention study feeding diets rich in
stearic acid (18 : 0) or in lauric, myristic (14 : 0) and palmitic
acids to men aged 25–60 years for 5 weeks showed higher
concentrations of CRP, fibrinogen, IL-6 and sE-selectin com-
pared with a diet enriched in oleic acid (18 : 1n-9)(586). There
are few other intervention studies chronically increasing SFA
intake in human subjects and reporting inflammatory markers.
Trans-fatty acids. Using a subgroup of the Nurses’ Health
Study, Lopez-Garcia et al.(580) identified significant positive
associations between the intake of trans-fatty acids in the
diet and the concentrations of all six inflammatory markers
assessed, including CRP, IL-6 and three soluble adhesion
molecules. In a 5-week intervention in healthy men, a trans-
fatty acid-enriched diet resulted in higher CRP and IL-6
concentrations than diets rich in oleic acid, stearic acid or
the combination of lauric, myristic and palmitic acids(586).
Furthermore, the concentration of sE-selectin was higher
than in all other dietary groups including the stearic acid
and lauric þ myristic þ palmitic groups. Thus, an association
study and an intervention study both demonstrate that dietary
trans-fatty acids elevate the concentrations of a range of
inflammatory markers including CRP, IL-6 and adhesion
molecules.
Conjugated linoleic acids. In vitro and animal feeding
studies have suggested marked effects of conjugated linoleic
acids (CLA) on inflammation(587–589). However, results from
human intervention studies using CLA-rich capsules are equiv-
ocal (Table 14)(590–596). For example, two studies demonstrate
that CLA, especially the trans-10, cis-12 isomer, increases CRP
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concentration, but not the concentrations of cytokines or sol-
uble adhesion molecules(593,594). However, at least four other
studies have failed to show an effect of CLA on CRP concen-
tration (see Table 14). Duration of intervention is not likely to
be an explanatory factor for differences in the findings, but,
since most studies have used mixtures of CLA isomers in
different proportions, the precise dose of the more potent
isomer (perhaps the trans-10, cis-12 isomer) may be an
explanation. The two studies showing increased CRP with
CLA provided 2·1(594) and 2·7(593) g/d of trans-10, cis-12 CLA.
The four studies showing no effect of CLA on CRP used
between 0·4 and 2·5 g/d of this isomer (see Table 14). The
question of whether CLA per se, or whether specific CLA iso-
mers, increase low-grade inflammation requires further study.
Linoleic and a-linolenic acids. Linoleic (18 : 2n-6) and
a-linolenic (18 : 3n-3) acids constitute the majority (.95 %)
of PUFA in most Western diets, with the former usually
being present in an excess of approximately 10-fold over the
latter. These two fatty acids are the parent n-6 and n-3
PUFA, respectively. Because of the role of linoleic acid as
the precursor of arachidonic acid (20 : 4n-6), which is, in
turn, the substrate for the synthesis of pro-inflammatory eico-
sanoids such as PGE2 and 4-series leukotrienes, it is widely
considered that elevated n-6 and low n-3 fatty acids (i.e. a
high n-6:n-3 PUFA ratio) in the diet will promote inflam-
mation. However, available evidence does not support this
contention.
Dietary intakes of linoleic acid were not associated with
CRP, IL-6, sTNFR1 or sTNFR2 concentrations in subgroups
of the Physicians’ Health Study and the Nurses’ Health
Study(583). The concentration of linoleic acid in blood
lipids(578,579) or granulocytes(374) was not associated with
CRP or IL-6 concentration, although a large Swedish study
reported an inverse association between linoleic acid in cho-
lesteryl esters and CRP concentration(582). Linoleic acid
makes a major contribution to the fatty acids within blood
lipids, especially cholesteryl esters, where it is the pre-
dominant n-6 PUFA. Total n-6 PUFA in serum fatty acids in
overweight, but not in lean, subjects were inversely associated
with IL-6 but not CRP concentration(577). The ratio of SFA:n-6
PUFA in serum lipids or in plasma phospholipids was
positively associated with IL-6 but not CRP concentration in
overweight subjects(577,579). This suggests that decreasing
SFA status while increasing n-6 PUFA status might reduce
low-grade inflammation. An intervention study in thirty-eight
healthy male and female volunteers (mean age 27 years) com-
pared diets with 18 % energy from oleic acid and 4 % from
linoleic acid or 4 % energy from oleic acid and 12 % from lino-
leic acid; plasma sICAM-1 concentrations were not different
between these two groups(597), suggesting that exchange of
oleic acid for linoleic acid, while keeping SFA intake constant,
does not affect this marker of inflammation.
Dietary a-linolenic acid intakes were not associated with
CRP, IL-6, sTNFR1 or sTNFR2 concentrations in one study on
subgroups of the Physicians’ Health Study and the Nurses’
Health Study(583). In a second study on another subgroup of
the Nurses’ Health Study, a-linolenic acid intakes were
not associated with CRP, sICAM-1, sE-selectin or sTNFR2
concentrations but were associated with lower IL-6 and
sVCAM-1 concentrations(373). The concentration of a-linolenic
acid in blood lipids(578,579,582) or granulocytes(374) was not
associated with CRP or IL-6 concentration. Data from an Italian
study showed no association between a-linolenic acid in
plasma fatty acids and several cytokines including IL-6 and
TNF-a, but there was an inverse association with CRP(578).
These association studies suggest a modest anti-inflammatory
effect of a-linolenic acid.
Several intervention studies have involved high a-linolenic
acid intakes usually by providing flaxseed oil in capsules or
in liquid form or foodstuffs made using flaxseed oil(598).
Frequently, these studies have used a control group with a
high intake of linoleic acid, with the comparison essentially
being replacement of linoleic acid with a-linolenic acid.
Thus, the focus of these studies is essentially to explore the
importance of the n-6:n-3 PUFA ratio of the diet. If linoleic
and a-linolenic acids have similar effects on low-grade inflam-
mation, then studies exchanging one of these fatty acids with
the other would be likely to see little effect. Table 15 summar-
ises intervention studies with a-linolenic acid that have
measured markers of low-grade inflammation as an outcome.
Findings are inconsistent with a number of studies identifying
the effects of a-linolenic acid on some markers and not others,
and some studies finding no effects (Table 15)(599–606). Many
studies have used very high intakes of a-linolenic acid,
relative to typical habitual intakes. The study of Paschos
et al.(601) is enlightening because it showed that a-linolenic
acid (8·1 g/d for 12 weeks) was less effective (i.e. induced
fewer and smaller effects) against a more healthy, than against
a less healthy, background diet. Thus, dose, duration, sample
size and the nature of the background diet are possible contri-
butors to the varied findings of studies with a-linolenic acid.
However, what is apparent from these observations is that a
substantial increase in the intake of a-linolenic acid can
decrease low-grade inflammation as indicated by circulating
CRP, IL-6 or soluble adhesion molecules (see Table 15). The
study of Zhao et al.(606) provides further insight: the change
in CRP and sVCAM-1 concentrations was correlated with the
change in the concentrations of different serum n-3 PUFA
(a-linolenic acid, EPA, docosapentaenoic acid (22 : 5n-6) and
DHA) that had occurred. The only significant relationships
were inverse and between the change in EPA status and the
changes in CRP and sVCAM-1 concentrations. This suggests
that the anti-inflammatory effect seen with the very high
intake of a-linolenic acid in this study is due to the conversion
of a-linolenic acid to EPA. A suitable conclusion may be that
high intakes of a-linolenic are anti-inflammatory acting via
the a-linolenic acid derivative, EPA.
Several of the intervention studies with a-linolenic acid
have involved a group consuming a high intake of linoleic
acid, frequently as the control for the high a-linolenic acid
intake. These groups provide some information about the
impact of linoleic acid on low-grade inflammation. The
study of Rallidis et al.(603,604) involved a control group con-
suming about 11 g/d of linoleic acid in addition to the dietary
intake; this approximately doubled linoleic acid intake. The
increase in linoleic acid intake did not alter the concentrations
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Table 13. Observational studies on the association between fatty acid intake or status and markers of low-grade inflammation
Subjects n (sex) Age (years) Exposure Association with low-grade inflammation Reference
Referrals for
coronary angiography
269 (M/F) Mean ,60 Granulocyte fatty acids Linoleic acid, aLNA, arachidonic acid,
docosapentaenoic acid: ¼ CRP
EPA: # CRP (trend)
DHA: # CRP
374
At risk of CHD 152 (M) Mean 70(SD 3) Serum non-esterified
arachidonic acid,
EPA and DHA
Serum non-esterified arachidonic acid:
¼ sICAM-1, sE-selectin, thrombomodulin, tissue
plasminogen activator antigen
# sVCAM-1, von Willibrand factor
Serum non-esterified EPA:
¼ thrombomodulin, tissue plasminogen
activator antigen
# sVCAM-1, sICAM-1, sE-selectin,
von Willibrand factor
Serum non-esterified DHA:
¼ sE-selectin, thrombomodulin, tissue
plasminogen activator antigen, von Willibrand factor
# sVCAM-1, sICAM-1
585
Healthy and
overweight
109 Healthy (M/F)
and 123
overweight (M/F)
Mean 38 (healthy)
and mean
44 (overweight)
Serum fatty acids Healthy subjects:
Total SFA, n-6 PUFA, n-3 PUFA: ¼ CRP, IL-6
Overweight subjects:
Total SFA: " IL-6, ¼ CRP
Total n-6 PUFA: ¼ CRP, # IL-6
Total n-3 PUFA: ¼ IL-6, # CRP
Saturated:n-6 PUFA: " IL-6, ¼ CRP
Saturated:n-3 PUFA: " CRP, ¼ IL-6
577
Healthy 405 (M) and 454 (F) Mean ,60
(men) and
,42 (women)
Dietary intakes of linoleic
acid, aLNA, EPA þ DHA
as percentage of energy
determined from FFQ
Linoleic acid: ¼ CRP, IL-6, sTNFR1, sTNFR2
aLNA: ¼ CRP, IL-6, sTNFR1, sTNFR2
EPA þ DHA: ¼ IL-6; # CRP, sTNFR1, sTNFR2
583
Healthy 727 (F) Mean ,56 Dietary intakes of aLNA,
EPA þ DHA, total n-3 PUFA
as g/d determined from FFQ
aLNA: ¼ CRP, sTNFR2, sICAM-1,
sE-selectin; # IL-6, sVCAM-1
EPA þ DHA: ¼ IL-6, sTNFR2; # CRP,
sICAM-1, sVCAM-1, sE-selectin
Total n-3 PUFA: ¼ sTNFR2; # CRP, IL-6,
sICAM-1, sVCAM-1, sE-selectin
373
Healthy 730 (F) Mean ,56 Dietary intake of trans-fatty
acids as g/d determined from FFQ
" CRP, IL-6, sTNFR2, sICAM-1,
sVCAM-1, sE-selectin
580
Patients with angina 291 (M/F) Mean ,60 Granulocyte EPA and DHA
Subcutaneous adipose tissue
EPA and DHA
Granulocyte EPA: ¼ sICAM-1,
sVCAM-1, sP-selectin
Granulocyte DHA: ¼ sICAM-1,
sVCAM-1, sP-selectin
Granulocyte total n-3 PUFA: ¼ sICAM-1,
sVCAM-1, sP-selectin
Adipose EPA: ¼ sICAM-1,
sVCAM-1, sP-selectin
Adipose DHA: " sVCAM-1;
¼ sICAM-1, sP-selectin
Adipose total n-3 PUFA: " sVCAM-1;
¼ sICAM-1, sP-selectin
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Table 13. Continued
Subjects n (sex) Age (years) Exposure Association with low-grade inflammation Reference
Overweight 60 (M/F) Mean ,12 Plasma phospholipid and
cholesteryl ester fatty acids
Plasma phospholipids:
Total SFA: " IL-6; ¼ CRP
Ratio of PUFA to SFA: ¼ CRP; # IL-6
Linoleic acid, aLNA, EPA, DHA: ¼ CRP, IL-6
Plasma cholesteryl esters:
Total SFA: " IL-6; ¼ CRP
Ratio of PUFA to SFA: ¼ CRP; # IL-6
Linoleic acid, DHA: ¼ CRP, IL-6
aLNA, EPA: ¼ IL-6; # CRP
579
Japanese general
population
aged .70 years
971 (M/F) Mean 76(SD 4) Dietary intake of n-3 fatty
acids as g/d determined
from FFQ
EPA þ DHA: # CRP
aLNA: ¼ CRP
581
General
population
aged .65 years
1123 (M/F) Mean ,68 Plasma fatty acids Linoleic acid: " IL-6R; ¼ CRP, IL-6, TNF-a,
IL-1b, IL-1ra, IL-10, TGF-b
aLNA: ¼ IL-6, TNF-a, IL-1b, IL-10, IL-6R,
TGF-b; # CRP, IL-1ra
Arachidonic acid: " TGF-b ¼ CRP, TNF-a,
IL-1b, IL-10, IL-6R; # IL-6, IL-1ra
EPA: " IL-10, TGF-b; ¼ CRP, TNF-a,
IL-1b, IL-1ra, IL-6R; # IL-6
DHA: " IL-10, TGF-b; ¼ CRP, IL-1b,
IL-6R; # IL-6, TNF-a, IL-1ra
Radio of arachidonic acid to EPA : ¼ CRP, IL-6,
TNF-a, IL-1b, IL-1ra, IL-6R, IL-10, TGF-b
Total n-6 PUFA: " TGF-b ¼ CRP, IL-6,
TNF-a, IL-1b, IL-6R; # IL-10, IL-1ra
Total n-3 PUFA: " IL-6R, IL-10, TGF-b
¼ CRP, IL-1b; # IL-6, TNF-a, IL-1ra
n-6:n-3: " IL-6, TNF-a, IL-1ra; ¼ CRP,
IL-1b, IL-6R; # IL-10, TGF-b
578
Healthy 767 (M) 50 (fatty acids)
and 70 (CRP)
Plasma cholesteryl
ester fatty acids
at age 50 years
v. CRP at age
70 years
Plasma cholesteryl ester 16 : 1n-7,
18 : 1n-9, 18 : 3n-6 " CRP
Plasma cholesteryl ester 18 : 2n-6 # CRP
582
Healthy 511 (M/F) 21–67 Dietary intake of
linoleic acid,
aLNA, EPA and DHA
Linoleic acid: # CRP (men only)
aLNA: # CRP (men only)
EPA, DHA, EPA þ DHA: # CRP (weak)
Total n-6 PUFA: # CRP (men only)
Total n-3 PUFA: # CRP (men only)
584
M, male; F, female; aLNA, a-linolenic acid; ¼ , no effect on; CRP, C-reactive protein; # , decreased; sICAM-1, soluble intercellular adhesion molecule-1; sVCAM-1, soluble vascular cell adhesion molecule-1; " , increased;
sTNFR, soluble TNF receptor; sP-selectin, soluble P-selectin; IL-1ra, IL-1 receptor antagonist; TGF, transforming growth factor.
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of CRP, IL-6, SAA, sICAM-1 or sE-selectin, but the concen-
tration of sVCAM-1 was decreased(603,604). In the study of
Paschos et al.(602), the control group consumed 11·2 g/d of
linoleic acid on top of their normal intake, which was approxi-
mately 11 g/d. This doubling of linoleic acid intake did not
affect TNF-a or adiponectin concentrations. These studies
did not alter any aspect of diet but required subjects to con-
sume oil providing linoleic or a-linolenic acids on top of the
normal diet. Thus, these studies show that markedly increas-
ing linoleic acid intake in those consuming on average
about 10 g/d does not increase low-grade inflammation.
The study of Zhao et al.(606) included a high linoleic acid
intervention group (13 % energy) and the control group con-
sumed what is described as an ‘average American diet’. This
provided 12·7 % of energy from SFA, 7·7 % from linoleic acid
and 0·8 % from a-linolenic acid. The corresponding values
for the linoleic and a-linolenic acid rich diets were 8·5, 12·6
and 3·6 and 8·2, 10·5 and 6·5, respectively. Thus, the linoleic
acid-rich diet contained more a-linolenic acid than the control
diet, while the a-linolenic acid diet contained more linoleic
acid than the control diet and almost as much linoleic acid
as the linoleic acid diet. Essentially, what this means is that
the linoleic acid diet is examining the effect of replacing
some SFA with the combination of linoleic and a-linolenic
acids and that the a-linolenic acid diet is examining the
effect of replacing some linoleic acid with a-linolenic acid.
In the linoleic acid group, the concentrations of CRP and
sICAM-1 decreased by 45 and 25 %, respectively; sVCAM-1
and sE-selectin also fell (by 15 and 7 %) but these changes
were not significant. Thus, replacing about one-third of SFA
with linoleic acid plus a-linolenic acid decreases low-grade
inflammation. This is consistent with the associations
described above and confirms that relative to SFA, the combi-
nation of linoleic and a-linolenic acids is anti-inflammatory.
The changes in inflammatory markers seen with the a-linole-
nic acid diet were greater than with the linoleic acid diet (75,
80, 37·5 and 12 % decreases in CRP, sVCAM-1, sICAM-1 and
sE-selectin concentrations, respectively). Since this diet is
effectively replacing some linoleic acid with a-linolenic acid,
relative to the amounts in the linoleic acid diet, these results
suggest that a-linolenic acid is more potent than linoleic
acid with regard to reducing inflammation.
The studies just described have focused on increasing
intake of linoleic and a-linolenic acids to study their effects.
The study of Liou et al.(607) used a different approach. They
kept the amount of a-linolenic acid in the diet of men aged
20–45 years constant over the study period at about 1 % of
energy. Linoleic acid intake was either 10·5 or 3·8 % of
energy. Saturated fat was also constant across the two diets
at about 8 % of energy. The manipulation of linoleic acid
was at the expense of oleic acid (17 or 10 % of energy). The
intervention duration was 4 weeks and a random order,
cross-over design was used. CRP and IL-6 concentrations
were not different after 4 weeks on either diet. This finding
is in accordance with that of Turpeinen et al.(597).
Arachidonic acid. Arachidonic acid intake in the diet is
low relative to that of its metabolic precursor linoleic acid
(approximately 500mg/d v. approximately 11g/d, respectively).
Nevertheless, arachidonic acid is the most prevalent n-6
PUFA and PUFA in the membranes of inflammatory cells
and other cells that might be involved in low-grade inflam-
mation such as endothelial cells and platelets. This reflects
the important functional role of arachidonic acid as a precur-
sor of the eicosanoid family of lipid mediators; this family
includes the 2-series PG and the 4-series leukotrienes. Since
these eicosanoids are classically associated with inflammatory
processes and are targeted by common anti-inflammatory
therapies, it is generally considered that arachidonic acid
will enhance inflammation. However, observations that classi-
cal pro-inflammatory mediators such as PGE2 can also exert
anti-inflammatory effects and that arachidonic acid gives rise
to anti-inflammatory mediators such as lipoxin A4 have started
to challenge the earlier view(608). Several studies have exam-
ined the association between arachidonic acid status and mar-
kers of low-grade inflammation. There was no association
between arachidonic acid in granulocytes and CRP concen-
tration(374). Serum free arachidonic acid was not associated
with sICAM-1 or sE-selectin concentrations and was actually
inversely associated with sVCAM-1 concentration(585). Ferrucci
et al.(578) reported no association between arachidonic acid in
plasma and CRP, TNF-a, IL-1b, IL-10 and sIL-6R concen-
trations, while there was an inverse association with IL-6
and IL-1ra concentrations and a positive association with
TGF-b concentration. These observations suggest either that
plasma arachidonic acid has little impact on low-grade
inflammation (does not affect CRP or TNF-a) or that it is
anti-inflammatory (lowers IL-6; increases TGF-b).
There are very few intervention studies with arachidonic
acid reporting on low-grade inflammation. In an uncon-
trolled study, Kelley et al.(609) reported higher granulocyte
numbers in the blood of a group of ten healthy men (aged
20–38 years) taking a supplement of 1·5 g/d of arachidonic
acid for 100 d compared with numbers after a run-in diet
providing 200 mg/d of arachidonic acid. In another small,
but controlled, study, eight subjects aged 55–75 years con-
sumed capsules providing 700 mg/d of arachidonic acid for
12 weeks(605); there was no effect on plasma sVCAM-1,
sICAM-1 or sE-selectin concentrations.
Marine-derived long-chain n-3 PUFA. The long-chain
n-3 PUFA EPA and DHA are found in seafood, especially
oily fish. They are also present in fish oils and in certain algal
oils; in some preparations, the fatty acids are in a more con-
centrated form than in natural fish oils. In fish oils, the fatty
acids are in the TAG form, but other forms of long-chain n-3
PUFA are also available, for example, as phospholipids or
ethyl esters. Increased intake of long-chain n-3 PUFA results
in increased proportions of those fatty acids in inflammatory
cell phospholipids(610–614). The incorporation of EPA and
DHA into human inflammatory cells is partly at the expense of
arachidonic acid, resulting in less substrate available for the syn-
thesis of the classic inflammatory eicosanoids such as PGE2.
Through altered eicosanoid production, n-3 PUFA could affect
inflammation and inflammatory processes, although they also
exert non-eicosanoid-mediated actions on cell signalling and
gene expression. The effects of long-chain n-3 PUFA have
been examined in many model systems and findings from
Diet and low-grade chronic inflammation S41
B
ri
ti
sh
Jo
u
rn
al
o
f
N
u
tr
it
io
n
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S0007114511005460
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 30 May 2017 at 13:31:36, subject to the Cambridge Core terms of use, available at
cell-culture systems and from animal models are generally con-
sistent in identifying anti-inflammatory actions(569). Further-
more, clinical trials have demonstrated anti-inflammatory
effects and clinical benefit from fish oil administration in dis-
eases with a frank inflammatory basis including rheumatoid
arthritis(615), inflammatory bowel diseases(616) and childhood
asthma(617).
Data from subgroups of the Physicians’ Health Study and
the Nurses’ Health Study showed inverse associations between
the dietary intake of EPA þ DHA and concentrations of CRP,
sTNFR1 and sTNFR2(583), and CRP, sICAM-1, sVCAM-1 and
sE-selectin(373). The concentration of either EPA or DHA in
granulocyte membranes was inversely associated with CRP
concentration in one study(374); the effect of DHA was stronger
than that of EPA. Serum non-esterified EPA and DHA were
both inversely associated with concentrations of sVCAM-1
and sICAM-1 in patients at risk of CHD(585); EPA was also
inversely associated with sE-selectin concentration. Plasma
cholesteryl ester EPA was inversely associated with CRP con-
centration in overweight subjects(579). In an elderly Italian
population, plasma EPA was inversely associated with IL-6
concentration and positively associated with the concen-
trations of the anti-inflammatory cytokines IL-10 and TGF-
b(578). Furthermore, plasma DHA was inversely associated
with IL-6 and TNF-a concentrations and was also positively
associated with the concentrations of IL-10 and TGF-b(578).
Thus, observational studies suggest that both EPA and DHA
are anti-inflammatory.
The ready availability of fish oil capsules has facili-
tated numerous supplementation studies of long-chain n-3
PUFA in various subject groups; these are summarised
in Table 16(164,605,618–646). Studies have shown that long-
chain n-3 PUFA lower the concentrations of CRP(621,624,639),
IL-6(621,624,639), TNF-a(639), IL-18(643), sICAM-1(625,628,645,646),
sVCAM-1(605,645) and sE-selectin(618) in various subject/patient
groups (see Table 16). For example, one study showed an
increase in adiponectin concentration when a weight-loss
programme and 4·2 g/d EPA þ DHA were combined in over-
weight, insulin-resistant women(632). Thus, there is quite a
lot of evidence for anti-inflammatory effects of supplemental
long-chain n-3 PUFA. In a group of overweight women with
type 2 diabetes, 8 weeks of a moderate dose of long-chain
n-3 PUFA (1·8 g/d of EPA þ DHA) decreased adiposity and
reduced expression of a number of inflammation-related
genes in the subcutaneous adipose tissue(630). The parallelism
between the down-regulation of these genes and the
reduction in adiposity and adipocyte diameter by n-3 PUFA
treatment suggests a positive relationship between adipose
cell size and adipose tissue inflammation, agreeing with
other observations(31,66). Also these findings in type 2 diabetic
women are paralleled by those from rodent studies: 6 weeks
of n-3 PUFA supplementation prevented adipose tissue
inflammation induced by a high-fat diet(647), and the presence
of n-3 PUFA in the diet of long-term insulin-resistant, sucrose-
fed rats decreased adipocyte diameter(648) and significantly
reduced several inflammation-related genes (unpublished
results, Guerre-Millo M, Naour N, Lombardo Y, Clement K,
Rizkalla S). These studies suggest that reducing adiposity
with n-3 PUFA could decrease adipose tissue inflammation
and macrophage infiltration. The beneficial effects of n-3
PUFA may be linked to local blunting of adipose tissue
inflammation.
Despite the large number of positive studies with long-chain
n-3 PUFA, there are a number of studies that have failed
to replicate these findings (see Table 16). Furthermore, two
early studies showed an enhancement of selected inflam-
matory markers following long-chain n-3 PUFA adminis-
tration(629,642). Seljeflot et al. provided 4·8 g/d of EPA þ DHA
in ethyl ester form to hyperlipidaemic male smokers for 6
weeks, while Johansen et al. provided 5·1 g/d of EPA þ DHA
in ethyl ester form to patients with CHD for 24 weeks.
Both studies identified an increase in sVCAM-1 (,10 %) and
sE-selectin (20 %) concentrations, with no effect on sP-selectin
and a decrease in von Willibrand factor and thrombomodulin
concentrations. In both cases, the authors ascribed the
effect of EPA þ DHA on sVCAM-1 and sE-selectin to increased
oxidant stress in these subjects.
Thus, although the overwhelming view is that EPA þ DHA
given at sufficient doses are anti-inflammatory, the evidence
from measurements of markers of low-grade inflammation is
not entirely consistent. The lack of consistency may be related
to differences in: duration of treatment; sample size; character-
istics of the populations studied (e.g. age, healthy v. diseased,
type of disease, smokers v. non-smokers); background diet;
dose of EPA þ DHA used; relative contribution of EPA and
DHA, since they may have different anti-inflammatory poten-
cies; chemical formulation (e.g. TAG v. ethyl ester); degree of
oxidative stress present. One other factor that has been
recently identified is genetic differences among individuals,
which may have an impact on the ability of n-3 PUFA to
exert an anti-inflammatory effect. This was first identified by
Grimble et al.(649) who showed that the ability of fish oil to
lower the LPS-stimulated production of TNF-a by blood
mononuclear cells was determined in part by polymorphisms
within the TNF-a and TNF-b genes. Another example of such
an interaction was identified by Shen et al.(650). They first
identified that the IL-1b 6054 G . A SNP was significantly
associated with CRP and adiponectin concentrations and
with the prevalence of the metabolic syndrome among a
group of 1120 men and women with a mean age of 49
years. There was also a significant interaction between this
polymorphism and erythrocyte membrane n-3 PUFA content.
Among subjects with low erythrocyte n-3 PUFA content
(below the median), the 6054 G allele was associated with
increased risk of the metabolic syndrome (OR 3·29, 95 % CI
1·49, 7·26 for GG and OR 1·95, 95 % CI 0·85, 4·46 for GA) com-
pared with the AA genotype, but there were no significant
genotype associations among subjects with high erythrocyte
n-3 PUFA content (above the median). The results suggest
that IL-1b genetic variants are associated with measures of
chronic low-grade inflammation and the risk of the metabolic
syndrome, and that genetic influences were more evident
among subjects with low erythrocyte n-3 PUFA status and
so, most probably low n-3 PUFA intake.
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Carbohydrates
Acute postprandial effects of hyperglycaemia. Hyper-
glycaemia, elevated TAG/NEFA and hyperinsulinaemia are
events that are mutually inherent to the initial development
of a diabetic state. The effects of the individual events are
difficult to study since they always present together. However,
some observations have suggested that hyperglycaemia and
hypertriacylglycerolaemia/elevated NEFA levels induce inde-
pendent effects and, when present together, act synergistically
to generate oxidative stress, inflammation, impaired endo-
thelial function and vascular disease(651–653). Oxidative stress
is known to induce damage to cell membranes, internal cell
structures and DNA as well as to induce inflammatory
responses (Fig. 8) (654). Ceriello et al.(652) observed that after
meals LDL oxidation increases and that this phenomenon is
correlated with the degree of hyperglycaemia. This clearly
points to hyperglycaemia-induced free radical production
that has an impact on a broad range of metabolic events.
NO, a potent vasodilator, is assumed to play a key role in
this respect. It has been suggested that hyperglycaemia
leads to an increased oxidation of NO, thereby reducing
NO levels which leads to impairment in vasodilatation(655).
Indeed, alloxan diabetic rats are observed to have reduced
NO levels in blood(656), and in human subjects, acute
hyperglycaemia attenuated endothelium-dependent vasodila-
tion(657). Postprandial hyperglycaemia is also correlated with
impaired myocardial perfusion in diabetic patients(658). The
fact that such a decrease can be prevented by supplying
various antioxidants such as vitamin C, vitamin E and
a-lipoic acid(659–662) or L-arginine(656,663), the precursor of
NO, suggests that increased NO oxidation and the related
NO drain have an impact on cells of the vasculature. This is
supported by other evidence. Restoration of NO availability
results in normalisation of endothelial function as well as
insulin sensitivity(659,660). During an oral glucose tolerance
test, plasma antioxidant status, measured as total plasma
radical trapping capacity, significantly decreased in normal
as well as in diabetic individuals. The consumption of a
glycaemic meal increases oxidative stress and reduces anti-
oxidant defences, with the increase being significantly greater
with higher levels of hyperglycaemia(169,664,665). Acute post-
meal hyperglycaemia was observed to induce the formation
of nitrotyrosine, a marker of oxidative stress, in healthy,
non-overweight individuals(666). It has been hypothesised
that acute hyperglycaemia may induce a drain of vitamin C
from cells because vitamin C and glucose share a common
transport system(667) and oxidative stress leads to a use of
intracellular vitamin C. Accordingly, Chen et al.(668) provided
evidence in vitro that acute hyperglycaemia leads to a signifi-
cant decrease in leucocyte vitamin C content. Evans et al.(662)
developed a unique oxidative stress hypothesis suggesting
that chronic elevation of hyperglycaemia (and NEFA) induces
an activation of the NF-kB, p38 MAPK and NH2-terminal
Jun kinase/stress-activated protein kinase pathways. This
happens along with the activation of the RAGE, protein
kinase C and sorbitol stress pathways. The authors suggest
that these events play a key role in causing late complicationsT
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in type 1 and type 2 diabetes, going along with insulin
resistance and impaired insulin secretion in type 2 diabetes.
Evans et al.(662) provided evidence that elevated glucose
causes oxidative stress due to increased production of
mitochondrial ROS, non-enzymatic glycation of proteins and
glucose auto-oxidation. They also pointed out that elevated
NEFA can cause oxidative stress due to increased mitochondrial
uncoupling and b-oxidation, the latter leading to an increased
production of ROS and to an activation of stress-sensitive
signalling pathways, which in turn impair insulin secretion
and action. Thus, oxidative stress induced by acute and chronic
elevations in glucose and NEFA plays a key role in causing insu-
lin resistance and b-cell dysfunction. A range of studies has
shown that acute and lasting hyperglycaemia leads to an
elevation in dicarbonyls and protein glycation (measured as
fructosamine or HbA1c). Glycosylated proteins, as well as
their metabolites, AGE, which bind to the AGE receptor
RAGE, induce a cascade of signals that initiate an inflammatory
response(669). Accordingly, pro-inflammatory transcription
factors, inflammatory markers including CRP, IL-6, IL-8,
TNF-a and matrix metalloproteinase and markers of endo-
thelial dysfunction VCAM-1, ICAM-1 and E-selectin have been
observed to be elevated in response to acute and persistent
hyperglycaemia(474,475,514,521,653,662,670,671).
Glycaemic index, glycaemic load and inflammation.
Dietary glycaemic index (GI) and glycaemic load (GL) were
both positively associated with plasma CRP concentration in
18 137 healthy women aged .45 years without diagnosed
diabetes(672). In another study in 974 subjects aged 42–87
years, dietary GI was positively associated with CRP concen-
tration(673). Qi et al.(315) examined the associations of dietary
GI and GL with plasma adiponectin among 780 diabetic
men from the Health Professionals’ Follow-Up Study. After
adjustment for other factors, dietary GI and GL were both
significantly inversely associated with plasma adiponectin
concentration in a dose-dependent fashion. Adiponectin
levels were 13 % lower in the highest quintile of dietary GI
than in the lowest quintile. For dietary GL, adiponectin
levels were 18 % lower in the highest quintile than in the
lowest. Several intervention studies have examined the
impact of dietary GI or GL on markers of chronic low-grade
inflammation. In one study, thirty-four healthy overweight
adults aged 24–42 years received energy-restricted diets with
high or low GL for 6 months(674); more subjects in the low
GL group showed a decline in serum CRP concentration
than in the high GL group. In another study, Shikany
et al.(675) found no differences in CRP, TNF-a, IL-6, fibrinogen,
sTNFR2 or PAI-1 concentrations when overweight or obese
men consumed diets with high or low GI for 4 weeks.
Likewise, 11-week interventions of high- or low-GL diets in
fifteen overweight subjects had no differential effects on
CRP, TNF-a, IL-6 or MCP-1 concentrations(676). Thus, evidence
from large observational studies is highly suggestive that there
is a positive association between GI/GL and low-grade
inflammation, but intervention trials do not support this
convincingly, perhaps because of the small size of most of
the latter trials.T
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Table 16. Intervention studies investigating the effect of marine n-3 PUFA intake on markers of low-grade inflammation
Subjects n (sex) Age (years) Intake (source; duration) Effect on low-grade inflammation Reference
Healthy 58 (M) in four groups 21–87 (mean 56) 0, 1·06, 2·13, 3·19 g/d EPA þ DHA
(FO capsules; up to 52 weeks)
¼ TNF-a, IL-1b, IL-1ra 620
Healthy and hyperlipidaemic 20 Healthy (M/F) and 39
hyperlipidaemic (M/F)
Mean ,51 0, 3·6 g/d EPA þ DHA (EE capsules; up to 6 weeks) ¼ sICAM-1, sVCAM-1
# sE-selectin
618
Hyperlipaemic smokers 41 (M) in four groups (two
received n-3 PUFA)
41–57 (mean ,48) 0, 4·8 g/d EPA þ DHA (EE capsules; 6 weeks) " sVCAM-1, sE-selectin
¼ sP-selectin, tissue plasminogen
activator antigen
# von Willibrand factor, thrombomodulin
642
Patients with CHD 54 (M/F) in two groups 43–73 (mean 57) 0, 5·1 g/d EPA þ DHA (EE capsules; 24 weeks) " sVCAM-1, Se-selectin
¼ sP-selectin, tissue plasminogen
activator antigen
# von Willibrand factor, thrombomodulin
629
Healthy and type 2 diabetics 21 Healthy (M) and
29 diabetics (M)
Mean ,55 2·0 g/d EPA þ DHA (FO capsules; 3 weeks) ¼ sICAM-1, sVCAM-1, sE-selectin,
PAI-1 activity, PAI-1 antigen
640
Healthy 24 (M/F) in three groups 55–75 0, 0·7 g/d DHA (DHA-rich algal oil capsules; 12 weeks),
1 g/d EPA þ DHA (FO capsules; 12 weeks)
EPA þ DHA:
¼ sICAM-1, sE-selectin
# sVCAM-1
DHA: ¼ sICAM-1, sVCAM-1, sE-selectin
605
Obese 48 (M) in four groups (two
received n-3 PUFA)
Mean 53(SD 7) 0, 3·5 g/d EPA þ DHA (EE capsules; 6 weeks) ¼ CRP, IL-6, TNF-a 623
Elderly at risk of CHD 171 (M) in four groups
(two received n-3 PUFA)
Mean 70(SD 3) 0, 2·4 g/d EPA þ DHA (FO capsules; 18 months) ¼ sICAM-1, sVCAM-1, sE-selectin,
tissue plasminogen activator antigen
# von Willibrand factor, thrombomodulin
619
Healthy on hormone
replacement therapy
30 (F) in three groups Mean 60 0, 1·09, 2·18 g/d EPA þ DHA
(FO capsules; 5 weeks)
# CRP, IL-6 624
Healthy 60 (M/F) in three groups 21–57 (mean 38) 0, 2·0, 6·6 g/d EPA þ DHA
(FO capsules; 12 weeks)
¼ CRP 633
Myocardial infarction survivors 300 (M/F) in two groups 28–87 (mean 65) 0, 3·5 g/d EPA þ DHA (EE capsules; 12 months) ¼ sICAM-1, sVCAM-1, sE-selectin 627
Type 2 diabetics 59 (M/F) in three groups 40–65 (mean 61) 0, 4 g/d EPA, 4 g/d DHA
(EPA EE or DHA EE capsules; 6 weeks)
¼ CRP, IL-6, TNF-a, von Willibrand
factor, tissue plasminogen activator
antigen, PAI-1 antigen, sP-selectin
636, 644
Healthy 60 (M/F) in three groups Mean ,38 0, 1·6, 5·8 g/d EPA þ DHA
(concentrated FO capsules; 3 years)
Low dose:
¼ sVCAM-1, sP-selectin
# sICAM-1 (especially in women)
High dose:
¼ sICAM-1, sVCAM-1
# sP-selectin
625
Obese 11 (M) Not given 1·1 g/d EPA þ DHA (FO capsules; 6 weeks) ¼ CRP, IL-6, sTNFR1, sTNFR2, PAI-1 164
Hyperlipidaemia 563 (M) in four groups
(two received n-3 PUFA)
64–76 (mean 70) 0, 2·4 g/d EPA þ DHA (FO capsules; 3 years) ¼ sVCAM-1, sE-selectin,
von Willibrand factor, tissue plasminogen
activator antigen
# sICAM-1, thrombomodulin
628
Healthy 93 young (M) and 62 older
(M) in four groups
Mean 24(SD 10)
Mean 61(SD 8)
0, 1·35, 2·7, 4·05 g/d EPA þ DHA (EPA-rich oil; 12 weeks) ¼ sICAM-1, sVCAM-1
" sE-selectin (young only)
622
Healthy 141 (M/F) in two groups Mean ,47 0, 0·96 g/d EPA þ DHA (FO in soya milk; 12 weeks) ¼ CRP, sTNFR1, sTNFR2 626
Overweight and insulin resistant 116 (F) in three groups 21–69 (mean 45) 0, 0 þ weight-loss programme, 4·2 g/d EPA þ DHA þ
weight-loss programme (concentrated FO
capsules; 24 weeks)
" Adiponectin
¼ CRP, TNF-a, IL-6
632
Healthy 80 (M/F) in two groups Mean ,30 0, 1·5 g/d DHA (DHA-rich algal oil; 4 weeks) ¼ CRP, fibrinogen, PAI-1 activity,
von Willibrand factor
641
Overweight type 2 diabetics 27 (F) in two groups Mean 55 0, 1·8 g/d EPA þ DHA (FO capsules; 8 weeks) ¼ IL-6, TNF-a, SAA, adiponectin
# PAI-1 activity, inflammatory gene
expression in adipose tissue
630
Overweight and obese 30 (F) in two groups Not given 0, 4·2 g/d EPA þ DHA (DHA-rich TAG capsules;
12 weeks; cross-over)
¼ Sialic acid, fibrinogen, PAI-1 activity
# CRP, IL-6
621
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Dietary fibre. In NHANES 1999–2000 in the USA, dietary
fibre intake was inversely associated with serum CRP
concentrations (OR 0·49 for 32 g/d v. 5·1 g/d) in diabetic
women (n 3920)(677), as well as in subjects with diabetes,
hypertension and obesity (n 7891)(678). Similar findings were
reported in a cross-sectional study with healthy subjects
(n 205) and in subjects with metabolic disorders (n 1653) in
Italy(679). In the Seasonal Variation of Blood Cholesterol
Levels Study involving 524 subjects, who had multiple
measurements of CRP and dietary intake, dietary total fibre
and soluble and insoluble fibre were all inversely related
to CRP concentration in the regression models adjusted for sev-
eral traditional cardiovascular risk factors, current infection
status and season of year(680). In contrast, the same authors
observed no correlation between dietary fibre intake and
blood CRP concentrations with a single measurement at base-
line in the Women’s Health Initiative Observational Study(681).
However, there was an inverse association between fibre
intake and IL-6 and sTNFR2 concentrations in this female
population. In a study with diabetic males (n 780, Health
Professionals’ Follow-Up Study), cereal fibre was positively
associated with adiponectin levels after controlling for a
number of confounding factors(315). King et al.(682) conducted
an intervention study with thirty-five lean normotensive
and seventeen obese hypertensive adults that involved a
randomised cross-over design. The two intervention diets
constituted either the Dietary Approaches to Stop
Hypertension (DASH) diet (naturally high in fibre i.e. 30 g
fibre/d) or a fibre-supplemented usual diet (30 g psyllium
fibre/d) each for a 3-week period. Both diets caused a
reduction in CRP concentration (14 and 18 %, respectively),
although this was significant only in lean normotensive
subjects in either intervention arm. The data generally support
that dietary fibre intake is associated with reduced low-grade
inflammation.
Milk peptides
Increased consumption of dairy products has been shown
to have beneficial effects on plasma CRP and adiponectin
concentrations in obese subjects(683). This effect has been
suggested to be partly explained by the intake of dairy
protein-derived peptides. Indeed, the casein-derived peptides
Ile-Pro-Pro and Val-Pro-Pro slightly, though not significantly,
lowered CRP concentration in hypertensive subjects after
10 weeks(684). Whey protein-derived peptides lowered CRP
concentration (after 6 weeks) in one study in hypertensive
subjects(685), but not in another(686). Minor dairy proteins and
peptides, especially lactoferrin, also show anti-inflammatory
effects in different models(687–689), and hence there is poten-
tial for a variety of milk peptides to have anti-inflammatory
effects, but there are no or insufficient human studies to
allow evaluation of their efficacy.
Micronutrients and phytochemicals
Iron
The topic of Fe in relation to low-grade chronic inflammation
is complex. Part of the complexity is related to the factTa
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that Fe status assessment is confounded in the presence of
inflammation(690–692). Fe status assessment relies on a battery
of laboratory tests spanning various stages of Fe deficiency.
These tests include: serum ferritin, which generally indicates
body Fe stores; soluble receptor of transferrin in serum
(transferrin receptor) reflecting tissue Fe; serum transferrin,
total Fe-binding capacity and transferrin saturation, which
indicate Fe-deficient erythropoiesis; finally, red cell indices
namely mean cell volume, Hb and haematocrit, which are
considered functional Fe indices. Others have suggested the
ratio of transferrin receptor:serum ferritin as an index of
total body Fe stores(693). Most tests of Fe status, however,
are affected in response to subclinical inflammation and
infections(690–692). Thus, it becomes difficult to study the
relationship of Fe with any outcome of interest when inflam-
mation is present. Recent studies have suggested that serum
transferrin receptor remains unaffected in the presence of
inflammation or infectious disease (reviewed in Ahluwalia(690)
and Northrop-Clewes(694)), thus allowing the examination of
the role of Fe in conditions with an underlying inflammatory
component.
Deficiency v. excess. Fe has been called a double-edged
sword, as both Fe deficiency and excess can have delete-
rious effects(695). Fe is important in immune/inflammatory
responses including neutrophil activation, macrophage
effector functions, and T-helper cell type-1 and -2 (Th1/Th2)
patterns (reviewed in Weiss(695)). Fe deficiency is associated
with alterations in the immune response and increased risk
of infections(695–697). On the other hand, because Fe is a
redox-active transition metal, it may contribute to the pro-
duction of ROS, oxidative stress and inflammation(698,699),
and thus Fe excess can augment the risk for diabetes and
CVD. It is important to indicate that ROS are produced by
free, and not bound, Fe(700) and the body has evolved a
metabolic system that minimises the availability of free
Fe(698). Most Fe in the body is not free, and is bound to pro-
teins such as ferritin, transferrin and Hb; thus, serum ferritin,
transferrin, transferrin saturation and Hb measurements do
not reflect the availability of ‘free’ or ‘labile’ Fe that is impli-
cated in the production of ROS. In recent years, the measure-
ment of non-transferring-bound labile Fe(701) has been
introduced; however, few studies have utilised this measure-
ment to date due to technical, cost and standardisation issues.
Iron status and low-grade inflammation. There is some
epidemiological evidence that higher Fe intake, particularly
that of haem Fe, and higher Fe status are associated with
increased risk of type 2 diabetes, atherosclerosis and
CHD(702–714), although not all of the literature is consistent.
It is not clear whether the association of Fe intake and
status with diabetes or CVD is mediated through the effects
of Fe on inflammatory pathways. In a small study with
thirty-one carbohydrate-intolerant patients, quantitative phle-
botomy was used to induce Fe depletion to near-deficiency
levels(715). The induced Fe deficiency was associated with
reductions in several CVD risk factors as well as in the
inflammatory marker fibrinogen. While uncertainty exists as
to whether Fe plays a causative role in the aetiology of
low-grade inflammation and its associated pathologies, past
and emerging evidence indicates that chronic low-grade
inflammation is associated with poor Fe status in obese
persons(716–721). A concomitant improvement in Fe status
(as measured by transferrin saturation) and decrease in
inflammation (CRP and orosomucoid concentrations) has
been observed after bariatric surgery intervention in morbidly
obese women(722). In total, emerging evidence indicates that
the low-grade inflammation of obesity may be associated
with low Fe status; however, further investigation of this
relationship is warranted.
A small number of studies have investigated the
effects of increasing total Fe or haem Fe intake on markers
of inflammation(723–725). In a small study involving three
healthy volunteers who received 120 mg Fe/d for a week,
there were no changes in circulating CRP concentration or
leucocyte counts, or in urinary neopterin concentration(725).
Furthermore, postpartum Fe supplementation (80 mg/d)
for 12 weeks in non-anaemic Fe-deficient women did not
significantly alter CRP concentration or leucocyte counts(726).
In a small study in 8–11-year-old Guatemalan children who
received twice the recommended daily amounts of Fe for
8 weeks (n 20) or placebo (n 20), no differences in CRP
or orosomucoid concentrations were noted, although a-1
antichymotrypsin levels were increased with the Fe sup-
plement(724). In another study examining the effect of
increasing lean red meat intake, participants were either
Hyperglycemia
• Fasting
• Postprandial
+
+
++
+
• Glycation
• Polyol-hexosamine
  pathway
• Glucose autoxidation
Free radicals
superoxide
PKC Peroxynitrite
Inflammatory responses
NF-κB
Fig. 8. Schematic representation of the general mechanisms by which hyper-
glycaemia can affect inflammation. PKC, protein kinase C. Reproduced with
permission from Giugliano et al.(654).
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assigned to a control group (maintain their usual diet) or to
partially replace energy from carbohydrate-rich foods with
200 g/d of lean red meat for 8 weeks(723). In this short
intervention, increased red meat intake was not associated
with increased oxidative stress or inflammation. Taken
together, the evidence from these limited studies examining
the effect of Fe supplementation or increased red meat
intake on inflammatory markers suggests no major effect on
inflammation; however, there is a need for further larger
well-designed studies to clarify this effect.
Vitamin D
Various immune cells including monocytes/macrophages,
dendritic cells, T-cells and B-cells can convert inactive vitamin
D3 to its active form (1,25(OH)2D3), and these cells can also
respond to the active vitamin D via its receptor which they
express(727). It seems likely that vitamin D plays a paracrine
modulatory role in the immune/inflammatory system(728).
Although a pro-inflammatory role of vitamin D has also
been suggested(729), epidemiological data show an association
between vitamin D deficiency and increased risk of several
inflammatory diseases including type 1 diabetes and athero-
sclerosis(730). Vitamin D has several anti-inflammatory actions.
It blunts the pro-inflammatory effects of AGE on endothelial
cells, suggesting that it acts as an endogenous vascular protec-
tor counteracting the possible deleterious effects of AGE(731).
Vitamin D inhibits the proliferation of lymphocytes and
induces their apoptosis(732). In addition, vitamin D affects
the expression of ICAM-1 on mononuclear cells and on endo-
thelial cells, suggesting that it suppresses the recruitment of
leucocytes to sites of inflammation(732). In vitro, vitamin D
modulates the pro-inflammatory profile of monocytes/macro-
phages from type 2 diabetic patients(733). Vitamin D also
suppresses TNF-a expression in monocytes/macrophages(734)
and down-regulates the expression of TLR2 and TLR4
in human monocytes(735–737). Indeed, vitamin D primes
monocytes to respond less effectively to bacterial cell wall
components, most probably due to the aforementioned
suppression of TLR(735). Vitamin D analogues selectively
inhibit the inducible cyclo-oxygenase-2(738), which could be
viewed as an anti-inflammatory action. Exposure to vitamin
D increases the rate of the de-phosphorylation of activated
extracellular signal-regulated kinases(739), a subset of the
mammalian MAPK family involved in inflammatory processes.
Serum vitamin D concentration was associated with leucocyte
telomere length in 2160 women aged 18–79 years (mean age
49 years) and was inversely associated with CRP concen-
tration(740). Within any tertile of vitamin D status, telomere
length was longer in those with lower CRP concentrations,
suggesting that inflammation plays a role in those processes
associated with telomere shortening.
There are several studies looking at the association between
vitamin D status (typically assessed as serum or plasma
25(OH)D3) and various markers of low-grade inflammation
in different population subgroups. Shea et al.(741) reported
no significant association between plasma vitamin D concen-
tration and concentrations of CRP, fibrinogen, TNF-a, IL-6,
sTNFR2, sICAM-1, MCP-1, sP-selectin and sCD40 ligand in
almost 1400 American adults with a mean age of 59 years.
Likewise, there was no association of vitamin D status with
serum CRP concentration in 650 Amish(742) or with CRP,
sICAM-1, MCP-1, IFN-g, IL-2, IL-4, IL-5, IL-10, IL-12, IL-13
or IL-17 concentrations in 437 overweight adults(743). Using
data from over 6500 British adults aged 45 years, Hypponen
et al.(744) reported that the significant inverse associations
between serum 25(OH)D3 concentration and serum CRP and
fibrinogen were lost after adjustment for confounding factors.
Among 261 healthy men and women, plasma 25(OH)D3 was
not correlated with resistin, adiponectin or IL-18 concen-
trations but was inversely correlated with leptin concen-
tration(745). Among forty-four morbidly obese subjects,
25(OH)D3 did not correlate with leptin, resistin, adiponectin
or IL-18. Jablonski et al.(746) examined the inflammatory phe-
notype of endothelial cells collected from the antecubital vein
of middle-aged and older subjects: endothelial cell expression
of NF-kB and of IL-6 were both higher in vitamin D-deficient
subjects, and IL-6 expression was inversely related to
25(OH)D3 concentration. Using data pooled from thirty-six
healthy subjects, twenty-four type 1 diabetics and twenty-six
type 1 diabetics with microvascular complications, Devaraj
et al.(747) found significant inverse relationships between
serum 25(OH)D3 and CRP concentration, monocyte NF-kB
activation and TLR4 expression. Most recently, NHANES data
for 5867 adolescents aged 12–19 years showed no relation-
ship between serum 25(OH)D3 and CRP concentrations
(748).
Thus, association studies have consistently found little,
if any, association between vitamin D status and circulating
markers of inflammation. However, two studies that investi-
gated cellular markers of inflammation both reported an
anti-inflammatory effect of vitamin D(747,748).
Most intervention studies with vitamin D have failed to
identify a reduction in markers of low-grade inflam-
mation(744,749,750). These studies each had a different design.
Pittas et al.(749) provided 700 IU (17·5mg) vitamin D3 plus
500 mg calcium citrate daily to adult non-diabetics for 3
years in a double-blind, randomised, controlled trial and
found no effect on plasma CRP or IL-6. Witham et al.(751) pro-
vided 100 000 IU (2500mg) vitamin D2 or placebo to elderly
patients with systolic heart failure at study entry (week 0)
and after 10 weeks and found no effect on plasma TNF-a at
10 or 20 weeks. Jorde et al.(743) provided 40 000 or 20 000 IU
(1000 or 500mg) vitamin D3 per week or placebo to over-
weight subjects for 1 year; there was no difference between
groups in the changes in concentrations of CRP, sICAM-1,
MCP-1, IFN-g, IL-2, IL-4, IL-5, IL-10, IL-12, IL-13 or IL-17
over the course of the study. Thus, these intervention studies
suggest little anti-inflammatory action of vitamin D in the sorts
of subjects studied. However, compared with placebo, vitamin
D (3300 IU (82.5mg)/d for 12 months) resulted in a decrease
(by 10 %) in TNF-a concentration in overweight subjects on
a weight-reduction programme(752). This finding suggests
that vitamin D dose, the nature of the supplementation regi-
men and the health status of the individuals under study,
as well as starting vitamin D status, may all be important
factors in determining the effect of supplemental vitamin D.
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Antioxidant vitamins (vitamin C, vitamin E and
carotenoids)
Vitamin C is a potent water-soluble antioxidant. Ascorbate is
the active form of vitamin C and exerts antioxidant function.
Upon its action as an antioxidant, ascorbate is oxidised to
dehydroascorbate which can be reduced back to ascorbate
by the oxidation of reduced glutathione to glutathione disul-
fide. Ascorbate is present at high concentrations in leucocytes,
suggesting a significant role in inflammation and in protection
against oxidative damage. Patients with the metabolic syn-
drome or diabetes showed decreased vitamin C status and
increased lipid peroxidation(753–756). These findings could be
explained by increased oxidative stress as a result of diabetes
leading to consumption of ascorbate or a role of low vitamin C
status as a risk factor for the development of diabetes. Obese
subjects have lower plasma vitamin C concentrations than
non-obese, and obesity was associated with moderately elev-
ated CRP concentrations(757). In another study, low plasma
vitamin C concentrations were related to central fat distri-
bution, independent of BMI(758).
Vitamin E is an umbrella term for a number of tocopherols
and tocotrienols, although dietary vitamin E mainly consists of
a- and g-tocopherols. Vitamin E is a potent chain-breaking
antioxidant that acts mainly in the lipid phase and interrupts
the chain reaction of lipid peroxidation and, consequently,
prevents the propagation of free radical-initiated reactions.
There are differences in the antioxidant activity between
a- and g-tocopherols. In vitro, vitamin E exerts a range of
anti-inflammatory actions with regard to the production of
pro-inflammatory cytokines and eicosanoids and adhesive
interactions of monocytes with endothelial cells(750,759–761).
There is growing evidence that g-tocopherol, in contrast
to a-tocopherol, exerts anti-inflammatory properties which
can be explained by an unsubstituted position on the chro-
manol ring providing g-tocopherol with the ability to trap
reactive N species and subsequent formation of 5-nitro-g-toco-
pherol(762,763). Supplementation with a-tocopherol decreases
g-tocopherol concentrations(764,765) due to a preference of
the a-tocopherol transfer protein in the liver for a-tocopherol.
This results in increased metabolism to carboxyethyl-hydroxy-
chroman derivatives and excretion of the metabolites
in the urine(766). g-Tocopherol and g-carboxyethyl-hydroxy-
chroman exert actions that are not shared by a-tocopherol
and a-carboxyethyl-hydroxychroman(767).
Carotenoids include, among others, a-carotene, b-carotene,
lycopene, b-cryptoxanthin, lutein and zeaxanthin. They
are highly prevalent in red, yellow and green vegetables
and fruits. Carotenoids exert antioxidant properties and
some of them serve as provitamin A. Among 3258 healthy
men (age 68 (SD 5) years; BMI 26·7 (SD 3·6) kg/m2), dietary
vitamin C intake and plasma vitamin C concentrations were
both inversely associated with CRP concentrations(329).
Among 5181 subjects from the MESA aged 45–84 years,
intakes of vitamin C, vitamin E or b-carotene were not associ-
ated with CRP, IL-6 or fibrinogen concentrations after adjusting
for a number of factors(768). Recent data from the Womens’
Health Study reported that higher plasma concentrations of
a- and b-carotene were associated with lower plasma CRP
concentrations(769). Similar results were reported from
NHANES III for carotenoids and CRP(770,771). However, the
use of latex-enhanced nephelometry instead of a high-sensi-
tivity ELISA, and the fact that 74 % of the population had
levels below the assay’s detection limit, limits the interpret-
ation of their results. In another study, dietary intakes of vita-
min C, vitamin E and b-carotene did not predict the
concentrations of CRP, IL-6 or TNF-a in normal-weight, over-
weight and obese Swiss children aged 6–14 years, but they
were significant predictors of leptin concentrations(772).
Using data from a small number of middle-aged (mean age
44 years) vegetarians and omnivores (n 30 per group),
plasma vitamin C concentrations were found to be inversely
associated with CRP concentrations(295). In 379 Dutch adults,
serum lutein and lycopene concentrations were inversely
associated with sICAM-1 concentrations, serum b-carotene
with total blood leucocyte numbers and CRP concentrations,
serum vitamin C with CRP concentrations, while plasma a-
tocopherol concentrations were positively associated with
CRP concentrations(773). Among 437 Japanese subjects,
serum b-carotene concentrations were positively associated
with adiponectin concentrations(774). Other associations
among a- and b-carotene and CRP and IL-6 concentrations
were lost after adjustment for confounding factors. A larger
Japanese study (n 778 men and 1404 women) reported an
inverse association between serum vitamin C and CRP concen-
trations after adjustment for confounders(775). The association
was strongest in non-smokers, in non-overweight women and
in postmenopausal women. Recently, plasma vitamin C con-
centrations have been reported to be inversely associated
with plasma CRP concentrations in a small number of lean
and obese men (n 8 per group) with a mean age of 21
years(776). In patients with coronary artery disease, plasma
concentrations of b-carotene, but not lycopene, were inver-
sely correlated with plasma CRP concentrations(777). In one
prospective study with young normal-weight adults, a high
intake of carotenoids (a-carotene, b-carotene, zeaxanthin/
lutein and b-cryptoxanthin) was inversely related to plasma
CRP and ICAM concentrations after 7 and 15 years of
follow-up(778). In a second prospective study, a high intake
of carotenoids in elderly subjects (BMI 28·8 (SD 6·8) kg/m2)
was associated with lower plasma IL-6 concentrations, while
a-tocopherol did not correlate significantly(779). Among 704
70-year-old Swedish men, dietary intakes of vitamin C and
a-tocopherol, but not of b-carotene, were inversely associated
with CRP and IL-6 concentrations measured 7 years after
the dietary information was collected(780). Thus, overall, cross-
sectional andprospective studies fairly consistently demonstrate
that a higher intake and status of vitamin C, vitamin E and
carotenoids is associated with lower levels of low-grade
inflammation.
Taking 1 g of vitamin C or 533 mg of a-tocopherol before
consuming a high-fat test meal blunted the acute CRP
response to the meal(781). Plasma 8-iso PGF2a and MCP-1
concentrations decreased after consumption of 72 mg/d of
vitamin C from a vegetable soup(634); concentrations of
TNF-a, IL-1b and IL-6 did not change. Vitamin C (1 g/d for
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14 d) did not alter sICAM-1 concentrations or markers of
monocyte and neutrophil activation (neopterin and elastase,
respectively) in smokers or non-smokers (n 20 of each)(782).
Likewise, vitamin C supplements (250 mg three times per
week for 2 months) did not alter plasma CRP concentrations
in thirty-three chronic haemodialysis patients(783). Tomato
juice (delivering 20·6 mg lycopene/d) was compared with
tomato juice fortified with vitamin C (delivering 435 mg
vitamin C/d) over a 2-week intervention period: the vitamin
C-enriched juice did not affect plasma CRP, TNF-a or IL-1b
concentrations in healthy volunteers(784). Vitamin C (1 g/d
for 6 months) lowered sP-selectin, but not sVCAM-1,
sICAM-1 or sE-selectin concentrations in patients with chronic
degenerative aortic stenosis(785); combining vitamin C with
a-tocopherol (267 mg/d) lowered sICAM-1 concentrations.
Smokers given 515 mg vitamin C/d for 2 months had a 24 %
reduction in plasma CRP concentrations(786). A mixture of
vitamin C with a-tocopherol (371 mg/d), g-tocopherol
(171 mg/d), mixed tocotrienols (252 mg/d) and a-lipoic acid
(95 mg/d) resulted in a smaller effect (4·7 % reduction that
was not significant), suggesting that tocopherols, tocotrienols
or a-lipoic acid, or the combination, prevents the anti-inflam-
matory effect of vitamin C. Vitamin C (2 g/d for 4 weeks) did
not affect serum IL-6, IL-1b, sVCAM-1 or sICAM-1 concen-
trations in smokers, but combining 533 mg/d a-tocopherol
with the vitamin C decreased the concentrations of all four
inflammatory mediators; the combination of vitamin C and
267 mg/d a-tocopherol was without effect(787).
a-Tocopherol (800 mg/d for 3 months) decreased plasma
CRP concentrations in type 2 diabetics(788). Dalgard et al.(789)
examined the effect of a 28 d intervention with orange
and blackcurrant juice (500 ml/d), vitamin E (15 mg RRR-a-
tocopherol/d) or the combination of the two in patients
with peripheral vascular disease. The juice but not vitamin E
decreased CRP (by 11 %) and fibrinogen, but there was no
effect on IL-6 or PAI-1. In a randomised, placebo-controlled,
double-blind trial, subjects with the metabolic syndrome
received 800 mg/d a-tocopherol, 800 mg/d g-tocopherol,
a combination of both (800 mg/d each) or placebo; there
was a decrease in CRP concentrations only in the combined
a- and g-tocopherol supplementation group, while TNF-a
decreased with a-tocopherol alone or in combination with
g-tocopherol(790). Biomarkers of oxidative stress decreased
with a-tocopherol, g-tocopherol or the combination, while
nitrotyrosine, a biomarker of nitrative stress, decreased
with g-tocopherol alone or in combination with a-toco-
pherol(646–648). In another randomised, placebo-controlled,
double-blind trial, overweight and obese and normal-weight
young adults completed a standardised 30 min cycle exercise
bout before and after 8 weeks of supplementation with 800
IU/d of vitamin E (form not stated), 500 mg/d of vitamin C
and 10 mg/d of b-carotene(791). Adiponectin concentrations
were increased by 22 % in the overweight and by 3 % in the
normal-weight group receiving the supplement, but was
reduced in the placebo group. Changes in circulating IL-6
concentrations during exercise were lower in the sup-
plemented groups, as were the changes in lipid hydroperox-
ides(791). In contrast, a double-blind, placebo-controlled trial,
in which type 2 diabetics received 500 mg/d a-tocopherol or
mixed tocopherols containing 315 mg/d g-tocopherol,
reported no effect on CRP, IL-6, TNF-a or MCP-1 concen-
trations, although there was a decrease in plasma F2-isopros-
tane concentrations, a biomarker of lipid peroxidation, in
the mixed tocopherol group(792). A small study conducted in
healthy subjects (n 12) and patients with CHD (n 12) investi-
gated the effect of increasing intake of a-tocopherol (100, 200
and 400 mg/d each for 3 weeks sequentially)(793). At 200 mg/d,
plasma CRP, IL-6 and fibrinogen concentrations were
decreased in the CHD patients. A long-term (3 years) interven-
tion with the combination of vitamin C (500 mg/d) and a-
tocopherol (182 mg/d) in 45–69-year-old men did not alter
CRP, TNF-a or IL-6 concentrations(794). In one study, fifteen
children with familial hyperlipidaemia given vitamins C plus
E (500 mg/d and 400 IU/d, respectively) for 6 weeks showed
no changes in CRP concentration(795). In another study, six
weeks’ supplementation with vitamin C (1 g/d) plus vitamin
E (300 mg/d RRR-a-tocopherol) did not alter the magnitude
of the increase in circulating CRP, TNF-a and IL-6 concen-
trations seen after running a marathon(796). Older men given
1 g/d of vitamin C plus 1000 mg/d vitamin E for 4 weeks
showed a decrease in plasma TNF-a concentrations(797).
Recently, a mixture of fruit-derived antioxidants has been
found not to alter CRP or IL-6 concentrations over 12 weeks
in type 2 diabetics(798). In an intervention study with caroten-
oid-rich vegetables and fruits, plasma concentrations of a- and
b-carotene, but not other carotenoids, were inversely associ-
ated with plasma CRP concentrations in healthy normal-
weight men(345). Lycopene (80 mg/d for 1 week) did not
affect plasma CRP, sVCAM-1 or sICAM-1 concentrations in
men and women with a mean age of 23 years(799).
Thus, in contrast to observational studies that provide a
fairly consistent picture of an anti-inflammatory effect of
vitamin C, vitamin E and carotenoids, intervention studies
using supplements of these antioxidant vitamins either alone
or in various combinations provide a less consistent set of
observations. A number of studies do demonstrate a reduction
in the concentrations of circulating inflammatory markers in a
variety of subgroups of individuals, including the overweight
persons and diabetics, but quite a number of studies did not
find an effect. The lack of consistency may be related to differ-
ences in: dose of antioxidant used (however, typically the
doses used are much greater than those that can be readily
achieved in the diet and are therefore much greater than
would have been present in the diets of subjects investigated
in the observational studies); duration of treatment (typically a
few weeks to a few months); sample size which has
often been small; characteristics of the populations studied
(e.g. age, healthy v. diseased, type of disease, smokers
v. non-smokers); background diet; interactions among the
different antioxidant vitamins used, since they may have
different anti-inflammatory potencies and some may even
act in a pro-inflammatory way under certain conditions;
degree of oxidative stress present. One other factor that has
recently been identified is genetic differences among individ-
uals, which may have an impact on the ability of antioxidants
to exert an anti-inflammatory effect. Such an effect has been
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identified by Belisle et al.(800) who showed that the ability of
a-tocopherol to lower the LPS-stimulated production of
TNF-a by whole blood was determined in part by polymorph-
isms within the TNF-a gene. Thus, it is possible that a greater
or lesser anti-inflammatory effect of antioxidant vitamins will
be observed in people with different genotypes related to
inflammatory processes. Clearly, this needs greater explora-
tion in properly designed studies.
Flavonoids
Polyphenols are secondary metabolites of plants involved in
pigmentation, reproduction and protection against pathogens.
There are more than 8000 known polyphenolic substances
sharing a common chemical structure (hydroxyl group on
an aromatic ring) with different constituents. Flavonoids are
the most abundant polyphenols present in the human diet,
and they can be divided into several classes according to
different constituents such as flavanones, flavones, flavanols
and flavonols. They can be found in almost all plant foods
and, among the flavonols, myricetin, kaempferol and querce-
tin are the most representative, while catechins are the most
abundant flavanols contained in tea leaves. Flavanones are
mainly represented in the diet by taxifolin, naringinin and
hesperitin. The main sources of flavanones are citrus fruits.
Flavones are less common. In addition to these, other classes
of flavonoids are present in the diet such as proanthocyanidins
and their oligomers.
The intake of flavonols and flavones was not correlated
with plasma concentrations of CRP or IL-6 in healthy
women (BMI 25·8–26·2 kg/m2)(801). While this study used
a rather limited flavonoid database, a more recent cross-
sectional study applying a comprehensive flavonoid database
reported anti-inflammatory effects associated with a high
flavonoid intake: total flavonoid, flavonol and anthocyanidin
intakes were inversely associated with plasma CRP con-
centrations(323). Data from the Nurses’ Health study were
used to assess the relationship between flavonoid intake and
biomarkers of inflammation(802): intake of six flavonoid
subclasses (flavonols, flavones, flavanones, flavan-3-ols, antho-
cyanidins and polymeric flavonoids) was assessed using a FFQ
administered in 1990 and blood samples collected in 1989–90
were used to measure concentrations of CRP, IL-6, IL-18,
sTNFR2, sVCAM-1 and sE-selectin. Multivariate-adjusted
mean plasma IL-18 concentrations were lower (by 9, 11 and
8 %, respectively) for women in the highest intake quintile
of flavones, flavanones and total flavonoids compared with
those in the lowest quintiles. Multivariate-adjusted geometric
plasma sVCAM-1 concentrations were lower by 4 % in
women in the highest intake quintile of flavonol compared
with those in the lowest quintile. Thus, the study suggests
that higher intakes of selected flavonoid subclasses are associ-
ated with modestly lower concentrations of some inflamma-
tory biomarkers.
In a randomised human intervention trial with healthy
normal-weight adults, supplementation with a bilberry
extract providing 300 mg anthocyanins/d (equal to 100 g of
fresh bilberries) reduced plasma concentrations of several
NF-kB-induced pro-inflammatory cytokines (IL-8, RANTES and
IFN-a)(337). In addition, NF-kB-inducing cytokines (IL-4 and
IL-13) tended to differ from controls, while plasma CRP
concentrations did not change(337). In subjects who had
survived myocardial infarction and had received statin
therapy for at least 6 months, supplementation with a choke-
berry flavonoid extract for 6 weeks significantly decreased
CRP and MCP-1 concentrations, while adiponectin was signifi-
cantly increased(803). In contrast, although the consumption
of black tea resulted in increased plasma catechin con-
centrations, these were not associated with changes in
plasma CRP concentrations in healthy overweight and obese
adults(389). A similar negative effect on CRP was observed
in a double-blind, placebo-controlled, cross-over study with
healthy adults (mean BMI 25·8 kg/m2) who were sup-
plemented with a sea buckthorn flavonol extract during 4
weeks(804). Quercetin (50, 100 or 150 mg/d for 2 weeks) did
not affect serum concentrations of TNF-a in healthy
adults(805). Overweight or obese subjects aged 25–65 years
with metabolic syndrome traits received 150 mg quercetin/d
in a double-blind, placebo-controlled, cross-over trial with
6-week treatment periods separated by a 5-week washout
period: quercetin did not affect CRP or TNF-a concentrations
compared with placebo(806). Quercetin (1 g/d for 21 d) failed
to attenuate muscle inflammation in ultramarathon run-
ners(807) and in trained cyclists(808,809). However, leucocyte
IL-8 and IL-10 mRNA were significantly reduced, indicating
that a high dose of quercetin may target blood cells but not
the muscle tissue.
Phyto-oestrogens
Genistein is an isoflavone and a phyto-oestrogen which
primarily occurs in soyabeans. Native phyto-oestrogens exist
as glycosides, while in experimental studies, mostly the
aglycones have been used. In two intervention studies with
healthy postmenopausal women, the intake of genistein (54
or 40 mg/d) for 6 months did not significantly affect plasma
CRP concentrations(810,811). The intake of soya either high or
low in isoflavones for 1, 2 or 4 months had also no effect
on CRP, SAA or TNF-a concentrations in hypercholesterolae-
mic men or in postmenopausal women(356,359,362). In obese
postmenopausal women, the combination of exercise with a
soya isoflavone supplement (duration 6 months) did not
decrease plasma CRP concentration compared with exercise þ
placebo(812). Consumption of a soya isoflavone-enriched
cereal bar (50 mg/d) for 8 weeks by postmenopausal
women had no effect on CRP or other plasma markers of
inflammation(813). A higher intake of soya isoflavones
(114 mg/d) for 3 months also did not reduce serum CRP or
sE-selectin concentrations in postmenopausal women(814). In
another study, isoflavone-rich soya (107 mg/d as aglycone;
50 % as genestein) for 6 weeks did not affect sVCAM-1,
sICAM-1 or sE-selectin concentrations in healthy postmeno-
pausal women compared with isoflavone-poor soya(815). In
contrast, a randomised, controlled study providing pasta
naturally enriched with isoflavone aglycones (33 mg/d) to
overweight hypercholesterolaemic subjects reported significantly
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reduced plasma CRP concentrations, which returned to
baseline when subjects were switched to conventional
pasta(816). Overall, the majority of the studies with soya-
derived isoflavones did not observe a significant effect on
inflammatory processes in human subjects. In contrast, a
lignan complex (500 mg/d) isolated from flax given to healthy
postmenopausal women significantly reduced plasma CRP
concentration during the 6-week placebo-controlled interven-
tion. No significant differences were found for IL-6, TNF-a,
sICAM-1, sVCAM-1 or MCP-1 concentrations(817). In a recent
study, flaxseed-derived lignans (360 mg/d) lowered CRP
concentrations in type 2 diabetic women but not in men
over 12 weeks compared with placebo, with no effect on
IL-6 concentrations(818). A cross-sectional study in 242 men
and postmenopausal women in Northern Italy revealed
inverse associations between dietary intake of the lignans
matairesinol and secoisolariciresinol and plasma concen-
trations of sICAM-1(819).
Other factors
Gut microbiota and probiotics
Probiotics are ‘live micro-organisms which, when consumed
in adequate quantities, confer a health benefit on the
host’(820,821). One differential characteristic of probiotics com-
pared with other micro-organisms is their ability to survive
during gastrointestinal transit(822). This allows them to interact
with commensal microbiota and/or intestinal epithelial cells
and also with gut-associated lymphoid cells, which results in
the induction or modulation of a number of biological activi-
ties that can provide beneficial effects for health. The capacity
of probiotics to modulate the mucosal immune system is
regarded as one of the most obvious beneficial properties.
The microbiota composition and the related local intestinal
metabolism undergoes significant changes in various disease
states that are characterised by chronic inflammation, such
as inflammatory bowel disease(823), colorectal cancer and
obesity(824,825). Mice raised under germ-free conditions fail to
develop experimental colitis, suggesting an important modu-
lating role of intestinal microbiota on local inflammatory pro-
cesses(826). Thus, there seems to be a strong association
between the nature of the gut microbiota and inflammation.
A number of studies have investigated the effects of various
probiotics on aspects of inflammation in a variety of subject
and patient groups, as reviewed elsewhere(827). However,
relatively few studies have focused on circulating markers of
inflammation in persons without an established inflammatory
disease. In a small study in institutionalised elderly subjects
(mean age 76 years), there was no effect of the combination
of Bifidobacterium longum and Lactobacillus acidophilus
(8 £ 109 colony forming units (CFU) of each/d for 28 d) on
serum TNF-a concentration(828). L. salivarius UCC118 (1010
CFU/d for 21 d) did not affect serum IL-1a, IL-1b, IL-4, sIL-2R,
sIL-6R, TNF-a or IFN-g concentrations in healthy adults
aged 20–65 years(829). Likewise, the combination of L. gasseri
CECT5714 and L. coryniformis CECT5711 (2 £ 109 CFU of
each/d) with Staphylococcus thermophilus (108 CFU/d) for 2
or 4 weeks had no effect on serum TNF-a or IL-12 concen-
trations in healthy adults aged 23–43 years(830,831). Kekkonen
et al.(832) compared L. rhamnosus GG ATCC53103 (1·6 £ 1010
CFU/d) with Bifidobacterium animalis ssp. lactis Bb12
(3·5 £ 1010 CFU/d) and Propionibacterium freudenreichii
ssp. Shermani JS (3·3 £ 1010 CFU/d) for 3 weeks in healthy
subjects with a mean age of 44 years (range 23–58 years).
There was no effect of serum TNF-a, IL-6, IL-10 or IFN-g
concentrations, but serum CRP concentration decreased in
the L. rhamnosus group. Ouwehand et al.(833) conducted a
6-month placebo-controlled trial with B. animalis ssp. lactis
Bb12 (109 CFU/d) or the combination of B. longum 2C
and B. longum 46 (109 CFU of each/d) in institutionalised
elderly subjects (mean age 84 years). Although there were
some changes over time, the groups did not differ in serum
TNF-a, IL-10 or TGF-b concentrations. Thus, although there
is the potential for probiotics to lower markers of chronic
low-grade inflammation, intervention studies performed to
date in human volunteers rarely demonstrate this effect.
Prebiotics
There are two recent definitions of prebiotics: ‘a selectively
fermented ingredient that allows specific changes, both
in the composition and/or activity in the gastrointestinal
microflora that confers benefits upon host well-being and
health’(834), and ‘a non-viable food component that confers
a health benefit on the host associated with modulation
of the microbiota’(835). Typically, though not exclusively,
prebiotics are carbohydrates including inulin-type fructans
(including oligofructose, fructo-oligosaccharides), lactulose,
galacto-oligosaccharides, xylo-oligosaccharides, D-tagatose,
resistant starch, soyabean oligosaccharides, pectin, guar,
carrageenan, konjac glucomannans, alginates and b-glucans
from oat, barley and mushroom. Prebiotics escape digestion
in the upper gastrointestinal tract and reach the large intestine
virtually intact, where they are fermented by the microbiota
and express their prebiotic activity(834). The latter is most
probably mediated through a quantitative increase in com-
mensal bacteria (e.g. bifidobacteria and lactobacilli), which
interact with other members of the gut microbiota. Further,
changes in the microbiota enzyme activities, leading to a
reduction of unfavourable substances that have an impact
on disease risk, such as secondary bile acids, and the pro-
duction of metabolites such as SCFA and vitamins also contrib-
ute to their impact on health and disease(834). In high-fat-fed
mice, oligofructose restored gut bifidobacteria, and normal-
ised systemic endotoxin levels and the inflammatory
state(836). Institutionalised elderly individuals (mean age 85
years) supplemented with oligofructose (8 g/d for 3 weeks)
showed increased faecal bifidobacteria counts and decreased
expression of IL-6 mRNA in blood monocytes(837). In another
study, in poorly nourished elderly subjects (age .70 years),
oligofructose (1·95–3·9 g/d for 12 weeks as part of a nutri-
tional supplement) had no effect on plasma TNF-a or sIL-6R
concentrations(838). Prebiotics have been studied in the con-
text of inflammatory conditions, especially those involving
the gastrointestinal tract, as reviewed elsewhere(839). There is
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some evidence of beneficial effects but results are inconsist-
ent. There are few studies of prebiotics and circulating inflam-
matory markers in the context of chronic low-grade
inflammation. Thus, it is premature to draw conclusions
about this relationship.
Hydration
When fluids are consumed, water distributes between intra-
and extracellular compartments according to osmotic load.
When water enters the cells, they swell and when water is
lost from the cells, for example, during dehydration, the
cells will shrink. The maintenance of adequate cell volume
can have a profound effect on protein function and cellular
performance. Cells employ an array of mechanisms to main-
tain cell volume constancy, including altered transport across
the cell membrane and metabolism. Hormones and mediators
may modify the activity of these cell volume regulatory mech-
anisms and thus influence cell volume-sensitive functions. Cell
volume regulatory mechanisms, therefore, participate in the
signalling of those hormones and mediators(840). Many meta-
bolic pathways are sensitive to cell volume(841), as a result
of activation, inhibition or altered expression of enzymes.
Cellular volume has the potential to have an impact directly
or indirectly on inflammation, but the effect of hydration
status on low-grade inflammation is not well documented.
Summary, conclusions and research gaps
Inflammation is part of the normal host defence mechanism
against infections. However, inflammatory mediators and the
inflammatory response can be damaging to the host if not
regulated appropriately and numerous diseases and con-
ditions have an overt chronic inflammatory basis. It is now
recognised that a lower level of inflammation, here termed
chronic low-grade inflammation, can also persist and may
be a cause of, or result from, the obese state. Adipose tissue
releases many of the characteristic mediators of inflammation
including some of the classic pro-inflammatory cytokines and
chemokines, as well as adiponectin which is considered to be
anti-inflammatory. The source of these mediators within adi-
pose tissue is not clear, but infiltrating macrophages seem to
be especially important in this regard, although adipocytes
themselves express some of the inflammatory mediators.
Obese people have higher circulating concentrations of
many inflammatory markers (measured in the ‘resting’ state,
i.e. in fasted blood), and these are believed to play a role in
causing insulin resistance and in other metabolic disturbances
of the metabolic syndrome and type 2 diabetes. Blood con-
centrations of inflammatory markers are lowered following
weight loss, whether this is induced by diet or surgery,
which most probably reflects the decrease in adipose tissue
mass. In the hours following the consumption of a meal,
there is an elevation in the concentrations of several inflamma-
tory mediators in the bloodstream. This postprandial inflam-
matory response is greater in obese subjects and type 2
diabetics. Both high-glucose and high-fat meals induce post-
prandial inflammation, and it is exaggerated by a high meal
content of AGE and partly ablated by the inclusion of certain
antioxidants or antioxidant-containing foods within the meal.
These latter observations link postprandial inflammation to
oxidative stress. Physical activity decreases low-grade inflam-
mation. Exercise itself is associated with transient and local
inflammation (e.g. in muscle) that may, in fact, be important
in inducing a protective and ultimately healthy anti-inflamma-
tory response. In addition to the direct effect of foods and
their constituents on postprandial inflammation, diet has an
impact on chronic low-grade inflammation, manifested as
the basal (i.e. fasting state) concentrations of inflammatory
markers in the bloodstream, including cytokines, chemokines,
acute-phase proteins, soluble adhesion molecules and cyto-
kine receptors, etc. Effects of diet and dietary components
on low-grade inflammation have been identified through
cross-sectional, prospective and intervention studies. The
former two study designs frequently involve large numbers
of subjects, while the intervention studies often have a small
sample size and a limited duration which might limit their
ability to identify effects; compliance may also be a limitation
of intervention studies. Healthy eating patterns such as the
Mediterranean diet, vegetarian diets and adherence to the
Food Guide Pyramid are associated with lower concentrations
of inflammatory markers; this is observed mainly from cross-
sectional and prospective studies, although intervention
studies with the Mediterranean diet have been positive.
Among the components of healthy diets, whole grains, veg-
etables and fruits, and fish are all seen to be associated with
lower inflammation. Strong evidence in favour of an anti-
inflammatory effect of tea (black or green), coffee (caffeinated
or decaffeinated) and cocoa is lacking, despite positive
effects on oxidative stress and the anti-inflammatory effects,
mainly demonstrated in model systems (e.g. cell cultures), of
components of these foods. Alcohol appears to have a
‘U-shaped’ effect on low-grade inflammation, with the most
protective action (i.e. the lowest inflammatory marker concen-
trations) corresponding to one or two alcoholic drinks per d.
Heated meals high in AGE and ALE enhance oxidative stress
and inflammation; intervention studies with low- and high-
AGE meals either acutely or chronically have associated AGE
with increased inflammatory marker concentrations and
show that these are decreased by meals low in AGE. However,
AGE and ALE are also generated in vivo and also as a result of
other, non-food-related, environmental exposures (e.g. smok-
ing), and so the overall impact of foods on the burden of AGE
and ALE is not currently clear; this is compounded by tech-
nical difficulties in measuring these complex chemical entities
in foods and in body fluids. Dietary fatty acids also influence
low-grade inflammation; best studied are PUFA. Available data
indicate that SFA and trans-MUFA are pro-inflammatory, and
that one isomer of conjugated linoleic acid may also be. Rela-
tive to SFA, PUFA are anti-inflammatory. Marine n-3 PUFA
have the greatest anti-inflammatory potential. Hyperglycaemia
induces both postprandial and chronic low-grade inflam-
mation, acting in part through oxidative stress. Dietary fibre
decreases low-grade inflammation. There may also be a role
for milk peptides, but these have not been sufficiently
evaluated. Vitamin D has the potential to reduce low-grade
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inflammation, with plausible mechanistic actions demonstrated
in model systems. There is good evidence from both model
systems and from human observational and intervention
studies that vitamin C, vitamin E and carotenoids decrease
the concentrations of inflammatory markers. a- and g-Toco-
pherols and the different carotenoids may have different
anti-inflammatory properties and potencies. The majority of
available evidence indicates that soya phyto-oestrogens and
soya protein do not affect low-grade inflammation. There
are likely to be many plant-derived substances that influence
low-grade inflammation and which may have a role as part
of a healthy ‘anti-inflammatory diet’. Several studies of various
probiotic bacteria have failed to demonstrate any consistent
effects on markers of chronic low-grade inflammation, despite
their apparent effectiveness in higher-grade inflammatory
states. The effect of prebiotics on chronic low-grade inflam-
mation is not clear and is underexplored.
The key conclusions are as follows:
(1) A state of chronic low-grade inflammation exists and this
is exaggerated in obese and type 2 diabetic individuals.
(2) Adipose tissue plays a role in establishing the chronic
low-grade inflammatory state because cells within that
tissue can produce and release the mediators involved.
(3) Chronic low-grade inflammation is believed to increase
the risk of insulin resistance, type 2 diabetes and CVD.
(4) Following consumption of a meal, there is a transient
state of inflammation that is linked with oxidative stress.
(5) Hyperglycaemia or a high-fat meal promote postprandial
inflammation.
(6) A healthy diet is associated with decreased low-grade
inflammation.
(7) Important protective factors in the diet are whole grains,
fibre, vegetables, fruits, fish, PUFA, especially marine n-3
PUFA, vitamin C, vitamin E and carotenoids.
(8) Plant-derived flavonoids are likely to be protective.
(9) Moderate alcohol consumption decreases low-grade
inflammation.
(10) Dietary factors that promote inflammation are oxidised
lipids, SFA and trans-fatty acids.
(11) Underexplored dietary factors include milk peptides,
vitamin D, probiotics and prebiotics.
A number of important research gaps were identified.
Perhaps the most important is that there is no consensus
regarding the inflammatory mediators which best represent
chronic low-grade inflammation. Most studies have measured
CRP, perhaps because it is long established, is linked to the
risk of CVD and is routinely measured in clinical laboratories.
However, it is not clear whether CRP is a ‘better’ marker of
low-grade inflammation than any of the other mediators
measured, which include a variety of cytokines, soluble
cytokine receptors, chemokines, soluble adhesion molecules
and so on. Furthermore, there has been little emphasis on
anti-inflammatory mediators. An expert review of the area of
inflammatory markers addressing the most valid and robust
markers and including a consideration of anti-inflammatory
factors is warranted. Identification of dietary components
that promote or prevent postprandial inflammation and
the underlying mechanisms involved is a further gap. The
impact of many dietary components on chronic low-grade
inflammation is underexplored in human intervention studies;
such components include flavonoids and other phytochem-
icals, milk peptides, vitamin D, probiotics and prebiotics.
Further, even where dietary components have been fairly
well explored through intervention studies, many of the
studies have been small in size and they have reported on
different inflammatory outcomes at different time points. For
these components (whole grains, fibre, vegetables, fruits,
fish, PUFA, especially marine n-3 PUFA, vitamin C, vitamin E
and carotenoids), a better knowledge of the dose–response
effect, the threshold dose (if any) and the time required for
an effect to occur would all be valuable information. Such
variations in study design may also explain the discordant
findings of studies with tea, coffee and cocoa, and these diet-
ary components require further investigation in the context of
robust markers of inflammation, appropriate sample size and
duration of exposure, and exploration of dose–response
relationships. Oxidative stress and inflammation are strongly
interlinked and effects of dietary components appear to
frequently involve increased or decreased oxidative stress.
In this regard, modified food components such as AGE and
ALE may be very potent markers of oxidative and inflam-
matory stress, although their causal impact remains elusive.
However, further exploration and greater understanding of
this area is impeded by lack of agreed analytical methods
for quantifying AGE in foods and in biological fluids, with
inter-laboratory cross-validation, and by lack of discrimination
between protein-bound and free AGE. Finally, the emerging
area of the role of gene polymorphisms in influencing or
even determining the effect of nutrients on markers of
low-grade inflammation requires much greater exploration.
Until these gaps are filled, our understanding of the interaction
between diet and postprandial and chronic low-grade inflam-
mation will remain incomplete.
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